<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia - Bergman, H - 2018 | Cochrane Library</title> <meta content="Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia - Bergman, H - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000459.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia - Bergman, H - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000459.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000459.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia" name="citation_title"/> <meta content="Hanna Bergman" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="hbergman@cochrane.org" name="citation_author_email"/> <meta content="John Rathbone" name="citation_author"/> <meta content="Bond University" name="citation_author_institution"/> <meta content="Vivek Agarwal" name="citation_author"/> <meta content="North Essex Partnership University NHS Foundation Trust" name="citation_author_institution"/> <meta content="Karla Soares‐Weiser" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD000459.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/02/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000459.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000459.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000459.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [*administration &amp; dosage, *adverse effects]; Dose‐Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Dyskinesia, Drug‐Induced [*drug therapy, prevention &amp; control]; Mental Disorders [drug therapy]; Randomized Controlled Trials as Topic; Schizophrenia [drug therapy]; Withholding Treatment" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000459.pub3&amp;doi=10.1002/14651858.CD000459.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000459\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000459\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000459.pub3",title:"Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia",firstPublishedDate:"Feb 6, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000459.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000459.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000459.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000459.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000459.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000459.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000459.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000459.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000459.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000459.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2900 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000459.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-sec-0230"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-sec-0102"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-sec-0211"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/appendices#CD000459-sec-0245"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/table_n/CD000459StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/table_n/CD000459StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information#CD000459-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hanna Bergman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information#CD000459-cr-0003">John Rathbone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information#CD000459-cr-0004">Vivek Agarwal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information#CD000459-cr-0005">Karla Soares‐Weiser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information/en#CD000459-sec-0267">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 February 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000459.pub3">https://doi.org/10.1002/14651858.CD000459.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000459-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000459-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000459-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000459-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000459-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000459-abs-0001" lang="en"> <section id="CD000459-sec-0001"> <h3 class="title" id="CD000459-sec-0001">Background</h3> <p>Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such as tardive dyskinesia (TD) – a problem often seen as repetitive involuntary movements around the mouth and face. Various strategies have been examined to reduce a person's cumulative exposure to antipsychotics. These strategies include dose reduction, intermittent dosing strategies such as drug holidays, and antipsychotic cessation. </p> </section> <section id="CD000459-sec-0002"> <h3 class="title" id="CD000459-sec-0002">Objectives</h3> <p>To determine whether a reduction or cessation of antipsychotic drugs is associated with a reduction in TD for people with schizophrenia (or other chronic mental illnesses) who have existing TD. Our secondary objective was to determine whether the use of specific antipsychotics for similar groups of people could be a treatment for TD that was already established. </p> </section> <section id="CD000459-sec-0003"> <h3 class="title" id="CD000459-sec-0003">Search methods</h3> <p>We updated previous searches of Cochrane Schizophrenia's study‐based Register of Trials including the registers of clinical trials (16 July 2015 and 26 April 2017). We searched references of all identified studies for further trial citations. We also contacted authors of trials for additional information. </p> </section> <section id="CD000459-sec-0004"> <h3 class="title" id="CD000459-sec-0004">Selection criteria</h3> <p>We included reports if they assessed people with schizophrenia or other chronic mental illnesses who had established antipsychotic‐induced TD, and had been randomly allocated to (a) antipsychotic maintenance versus antipsychotic cessation (placebo or no intervention), (b) antipsychotic maintenance versus antipsychotic reduction (including intermittent strategies), (c) specific antipsychotics for the treatment of TD versus placebo or no intervention, and (d) specific antipsychotics versus other antipsychotics or versus any other drugs for the treatment of TD. </p> </section> <section id="CD000459-sec-0005"> <h3 class="title" id="CD000459-sec-0005">Data collection and analysis</h3> <p>We independently extracted data from these trials and estimated risk ratios (RR) or mean differences (MD), with 95% confidence intervals (CI). We assumed that people who dropped out had no improvement. </p> </section> <section id="CD000459-sec-0006"> <h3 class="title" id="CD000459-sec-0006">Main results</h3> <p>We included 13 RCTs with 711 participants; eight of these studies were newly included in this 2017 update. One trial is ongoing. </p> <p>There was low‐quality evidence of a clear difference on no clinically important improvement in TD favouring switch to risperidone compared with antipsychotic cessation (with placebo) (1 RCT, 42 people, RR 0.45 CI 0.23 to 0.89, low‐quality evidence). Because evidence was of very low quality for antipsychotic dose reduction versus antipsychotic maintenance (2 RCTs, 17 people, RR 0.42 95% CI 0.17 to 1.04, very low‐quality evidence), and for switch to a new antipsychotic versus switch to another new antipsychotic (5 comparisons, 5 RCTs, 140 people, no meta‐analysis, effects for all comparisons equivocal), we are uncertain about these effects. There was low‐quality evidence of a significant difference on extrapyramidal symptoms: use of antiparkinsonism medication favouring switch to quetiapine compared with switch to haloperidol (1 RCT, 45 people, RR 0.45 CI 0.21 to 0.96, low‐quality evidence). There was no evidence of a difference for switch to risperidone or haloperidol compared with antipsychotic cessation (with placebo) (RR 1 RCT, 48 people, RR 2.08 95% CI 0.74 to 5.86, low‐quality evidence) and switch to risperidone compared with switch to haloperidol (RR 1 RCT, 37 people, RR 0.68 95% CI 0.34 to 1.35, very low‐quality evidence). </p> <p>Trials also reported on secondary outcomes such as other TD symptom outcomes, other adverse events outcomes, mental state, and leaving the study early, but the quality of the evidence for all these outcomes was very low due mainly to small sample sizes, very wide 95% CIs, and risk of bias. No trials reported on social confidence, social inclusion, social networks, or personalised quality of life, outcomes that we designated as being important to patients. </p> </section> <section id="CD000459-sec-0007"> <h3 class="title" id="CD000459-sec-0007">Authors' conclusions</h3> <p>Limited data from small studies using antipsychotic reduction or specific antipsychotic drugs as treatments for TD did not provide any convincing evidence of the value of these approaches. There is a need for larger trials of a longer duration to fully investigate this area. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000459-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000459-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000459-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000459-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000459-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000459-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000459-abs-0003" lang="en"> <h3>Antipsychotic‐reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia </h3> <p><b>Review question</b> </p> <p>To determine whether stopping or reducing antipsychotic drugs helps in the reduction of tardive dyskinesia for people with schizophrenia. To examine whether specific antipsychotic drugs could be a treatment for tardive dyskinesia. </p> <p><b>Background</b> </p> <p>People with schizophrenia often hear voices and see things (hallucinations) and have strange beliefs (delusions). The main treatment for schizophrenia is antipsychotic drugs. However, these drugs can have debilitating side effects. Tardive dyskinesia is an involuntary movement that causes the face, mouth, tongue, and jaw to convulse, spasm, and grimace. It is caused by long‐term use or high doses of antipsychotic drugs, is difficult to treat, and can be incurable. Various strategies have been proposed to reduce a person’s exposure to antipsychotic drugs. These include lowering the dose of medication, intermittent ‘drug holidays’, and stopping taking antipsychotic medication altogether. </p> <p><b>Study characteristics</b> </p> <p>The review includes 13 trials with a total of 711 people with schizophrenia and other psychiatric diagnoses. </p> <p><b>Key results</b> </p> <p>Due to the poor quality, small size, and limited data from the 13 studies, there is limited evidence. It is not known if strategies such as dose reduction, ‘drug holidays’, and stopping medication are helpful in the treatment of tardive dyskinesia. There is limited evidence on specific antipsychotic drugs in the treatment of tardive dyskinesia. </p> <p><b>Quality of the evidence</b> </p> <p>Evidence is poor, small scale, and of short duration. There is a need for larger trials of a longer duration in order to fully investigate this area. </p> <p>This plain language summary was adapted by the review authors from a summary originally written by Ben Gray, Senior Peer Researcher, McPin Foundation (<a href="http://mcpin.org/" target="_blank">http://mcpin.org/</a>). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000459-sec-0230" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000459-sec-0230"></div> <h3 class="title" id="CD000459-sec-0231">Implications for practice</h3> <section id="CD000459-sec-0231"> <section id="CD000459-sec-0232"> <h5 class="title">1. For people with tardive dyskinesia</h5> <p>Currently, this review has no data derived from randomised controlled trials (RCTs) that can adequately support the notion that any particular antipsychotic is an effective treatment for tardive dyskinesia (TD). While products such as clozapine, and the newer 'atypical' antipsychotics such as risperidone have favourable extrapyramidal adverse effect profiles compared with classical antipsychotics, it remains to be seen if these products are associated with lower incidence rates of TD. </p> </section> <section id="CD000459-sec-0233"> <h5 class="title">2. For clinicians</h5> <p>This review cannot provide clinicians with an effective treatment algorithm involving antipsychotic medications for the treatment of people with TD. While many practice guidelines continue to recommend antipsychotic reduction or cessation, or both (<a href="./references#CD000459-bbs2-0149" title="American Psychiatry Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC, 1992. ">APA 1992</a>; <a href="./references#CD000459-bbs2-0154" title="BarnesTRE , EdwardsJG . The side‐effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: BarnesTRE editor(s). Antipsychotic drugs and their side‐effects. London: Academic Press/Harcourt Brace &amp; Company, 1993. ">Barnes 1993</a>; <a href="./references#CD000459-bbs2-0202" title="JesteDV , CaligiuriMP . Tardive dyskinesia. Schizophrenia Bulletin1993;19(2):303‐15. ">Jeste 1993</a>; <a href="./references#CD000459-bbs2-0226" title="ShaleH , TannerC . Pharmacological options for the management of dyskinesias. Drugs1996;52(6):849‐60. ">Shale 1996</a>), this treatment option lacks a sound evidence‐base. There are a considerable amount of RCT‐derived data that demonstrate that this intervention is not safe because of the increased risk of relapse of psychoses (<a href="./references#CD000459-bbs2-0190" title="GilbertPL , HarrisJ , McAdamLA , JesteDV . Neuroleptic withdrawal in schizophrenic patients ‐ a review of the literature. Archives of General Psychiatry1995;52:173‐88. ">Gilbert 1995</a>). </p> <p>As outlined in the <a href="#CD000459-sec-0023">Background</a> section of this review, there are features related to the interactions between antipsychotics and TD that need to be taken into account when assessing the evidence presented in this review. In particular, TD is thought to worsen in the short term following antipsychotic dose reduction and/or cessation, and TD is thought to be suppressed or masked in the short term following antipsychotic dose increment. These factors combine to favour antipsychotics when compared with placebo for the treatment of TD. </p> </section> <section id="CD000459-sec-0234"> <h5 class="title">3. For managers and policy makers</h5> <p>There are no adequate data available from this review to provide evidence for managers and policy makers on best practice. </p> </section> </section> <h3 class="title" id="CD000459-sec-0235">Implications for research</h3> <section id="CD000459-sec-0235"> <section id="CD000459-sec-0236"> <h5 class="title">1. General</h5> <p>The power of this review would have been greatly enhanced by better reporting of data. For example, only three studies made explicit how randomisation was undertaken, and none described allocation concealment. We realise that much of the work for these trials predates CONSORT, which was first published in 1996 (<a href="./references#CD000459-bbs2-0155" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA1996;276(8):637‐9. [PUBMED: 8773637] ">Begg 1996</a>), and that it is only too easy to judge studies of the past by standards of today. Future studies, however, should report to a much higher standard. </p> </section> <section id="CD000459-sec-0237"> <h5 class="title">2. Specific</h5> <section id="CD000459-sec-0238"> <h6 class="title">2.1 Reviews suggested by excluded studies</h6> <p>As is usual with systematic reviews, we had to exclude several studies that contained comparisons that were in some way related to movement disorders and their treatment. In the case of this review, every one of these trials should have an existing Cochrane Review in which to be considered (<a href="#CD000459-tbl-0006">Table 2</a>). </p> <div class="table" id="CD000459-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies relevant to schizophrenia: comparisons for existing or potential reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants – people with:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison for review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cochrane Review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0030" title="CaiN . A controlled study on the treatment of tardive dyskinesia using 1‐stepholidine. Chinese Journal of Neurology and Psychiatry1988;21(5):281‐3. ">Cai 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐stepholidine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐stepholidine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0129" title="BarnesTRE , SpellerJC , CursonDA , PantelisC , AlbertsJL . A one‐year dose reduction study in chronic schizophrenic inpatients: amisulpride vs haloperidol. Schizophrenia Research1992;6(2):107. [EMBASE 1997383387] SpellerJC , BarnesTRE , CursonDA , PantelisC , AlbertsJL . One‐year, low‐dose neuroleptic study of in‐patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. British Journal of Psychiatry1997;171(December):564‐8. [EMBASE 1997383387] ">Speller 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amisulpride vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amisulpride versus haloperidol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0063" title="GerlachJ , SimmelsgaardH . Tardive dyskinesia during and following treatment with haloperidol, haloperidol and biperiden, thioridazine and clozapine. Psychopharmacology1978;59:105‐12. ">Gerlach 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biperiden vs no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Anticholinergic drugs for tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0104" title="GerlachJ . Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale1988;XIV:227‐32. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology1986;90(4):423‐9. PovlsenUJ , NoringU , MeidahlB , KorsgaardS , WaehrensJ , GerlachJ . [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger1987;149(25):1682‐5. ">NDSG 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorprothixene versus haloperidol vs perphenazine vs haloperidol + biperiden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0070" title="GreilW , HaagH , RossnaglG , RutherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. [MEDLINE: 85001048; PMID 6148119] ">Greil 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biperiden vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0041" title="ChouinardG , AnnableL , Ross‐ChouinardA , KropskyML . Ethopropazine and benztropine in neuroleptic‐induced parkinsonism. Journal of Clinical Psychiatry1979;40(3):147‐52. ">Chouinard 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethopropazine vs benztropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics for parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0131" title="SpohnHE , CoyneL , SprayJ . The effect of neuroleptics and tardive dyskinesia on smooth‐pursuit eye movement in chronic schizophrenia. Archives of General Psychiatry1988;45:833‐40. ">Spohn 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abrupt neuroleptic cessation vs neuroleptic maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>Antipsychotic reduction or withdrawal for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0132" title="SpohnHE , CoyneL . The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics. Special Issue: tardive dyskinesia and cognitive dysfunction. Brain and Cognition1993;23(1):28‐39. ">Spohn 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abrupt neuroleptic cessation vs neuroleptic maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0140" title="WistedtB , WilesD , JorgensenA . A depot neuroleptic withdrawal study neurological effects. Psychopharmacology1983;80:101‐5. ">Wistedt 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine/flupenthixol decanoate continuation vs withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0069" title="GoldbergSC , ShenoyRS , SadlerA , HamerR , RossB . The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics. Psychopharmacology Bulletin1981;17(1):116‐7. [MEDLINE: 81200009; PMID 7232638] ShenoyRS , SadlerAG , GoldbergSC , HamerRM , RossB . Effects of a six‐week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology1981;1(3):141‐5. ">Goldberg 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal of fluphenazine decanoate vs continuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0073" title="HershonHI , KennedyPF , McGuireRJ . Persistence of extra‐pyramidal disorders and psychiatric relapse after withdrawal of long‐term phenothiazine therapy. British Journal of Psychiatry1972;120(554):41‐50. ">Hershon 1972</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trifluoperazine withdrawal vs trifluoperazine continuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0083" title="JohnsonDA , LudlowJM , StreetK , TaylorRD . Double‐blind comparison of half‐dose and standard‐dose flupenthixol decanoate in the maintenance treatment of stabilised out‐patients with schizophrenia. British Journal of Psychiatry1987;151:634‐8. ">Johnson 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose reduction vs maintenance (both arms used flupenthixol decanoate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0088" title="KinonB , StaufferVL , WangL , ThiKT , Kollack‐WalkerS . Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study. International Journal of Neuropsychopharmacology. Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum2002;5(Suppl 1):S165. KinonBJ , JesteDV , Kollack‐WalkerS , StaufferV , Liu‐SeifertH . Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Progress in neuro‐psychopharmacology &amp; biological psychiatry2004;28(6):985‐96. KinonBJ , StaufferVL , WangL , ThiK , NiewoehnerJ , Kollack‐WalkerS . Olanzapine improves dyskinesia in patients with schizophrenia. International Congress on Schizophrenia Research (ICSR) March 29‐April 2, 2003, Colorado Springs, Colorado. 2003. KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA, USA. 2002. KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophrenia Research2002;53(3 Suppl.1):191. [MEDLINE: 96173072; PMID 11580001] Kollack‐WalkerS , KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophrenia Research2003;60:359. [PsycINFO 2003‐06156‐011; PMID 12765745] ">Kinon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine with different timings of dose‐reduction periods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0094" title="LevineJ , SchoolerNR , SevereJ , EscobarJ , GelenbergA , MandelM , et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Advances in Biochemical Psychopharmacology1980;24:483‐93. ">Levine 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine withdrawal vs continuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0100" title="MarderSR , VanPuttenT , MintzJ , LebellM , McKenzieJ , MayPRA . Low‐ and conventional‐dose maintenance therapy with fluphenazine decanoate: two‐year outcome. Archives of General Psychiatry1987;44:518‐21. MarderSR , VanPuttenT , MintzJ , McKenzieJ , LebellM , FalticoG , et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry1984;41:1025‐9. ">Marder 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐ vs conventional‐dose maintenance therapy with fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0105" title="NewcomerJW , RineySJ , VinogradovS , CsernanskyJG . Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease. Psychopharmacology Bulletin1992;28(1):101‐7. ">Newcomer 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol dose reduction vs maintained dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0125" title="SinghH , HuntJI , VitielloB , SimpsonGM . Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Journal of Clinical Psychiatry1990;51:319‐21. ">Singh 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abrupt neuroleptic cessation vs neuroleptic maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0145" title="ZengZX , LiZC , YuXW , ZhangYD , CaoZC . A double‐blind trial of flunarizine therapy for tardive dyskinesia. Chinese Journal of Pharmaco Epidemiology1994;3(4):183‐4. ">Zeng 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flunarizine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcium channel blockers for neuroleptic‐induced tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0080" title="JesteDV , OlgiatiSG , GhaliAY . Masking of tardive dyskinesia with four times‐a‐day administration of chlorpromazine. Diseases of the Nervous System1977;38(9):755‐8. ">Jeste 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorpromazine schedule A vs chlorpromazine schedule B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorpromazine timing of dose for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0104" title="GerlachJ . Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale1988;XIV:227‐32. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology1986;90(4):423‐9. PovlsenUJ , NoringU , MeidahlB , KorsgaardS , WaehrensJ , GerlachJ . [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger1987;149(25):1682‐5. ">NDSG 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorprothixene vs haloperidol vs perphenazine vs haloperidol + biperiden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorprothixene for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0017" title="AndiaI , ZumarragaM , ZabaloMJ , BulbenaA , DavilaR . Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia. Biological Psychiatry1998;43:20‐3. ">Andia 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clozapine versus haloperidol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0062" title="GerlachJ , ThorsenK , FogR . Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia1975;40(4):341‐50. ">Gerlach 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0022" title="BitterI , SlabberM , PretoriusJ , BartkoGY , DanicsZ , DossenbachM , et al. Olanzapine versus clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S141. ">Bitter 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clozapine versus olanzapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0079" title="Jean‐NoelB , WoodAJ , KieslerGM , BirkettM , TollefsonGD . Olanzapine vs. clozapine: an international double blind study in the treatment of resistant schizophrenia. 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999; Vol. 2:143. ">Jean‐Noel 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0031" title="CaineED , PolinskyRJ , KartzinelR , EbertMH . The trial use of clozapine for abnormal involuntary movement disorders. American Journal of Psychiatry1979;136:317‐20. ">Caine 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gilles de la Tourette's, Huntington's disease and drug‐induced atypical dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine versus placebo for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0043" title="ChouinardG , VainerJL , BelangerMC , TurnierL , BeaudryP , RoyJY , et al. Risperidone and clozapine in the treatment of drug‐resistant schizophrenia and neuroleptic‐induced supersensitivity psychosis. Progress in Neuro‐psychopharmacology &amp; Biological Psychiatry1994;18(7):1129‐41. ">Chouinard 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine versus risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine versus risperidone for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0042" title="ChouinardG , AnnableL , CampbellW . A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of Clinical Psychopharmacology1989;9(4):247‐53. ">Chouinard 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol decanoate vs fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Depot fluphenazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0045" title="CooksonJC . Side effects during long‐term treatment with depot antipsychotic medication. Clinical Neuropharmacology1991;14(Suppl 2):S24‐32. ">Cookson 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs haloperidol decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0052" title="CursonDA , BarnesTR , BamberRW , PlattSD , HirschSR , DuffyJC . Long term depot maintenance of chronic schizophrenic out patients: the seven year follow up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side effects, neurotic symptoms and depression. British Journal of Psychiatry1985;146:469‐74. ">Curson 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0101" title="McCreadieRG , DingwallJM , WilesDH , HeykantsJJ . Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1980;137(6):510‐7. ">McCreadie 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs intermittent pimozide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0107" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry1982;43:195‐6. ">Odejide 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs vitamin B complex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0040" title="ChouinardG , AnnableL , KropskyM . A double‐blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Pharmacology1978;18(2‐3):148‐54. ">Chouinard 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine ethanoate vs pipothiazine palmitate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0042" title="ChouinardG , AnnableL , CampbellW . A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of Clinical Psychopharmacology1989;9(4):247‐53. ">Chouinard 1989</a>, <a href="./references#CD000459-bbs2-0045" title="CooksonJC . Side effects during long‐term treatment with depot antipsychotic medication. Clinical Neuropharmacology1991;14(Suppl 2):S24‐32. ">Cookson 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol decanoate vs fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depot haloperidol decanoate for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0040" title="ChouinardG , AnnableL , KropskyM . A double‐blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Pharmacology1978;18(2‐3):148‐54. ">Chouinard 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine ethanoate vs pipothiazine palmitate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depot pipothiazine for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0028" title="BurnerM , GirouxC , L'HeritierC , GarreauM , MorselliPL . Preliminary observations on the therapeutic action of progabide in tardive dyskinesia. Brain Dysfunction1989;2(6):289‐96. [MEDLINE: 87273387; PMID 2886223] ">Burner 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progabide vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GABA for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0021" title="BatemanDN , DuttaDK , McClellandHA , RawlinsMD . The effect of metoclopramide and haloperidol on tardive dyskinesia. British Journal of Pharmacology1979;66(3):475‐6. ">Bateman 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia and psychiatric history</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metoclopramide (10 mg, 20 mg or 40 mg) vs haloperidol (5 mg or 10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperdiol dose for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0136" title="TranPV , DellvaMA , TollefsonGD , BeasleyCMJr , PotvinJH , KieslerGM . Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of clinical psychiatry1997; Vol. 58, issue 5:205‐11. ">Tran 1997</a>, <a href="./references#CD000459-bbs2-0118" title="RosenheckR , PerlickD , BinghamS , Liu‐MaresW , CollinsJ , WarrenS , et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA2003;290(20):2693‐702. ">Rosenheck 2003</a>, <a href="./references#CD000459-bbs2-0135" title="BeasleyCM , DellvaMA , TamuraRN , MorgensternH , GlazerWM , FergusonK , et al. A randomised double‐blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long‐term treatment with olanzapine or haloperidol. British Journal of Psychiatry1999;174:23‐30. TamuraRN , TollefsonGD , DellvaMA , BeasleyCM , GlazerWM , MorgensternH . What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?. Schizophrenia Research1998;29:176. TollefsonGD , BeasleyCM , TamuraRN , TranPV , PotvinJH . Blind, controlled, long term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry1997;154:1248‐54. ">Tollefson 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs olanzapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0104" title="GerlachJ . Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale1988;XIV:227‐32. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology1986;90(4):423‐9. PovlsenUJ , NoringU , MeidahlB , KorsgaardS , WaehrensJ , GerlachJ . [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger1987;149(25):1682‐5. ">NDSG 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorprothixene vs haloperidol vs perphenazine vs haloperidol + biperiden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs perphenazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0090" title="KopalaL , RabinowitzJ , EmsleyR , McGorryP . Extra‐pyramidal signs and symptoms (EPS) in recent onset schizophrenia: a comparison of risperidone and haloperidol. Schizophrenia Research2004;67(1):187. ">Kopala 2004</a>, <a href="./references#CD000459-bbs2-0139" title="WirshingDA , MarshallBDJr , GreenMF , MintzJ , MarderSR , WirshingWC . Risperidone in treatment‐refractory schizophrenia. American Journal of Psychiatry1999;156(9):1374‐9. ">Wirshing 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="21" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs risperidone for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0084" title="JolleyAG , HirschSR , McRinkA , ManchandaR . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ1989;298(6679):985‐90. JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301(6756):837‐42. ">Jolley 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brief intermittent antipsychotic treatment vs fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Intermittent antipsychotic treatment for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0101" title="McCreadieRG , DingwallJM , WilesDH , HeykantsJJ . Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1980;137(6):510‐7. ">McCreadie 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs intermittent pimozide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0106" title="NewtonJE , CannonDJ , CouchL , FodyEP , McMillanDE , MetzerWS , et al. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. Journal of Clinical Psychiatry1989;50:132‐5. ">Newton 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol with 'drug holiday' vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0069" title="GoldbergSC , ShenoyRS , SadlerA , HamerR , RossB . The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics. Psychopharmacology Bulletin1981;17(1):116‐7. [MEDLINE: 81200009; PMID 7232638] ShenoyRS , SadlerAG , GoldbergSC , HamerRM , RossB . Effects of a six‐week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology1981;1(3):141‐5. ">Goldberg 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal of fluphenazine decanoate vs continuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0099" title="MacKayAV , SheppardGP , SahaBK , MotleyB , JohnsonA , MarsdenCD . Failure of lithium treatment in established tardive dyskinesia. Psychological Medicine1980;10(3):583‐7. ">MacKay 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithium vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithium for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0024" title="BorisonRL , ShahC , WhiteTH , DiamondBI . Atypical and typical neuroleptics and tardive dyskinesia. Psychopharmacology Bulletin1987;23(1):218‐20. ">Borison 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Molidone vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Molidone vs haloperidol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0138" title="WilliamsonDJ , TranPV , BeasleyCM , TollefsonGD , SangerT , SatterleeWG . Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Journal of Psychopharmacology1995;9:A47. ">Williamson 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine 1 mg vs olanzapine 10 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine dose for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0054" title="deJesus MariJ , LimaMS , CostaAN , AlexandrinoN , Rodrigues‐FilhoS , deOliveiraIR , et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. European Archives of Psychiatry and Clinical Neuroscience2004;254(6):356‐61. [DOI: 10.1007/s00406‐004‐0514‐1] ">de Jesus Mari 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine vs "conventional antipsychotic drugs"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Olanzapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0111" title="PelusoMJ , LewisSW , BarnesTRE , JonesPB . Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. British Journal of Psychiatry2012;200(5):387‐92. ">Peluso 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First‐generation antipsychotic vs second‐generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0088" title="KinonB , StaufferVL , WangL , ThiKT , Kollack‐WalkerS . Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study. International Journal of Neuropsychopharmacology. Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum2002;5(Suppl 1):S165. KinonBJ , JesteDV , Kollack‐WalkerS , StaufferV , Liu‐SeifertH . Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Progress in neuro‐psychopharmacology &amp; biological psychiatry2004;28(6):985‐96. KinonBJ , StaufferVL , WangL , ThiK , NiewoehnerJ , Kollack‐WalkerS . Olanzapine improves dyskinesia in patients with schizophrenia. International Congress on Schizophrenia Research (ICSR) March 29‐April 2, 2003, Colorado Springs, Colorado. 2003. KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA, USA. 2002. KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophrenia Research2002;53(3 Suppl.1):191. [MEDLINE: 96173072; PMID 11580001] Kollack‐WalkerS , KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophrenia Research2003;60:359. [PsycINFO 2003‐06156‐011; PMID 12765745] ">Kinon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine with different timings of dose reduction periods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine reduction for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0111" title="PelusoMJ , LewisSW , BarnesTRE , JonesPB . Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. British Journal of Psychiatry2012;200(5):387‐92. ">Peluso 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First‐generation antipsychotic versus second‐generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine vs other atypical antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0138" title="WilliamsonDJ , TranPV , BeasleyCM , TollefsonGD , SangerT , SatterleeWG . Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Journal of Psychopharmacology1995;9:A47. ">Williamson 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine 1 mg vs olanzapine 10 mg vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine vs placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0111" title="PelusoMJ , LewisSW , BarnesTRE , JonesPB . Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. British Journal of Psychiatry2012;200(5):387‐92. ">Peluso 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First‐generation antipsychotic vs second‐generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perphenazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0101" title="McCreadieRG , DingwallJM , WilesDH , HeykantsJJ . Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1980;137(6):510‐7. ">McCreadie 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs intermittent pimozide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pimozide for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0046" title="CorteseL , CaligiuriMP , WilliamsR , SchieldropP , ManchandaR , MallaA , et al. Reduction in neuroleptic‐induced movement disorders after a switch to quetiapine in patients with schizophrenia. Journal of Clinical Psychopharmacology2008;28(1):69‐73. ">Cortese 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quetiapine vs continuation of usual antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quetiapine vs continuation of usual antipsychotic for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD000459-bbs2-0111" title="PelusoMJ , LewisSW , BarnesTRE , JonesPB . Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. British Journal of Psychiatry2012;200(5):387‐92. ">Peluso 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>First generation antipsychotic vs second‐generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quetiapine vs other atypical antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quetiapine vs typical antipsychotic medications for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone vs olanzapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone vs other atypical antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0046" title="CorteseL , CaligiuriMP , WilliamsR , SchieldropP , ManchandaR , MallaA , et al. Reduction in neuroleptic‐induced movement disorders after a switch to quetiapine in patients with schizophrenia. Journal of Clinical Psychopharmacology2008;28(1):69‐73. ">Cortese 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quetiapine vs continuation of usual antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching antipsychotic for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0124" title="SingerK , ChengMN . Thiopropazate hydrochloride (Dartalan) in persistent dyskinesia with phenothiazine therapy. 5th World Congress of Psychiatry; 1971 Nov 28 ‐ Dec 4; Ciudad de Mexico, Mexico. 1971:528. [MEDLINE: 79081577; PMID 215095] SingerK , ChengMN . Thiopropazate hydrochloride in persistent dyskinesia. British Medical Journal1971;4:22‐5. ">Singer 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiopropazate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiopropazate for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD000459-bbs2-0091" title="LalS , EttigiP . Comparison of thiopropazate and trifluoperazine on oral dyskinesia ‐ a double blind study. Current Therapeutic Research, Clinical and Experimental1974;16(9):990‐7. ">Lal 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thiopropazine vs trifluoperazine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiopropazine vs placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiopropazine vs trifluoperazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD000459-bbs2-0055" title="DelwaidePJ , DesseillesM . Controlled therapeutic study of spontaneous bucco‐linguo‐facial dyskinesias [Etude therapeutique controlee des dyskinesies bucco‐linguo‐faciales spontanees]. Semaine des Hopitaux1979;55(35‐6):1585‐9. [MEDLINE: 97392141; PMID 9248874] ">Delwaide 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thioproperazine and tiapride vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thioproperazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tiapride for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0029" title="BurumaOJ , RoosRA , BruynGW , KempB , Van derVeldeEA . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989; PMID 6121443] ">Buruma 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiapride vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD000459-bbs2-0050" title="CraneGH . High doses of trifluperazine and tardive dyskinesia. Archives of Neurology1970;22(2):176‐80. ">Crane 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trifluoperazine high‐dose vs trifluoperazine low‐dose vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trifluoperazine dose for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trifluoperazine vs placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0091" title="LalS , EttigiP . Comparison of thiopropazate and trifluoperazine on oral dyskinesia ‐ a double blind study. Current Therapeutic Research, Clinical and Experimental1974;16(9):990‐7. ">Lal 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiopropazine vs trifluoperazine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0107" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry1982;43:195‐6. ">Odejide 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs vitamin B complex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamins for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0111" title="PelusoMJ , LewisSW , BarnesTRE , JonesPB . Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. British Journal of Psychiatry2012;200(5):387‐92. ">Peluso 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First‐generation antipsychotic vs second‐generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ziprasidone vs other atypical antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> </div> </section> <section id="CD000459-sec-0239"> <h6 class="title">2.2 Trials</h6> <p>There is a need to assess the utility of second‐generation antipsychotics in the management of established TD. The recent literature highlights the finding that TD can be found in people with schizophrenia who have never been treated, thus challenging basic assumptions about the causality of TD (<a href="./references#CD000459-bbs2-0238" title="WaddingtonJL , CrowTJ . Abnormal involuntary movements and psychosis in the preneuroleptic era and in unmedicated patients: implications for the concept of tardive dyskinesia. In: WolfME , MosnaimAD editor(s). Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. Washington DC: American Psychiatric Press, 1988. ">Waddington 1988</a>). Research is required to differentiate underlying vulnerability to movement disorders (that may be part of a latent trait underlying schizophrenia and TD) from that proportion of TD causally related to antipsychotic use. Research is required that can separate out the variable trajectory inherent in young and midlife‐onset TD from the impact of traditional and 'atypical' antipsychotics. </p> <p>Well‐designed RCTs, involving a large number of participants over protracted periods of time, are needed if we are to see what role antipsychotics could have in prevention and treatment of TD. Such studies are of importance to people with the problem (<a href="#CD000459-fig-0001">Figure 1</a>) and have long been ignored. </p> <section id="CD000459-sec-0240"> <p><b>2.2.1 Use of cross‐over design</b></p> <p>Trialists find it difficult to identify people with both TD and schizophrenia to participate in trials (<a href="./references#CD000459-bbs2-0223" title="SchmidtM , MeisterP , BaumannP . Treatment of tardive dyskinesias with vitamin E. European Psychiatry1991;6:201‐7. ">Schmidt 1991</a>). Randomised, cross‐over design is used in the hope of improving the power of the study to find outcomes of interest. This design initially asks participants to be randomised to one of the experimental interventions, and then, at a pre‐specified time, to be crossed over to the treatment that they did not at first receive. Conditions with a more stable time course than TD are better suited for cross‐over studies (<a href="./references#CD000459-bbs2-0184" title="FleissJL . The crossover study. The Design and Analysis of Clinical Experiments. Chichester: John Wiley &amp; Sons, 1984. ">Fleiss 1984</a>). Further difficulties are related to the carry‐over effect. Unless cross‐over studies include a mid‐study washout period (where the person is free of treatment before starting the next arm of the study), any effect of the first intervention may continue into the second half placebo arm of the trial – the 'carry‐over effect'. Also, carry‐over may involve the re‐growth or retreat of neuroreceptors. This slow re‐balancing, if started, could continue long after all traces of intervention drugs are gone, so physiological half‐life of the experimental treatment may not be the only variable to consider when thinking though the issues of carry‐over. TD is also an unstable condition and people with TD may not remain compliant with medication. All these factors make the arguments for not using cross‐over methodology strong, despite the initial attraction (<a href="./references#CD000459-bbs2-0150" title="ArmitageP . Should we cross off the crossover?. Journal of Clinical Pharmacology1991;32:1‐2. ">Armitage 1991</a>; <a href="./references#CD000459-bbs2-0184" title="FleissJL . The crossover study. The Design and Analysis of Clinical Experiments. Chichester: John Wiley &amp; Sons, 1984. ">Fleiss 1984</a>; <a href="./references#CD000459-bbs2-0221" title="PocockSJ . Crossover trials. Clinical trials. A practical approach. Chichester: John Wiley &amp; Sons, 1983. ">Pocock 1983</a>). </p> </section> <section id="CD000459-sec-0241"> <p><b>2.2.2 Length of study</b></p> <p>Only five studies included in this review (<a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>; <a href="./references#CD000459-bbs2-0007" title="EmsleyR , TurnerHJ , SchronenJ , BothaK , SmitR , OosthuizenPP . A single‐blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry2004;65(5):696‐701. [MEDLINE: 15163258] EmsleyRA , TurnerJ , SchronenJ , BothaK , SmitR , OosthuizenPP . Quetiapine: greater improvements in tardive dyskinesia versus haloperidol. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, USA. 2004. [APA Conference Abstracts NR574] ">Emsley 2004</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>; <a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a>) used the intervention for more than six months. TD, however, is a chronic condition of insidious onset, the severity of which fluctuates spontaneously (<a href="./references#CD000459-bbs2-0149" title="American Psychiatry Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC, 1992. ">APA 1992</a>). Another problem in TD research is that spontaneous, age‐related, non‐neuroleptic‐induced dyskinesias occur in people with schizophrenia (<a href="./references#CD000459-bbs2-0182" title="FentonWS . Prevalence of spontaneous dyskinesia in schizophrenia. Journal of Clinical Psychiatry2000;61(suppl 4):10‐14. ">Fenton 2000</a>). The spontaneous dyskinetic movements are more prevalent in older age and appear identical to the movements of antipsychotic‐induced tardive dyskinesia (<a href="./references#CD000459-bbs2-0182" title="FentonWS . Prevalence of spontaneous dyskinesia in schizophrenia. Journal of Clinical Psychiatry2000;61(suppl 4):10‐14. ">Fenton 2000</a>). In addition, since reducing or switching antipsychotic may have a swift but reversible effect (<a href="./references#CD000459-bbs2-0167" title="CavallaroR , RegazzettiMG , MundoE , BrancatoV , SmeraldiE . Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence. Neuropsychopharmacology1993;8(3):233‐9. ">Cavallaro 1993</a>; <a href="./references#CD000459-bbs2-0229" title="SmithJM , BalessariniRJ . Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry1980;37:1368‐73. ">Smith 1980</a>), it is the long‐term outcomes that must be considered of most clinical value. </p> </section> <section id="CD000459-sec-0242"> <p><b>2.2.3 Outcomes</b></p> <p>Scale‐derived data do have their place. Trials most commonly used the AIMS scale. This is a very widely applied tool utilised to measure the severity of symptoms of those who have TD. The use of this scale to measure change as a result of treatment is, however, problematic (<a href="./references#CD000459-bbs2-0156" title="BergenJA , GriffithsDA , ReyJM , BeumontPJV . Tardive dyskinesia: fluctuating patient or fluctuating rater. British Journal of Psychiatry1984;144:498‐502. ">Bergen 1984</a>). It is therefore important that a scale is validated for measuring changes secondary to treatment in those with TD. In addition, many of the outcomes we initially desired when we started this review have not been investigated. Finally, a service user consultation also informed the addition of outcomes of special importance to patients. We have reconsidered all these outcomes in case they were too ambitious and tried to tailor them to a real‐world pragmatic trial design (see <a href="#CD000459-tbl-0007">Table 3</a>). </p> <div class="table" id="CD000459-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggestions for design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, with sequence generation and concealment of allocation clearly described<br/> Blindness: double, tested<br/> Duration: 12 months beyond end of intervention at least<br/> Raters: independent </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with antipsychotic‐induced tardive dyskinesia<sup>a</sup><br/> Age: any<br/> Sex: both<br/> History: any<br/> N = 300<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Antipsychotic reduction/cessation (N = 150) vs antipsychotic maintenance (N = 150)</p> <p>OR</p> <p>2. Specific antipsychotic (N = 150) vs other specific antipsychotic (N = 150)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tardive dyskinesia: any clinically important improvement in tardive dyskinesia, any improvement, deterioration<sup>c</sup><br/> Adverse effects: no clinically significant extrapyramidal adverse effects ‐ any time period<sup>c</sup>, use of any antiparkinsonism drugs, other important adverse events<br/> Leaving the study early<br/> Service outcomes: admitted, number of admissions, length of hospitalisation, contacts with psychiatric services<br/> Compliance with drugs<br/> Economic evaluations: cost‐effectiveness, cost‐benefit<br/> General state: relapse, frequency and intensity of minor and major exacerbations<br/> Social confidence, social inclusion, social networks, or personalised quality of life: binary measure<br/> Distress among relatives: binary measure<br/> Burden on family: binary measure </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>a</sup>This could be diagnosed by clinical decision. If funds were permitting all participants could be screened using operational criteria, otherwise a random sample should suffice. </p> <p><sup>b</sup>Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.<br/> <sup>c</sup>Primary outcome. The same applies to the measure of primary outcome as for diagnosis. Not everyone may need to have operational criteria applied if clinical impression is proved to be accurate. </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000459-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000459-sec-0022"></div> <div class="table" id="CD000459-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Reduced dose of antipsychotics compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Reduced dose of antipsychotic compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychiatric patients (schizophrenia or schizoaffective disorder) with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients and outpatients in the UK (1 study) and the USA (1 study)<br/> <b>Intervention</b> : Reduced dose of antipsychotic<br/> <b>Comparison:</b> Antipsychotic maintenance </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antipsychotic maintenance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with reduced dose of antipsychotic</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: no clinically important improvement<br/> Follow‐up: 44‐48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.42<br/> (0.17 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>875 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1000<br/> (149 to 910) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: deterioration of symptoms<br/> Follow‐up: 44‐48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.61<br/> (0.11 to 3.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000<br/> (28 to 828) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>General mental state: relapse<br/> Follow‐up: 44‐48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.00<br/> (0.16 to 57.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effect: any ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effect: extrapyramidal symptoms ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acceptability of the treatment: leaving the study early<br/> Follow‐up: 44‐48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.06 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000<br/> (45 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for risk of bias: none of the studies adequately described allocation concealment, one study was a subsample from one site of an RCT, and one study's baseline characteristics were not balanced between study groups.<br/> <sup>2</sup>Downgraded two levels for imprecision: 95% CI includes both no effect and appreciable benefit for antipsychotic reduced dose; very small sample size.<br/> <sup>3</sup>Downgraded one level for risk of bias: allocation concealment was not adequately described, only a subsample from one site of an RCT qualified for inclusion.<br/> <sup>4</sup>Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000459-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antipsychotic cessation compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antipsychotic cessation compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> psychiatric patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients and outpatients in any country<br/> <b>Intervention:</b> Antipsychotic cessation<br/> <b>Comparison:</b> Antipsychotic maintenance </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antipsychotic maintenance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antipsychotic cessation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>There is no evidence about the effects of withdrawal of antipsychotics compared with continuation of antipsychotics; none of the included studies evaluated this comparison. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD000459-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Switch to another antipsychotic compared with antipsychotic cessation for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Switch to another antipsychotic compared with antipsychotic cessation for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients in Canada (1 study) and Taiwan (1 study)<br/> <b>Intervention:</b> Switch to another antipsychotic (risperidone, haloperidol)<br/> <b>Comparison:</b> Antipsychotic cessation (with placebo; from FGAs) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antipsychotic cessation (placebo)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with switch to another antipsychotic</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: no clinically important improvement<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.45<br/> (0.23 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>315 per 1000<br/> (161 to 623) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia: deterioration of symptoms ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General mental state: average endpoint score (BPRS, high = poor)<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general mental state average endpoint score (BPRS, high = poor) was 19</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.30 lower<br/> (10.48 lower to 1.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effect: any ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: use of antiparkinsonism drugs<br/> Follow‐up: 8‐12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.08<br/> (0.74 to 5.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>48<br/> (1 RCT) <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Another study reported ESRS scale data for parkinsonism and also found little or no difference between groups (MD ‐0.4 95% CI ‐1.25 to 0.45, 42 participants). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>567 per 1000<br/> (202 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acceptability of the treatment: leaving the study early<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/> (0.16 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000<br/> (32 to 450) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FGA:</b> first‐generation antipsychotic; <b>MD</b> : mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for risk of bias: generation of random sequence and allocation concealment not adequately described.<br/> <sup>2</sup> Downgraded one level for imprecision: very small sample size.<br/> <sup>3</sup> Downgraded two levels for imprecision: 95% CI includes appreciable benefit for both interventions as well as no effect; very small sample size.<br/> <sup>4</sup> Two comparisons from one study.<br/> <sup>5</sup> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000459-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Switch to a specific antipsychotic compared with switch to a different specific antipsychotic for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Switch to specific antipsychotic compared with switch to a different specific antipsychotic for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychiatric patients (mainly schizophrenia) with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients and outpatients in Canada (1 study), Denmark and Finland (1 study), South Africa (1 study), Taiwan (2 studies) and the USA (5 studies)<br/> <b>Interventions:</b> switch to specific antipsychotic (amisulpride, clozapine, haloperidol, molindone, olanzapine, risperidone, thiopropazate, quetiapine, ziprasidone, zuclopenthixol) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with specific antipsychotic 1</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with specific antipsychotic 2</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: no clinically important improvement</p> <p>Follow‐up: 3‐50 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>140<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No meta‐analysis, studies stratified by antipsychotic. The following comparisons found no clinically important improvement: THI vs HAL, ZUC vs HAL, OLZ vs RIS, QUE vs HAL </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: deterioration</p> <p>Follow‐up: 3‐4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No meta‐analysis, studies stratified by antipsychotic. The following comparisons found no difference in deterioration: THI vs HAL, ZUC vs HAL </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>General mental state: deterioration</p> <p>Follow‐up: 3‐50 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>120<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No meta‐analysis, studies stratified by antipsychotic. The following comparisons found no difference in mental state deterioration: ZUC vs HAL, OLZ vs RIS, QUE vs HAL </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: extrapyramidal symptoms (need of antiparkinsonism drugs)</p> <p>Follow‐up: 8‐50 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>53<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No meta‐analysis, studies stratified by antipsychotic. HAL more likely to need antiparkinsonism drugs than QUE (1 RCT, 45 participants, RR 0.45, 95% CI 0.21 to 0.96). No difference: RIS vs HAL </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: general adverse events (UKU Average change score)</p> <p>Follow‐up: 24 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No meta‐analysis, 3‐arm study comparing OLZ, ASP and unspecified FGAs found no difference in general adverse events for all pairwise comparisons. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acceptability of the treatment: leaving the study early</p> <p>Follow‐up: 2 weeks ‐ 18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>466<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RIS more likely to leave study early than OLZ (2 RCTs, 130 participants, RR 0.73, 95% CI 0.57 to 0.95). Remaining studies no meta‐analysis, no difference (6 RCTs, 450 participants): MOL/THI/CLO/QUE vs HAL, OLZ/ASP vs unspecified FGAs, OLZ vs QUE/ZIP, QUE vs ZIP/RIS, ZIP vs RIS </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>ASP:</b> amisulpride; <b>CI:</b> confidence interval; <b>CLO:</b> clozapine; <b>FGA:</b> first‐generation anti‐psychotic; <b>HAL:</b> haloperidol; <b>MOL:</b> molindone; <b>OLZ:</b> olanzapine; <b>RCT:</b> randomised controlled trial; <b>RIS:</b> risperidone; <b>RR:</b> risk ratio; <b>THI:</b> thiopropazate; <b>QUE:</b> quetiapine; <b>ZIP:</b> ziprasidone; <b>ZUC:</b> zuclopenthixol </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one step for risk of bias: randomisation procedure, allocation concealment or blinding were not adequately described.<br/> <sup>2</sup>Downgraded two steps for imprecision: small sample size, and 95% CI includes appreciable benefit for both or one of the interventions as well as no effect.<br/> <sup>3</sup>Downgraded one step for imprecision: small sample size.<br/> <sup>4</sup>Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000459-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Specific antipsychotic compared with other drugs for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Specific antipsychotic compared with other drugs for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychiatric patients (mainly schizophrenia) with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients in the USA (1 study)<br/> <b>Intervention</b> : specific antipsychotic (haloperidol)<br/> <b>Comparison</b>: other drugs (tetrabenazine) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tetrabenazine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with haloperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: not improved to a clinically important extent<br/> Follow‐up: 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.51 to 2.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>713 per 1000<br/> (340 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: deterioration of symptoms<br/> Follow‐up: 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.07 to 10.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000<br/> (12 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effect: any ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effect: extrapyramidal symptoms ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acceptability of the treatment: leaving the study early<br/> Follow‐up: 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.38<br/> (0.25 to 76.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one step for risk of bias: randomisation procedure, allocation concealment and blinding were not adequately described.<br/> <sup>2</sup>Downgraded two steps for imprecision: small sample size, and 95% CI includes appreciable benefit for both interventions.<br/> <sup>3</sup>Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000459-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000459-sec-0023"></div> <section id="CD000459-sec-0024"> <h3 class="title" id="CD000459-sec-0024">Description of the condition</h3> <p>Since the 1950s antipsychotic (neuroleptic) medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs can effectively control symptoms such as abnormal perceptions (hallucinations), disordered thinking, and fixed false beliefs (delusions). In addition, maintenance therapy with antipsychotic medication is associated with reduced risk of relapse (<a href="./references#CD000459-bbs2-0224" title="SchoolerNR , KeithSJ . Clinical research for the treatment of schizophrenia. Psychopharmacology Bulletin1993;29:431‐46. ">Schooler 1993</a>). Antipsychotic medication, however, has also been associated with a wide range of adverse effects, including movement disorders. The appearance of these disorders can be extremely disfiguring, compounds stigma, and is associated with poor compliance to antipsychotic treatment (<a href="./references#CD000459-bbs2-0154" title="BarnesTRE , EdwardsJG . The side‐effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: BarnesTRE editor(s). Antipsychotic drugs and their side‐effects. London: Academic Press/Harcourt Brace &amp; Company, 1993. ">Barnes 1993</a>; <a href="./references#CD000459-bbs2-0235" title="TarsyD , LunguC , BaldessariniRJ . Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbook of Clinical Neurology2011;100:601‐16. ">Tarsy 2011</a>). </p> <p>Tardive dyskinesia (TD) is one such iatrogenic movement disorder and it is characterised by abnormal repetitive and involuntary movements. The clinical features include: tongue protrusion, side‐to‐side or rotatory movement of the jaw, lip smacking, puckering and pursing, and rapid eye blinking (<a href="./references#CD000459-bbs2-0166" title="CaseyDE . Tardive dyskinesia and atypical antipsychotic drugs. Schizophrenia Research1999;35:S31‐S36. ">Casey 1999</a>). In some people rapid movements of the arms, legs, and trunk may also occur. TD is a chronic condition of insidious onset, the severity of which fluctuates spontaneously (<a href="./references#CD000459-bbs2-0149" title="American Psychiatry Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC, 1992. ">APA 1992</a>). Although the most frequent cause of TD is the use of antipsychotic medication, it is striking that dose reduction can lead to a temporary exacerbation in symptoms. Conversely, increasing the dose is often associated with a temporary remission (<a href="./references#CD000459-bbs2-0167" title="CavallaroR , RegazzettiMG , MundoE , BrancatoV , SmeraldiE . Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence. Neuropsychopharmacology1993;8(3):233‐9. ">Cavallaro 1993</a>; <a href="./references#CD000459-bbs2-0229" title="SmithJM , BalessariniRJ . Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry1980;37:1368‐73. ">Smith 1980</a>). </p> <p>The exact mechanisms of the pathophysiology of TD are unknown. Antipsychotic drugs block certain chemical receptor sites in the brain ‐ one of these is specific for dopamine (<a href="./references#CD000459-bbs2-0165" title="CaseyDE . Tardive dyskinesia: pathophysiology. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Casey 1994</a>). One hypothesis explaining the cause of antipsychotic‐induced TD is that chronic blockade of dopamine receptors in specific cells of the brain (neurones from the nigrostriatum) causes an overgrowth of these receptors (<a href="./references#CD000459-bbs2-0165" title="CaseyDE . Tardive dyskinesia: pathophysiology. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Casey 1994</a>). However, there is some suggestion that the chronic use of antipsychotics may also cause an abnormal production of highly active atoms and chemical groups (cytotoxic free radicals), which may damage specific cells in the brain. This, in turn, could be responsible for the appearance of TD (<a href="./references#CD000459-bbs2-0163" title="CadetJL , LohrJB . Possible involvement of free radical in neuroleptic‐induced movement disorders. Annals of the New York Academy of Sciences1989;570:176‐85. ">Cadet 1989</a>). This theory is supported by the persistent nature of the syndrome, once established. </p> <p>Studies on the natural history of TD have reported widely variable remission rates (1% to 62%) depending on patient age, psychiatric diagnosis, course of the psychiatric disorder, and duration of therapy (<a href="./references#CD000459-bbs2-0157" title="BergenJA , EylandEA , CampbellJA . The course of tardive dyskinesia in patients on long‐term neuroleptics. British Journal of Psychiatry1989;154:523‐8. ">Bergen 1989</a>; <a href="./references#CD000459-bbs2-0183" title="FernandezHH , KruppB , FriedmanJH . The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14‐year follow‐up. Neurology2001;56:805‐7. ">Fernandez 2001</a>; <a href="./references#CD000459-bbs2-0191" title="GlazerWM , MorgensternH , SchoolerN , BerkmanCS , MooreDC . Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. British Journal of Psychiatry1990;157:585‐92. ">Glazer 1990</a>). TD occurs in more than 20% of people that use first‐generation antipsychotic drugs (FGAs) continually for longer than three months (<a href="./references#CD000459-bbs2-0235" title="TarsyD , LunguC , BaldessariniRJ . Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbook of Clinical Neurology2011;100:601‐16. ">Tarsy 2011</a>). Every year 4% to 5% of adults and 25% to 30% of elderly people who continually use these drugs begin to show signs of TD (<a href="./references#CD000459-bbs2-0149" title="American Psychiatry Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC, 1992. ">APA 1992</a>; <a href="./references#CD000459-bbs2-0172" title="CorrellCU , LeuchtS , KaneJM . Lower risk for tardive dyskinesia associated with second‐generation antipsychotics: a systematic review of 1‐year studies. American Journal of Psychiatry2004;161(3):414‐25. ">Correll 2004</a>). Advancing age is a risk factor for both TD's prevalence and severity, with those who are under 60 years of age being three times more likely to spontaneously remit (<a href="./references#CD000459-bbs2-0229" title="SmithJM , BalessariniRJ . Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry1980;37:1368‐73. ">Smith 1980</a>). </p> <p>When the second‐generation antipsychotic drugs were introduced in the 1990s many hoped that they would not cause TD (<a href="./references#CD000459-bbs2-0215" title="MillerDD , EudiconeJM , PikalovA , KimE . Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. The Journal of Clinical Psychiatry2007;68(12):1901‐6. ">Miller 2007</a>; <a href="./references#CD000459-bbs2-0222" title="RosenheckRA . Evaluating the cost‐effectiveness of reduced tardive dyskinesia with second‐generation antipsychotics. British Journal of Psychiatry2007;191:238‐45. ">Rosenheck 2007</a>). Although the risk of developing TD with second‐generation antipsychotic drugs does seem to be reduced, TD risks have not been eliminated (<a href="./references#CD000459-bbs2-0215" title="MillerDD , EudiconeJM , PikalovA , KimE . Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. The Journal of Clinical Psychiatry2007;68(12):1901‐6. ">Miller 2007</a>; <a href="./references#CD000459-bbs2-0235" title="TarsyD , LunguC , BaldessariniRJ . Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbook of Clinical Neurology2011;100:601‐16. ">Tarsy 2011</a>). There is even some evidence to indicate that rates of TD do not differ at all between first‐ and second‐generation anti‐psychotic drugs (<a href="./references#CD000459-bbs2-0208" title="LeuchtS , KisslingW , DavisJM . Second‐generation antipsychotics for schizophrenia: can we resolve the conflict?. Psychological Medicine2009;39(10):1591‐602. ">Leucht 2009</a>; <a href="./references#CD000459-bbs2-0222" title="RosenheckRA . Evaluating the cost‐effectiveness of reduced tardive dyskinesia with second‐generation antipsychotics. British Journal of Psychiatry2007;191:238‐45. ">Rosenheck 2007</a>; <a href="./references#CD000459-bbs2-0239" title="WoodsSW , MorgensternH , SaksaJR , WalshBC , SullivanMC , MoneyR , et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. Journal of Clinical Psychiatry2010;71(4):463‐74. ">Woods 2010</a>). The large, definitive, US randomised trial of antipsychotic treatments for schizophrenia (CATIE), with a four‐year period of follow‐up, obtained an incidence rate of TD of around 17% (<a href="./references#CD000459-bbs2-0216" title="MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008;193(4):279‐88. ">Miller 2008</a>). Due to widespread use of second‐generation antipsychotic drugs, increased off‐label use, and an ageing population, the frequency of TD is likely to be higher than thought (<a href="./references#CD000459-bbs2-0171" title="CloudLJ , ZutshiD , FactorSA . Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics2014;11(1):166‐76. ">Cloud 2014</a>; <a href="./references#CD000459-bbs2-0211" title="MaherAR , TheodoreG . Summary of the comparative effectiveness review on off‐label use of atypical antipsychotics. Journal of Managed Care Pharmacy2012;18(5 Suppl B):S1‐20. ">Maher 2012</a>) and increasing. The problem will be considerably greater for people in countries where use of newer drugs is less prevalent (<a href="./references#CD000459-bbs2-0152" title="BallesterosJ , Gonzalez‐PintoA , BulbenaA . Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta‐analysis of seven independent studies. Journal of Clinical Psychopharmacology2000;20(2):188‐94. ">Ballesteros 2000</a>; <a href="./references#CD000459-bbs2-0214" title="MartinsES , RossoA , CoutinhoE , AdamsC , HufG . Prevalence of tardive dyskinesia and all‐cause mortality amongst patients in a large psychiatric institute in Rio de Janeiro. Revista de Psiquiatria Clínica2011;38:44. ">Martins 2011</a>). </p> </section> <section id="CD000459-sec-0025"> <h3 class="title" id="CD000459-sec-0025">Description of the intervention</h3> <p>Various strategies have been examined in order to reduce a person's cumulative exposure to antipsychotics. These strategies include dose reduction, intermittent dosing strategies, such as drug holidays, and antipsychotic cessation. The prevention and treatment of TD provided much of the impetus for these studies. While antipsychotic reduction or cessation, or both would seem to be a logical first step in the management of antipsychotic‐induced TD, this is not always possible in the clinical setting because of the overriding need to manage current psychotic symptoms or to reduce the risk of relapse, or both. In this review we undertook a comprehensive study of the impact of antipsychotic dose reduction and/or cessation strategies for those who were already presenting with TD. </p> <p>In the search for ways to manage antipsychotic‐induced TD, certain antipsychotic medications have themselves been proposed as specific treatments for the condition. The usual rationale for such trials relates to variations in receptor‐blocking profile that distinguishes the compound of interest from antipsychotics in general. </p> </section> <section id="CD000459-sec-0026"> <h3 class="title" id="CD000459-sec-0026">How the intervention might work</h3> <p>Although the pathophysiology of TD is not entirely clear, one of the possible underlying mechanisms is believed to be hypersensitivity of postsynaptic dopamine receptors (<a href="./references#CD000459-bbs2-0212" title="MargoleseHC , ChouinardG , KolivakisTT , BeauclairL , MillerR . Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie2005;50(9):541‐7. ">Margolese 2005</a>). The risk appears to increase with higher cumulative exposure to antipsychotics, especially those with stronger D2 dopamine receptor blockade. Newer antipsychotic medications, which cause less dopamine D2 blockade, have been shown to cause less TD (<a href="./references#CD000459-bbs2-0172" title="CorrellCU , LeuchtS , KaneJM . Lower risk for tardive dyskinesia associated with second‐generation antipsychotics: a systematic review of 1‐year studies. American Journal of Psychiatry2004;161(3):414‐25. ">Correll 2004</a>). The primary intervention of interest (reduction/cessation of antipsychotics), is likely to help by reducing the cumulative exposure to antipsychotics. The other intervention (specific antipsychotics) is likely to work as a result of the reduction in the levels of dopamine D2 receptor blockade, a characteristic property of many of the newer antipsychotic medications. </p> </section> <section id="CD000459-sec-0027"> <h3 class="title" id="CD000459-sec-0027">Why it is important to do this review</h3> <p>TD can result in considerable social and physical disability (<a href="./references#CD000459-bbs2-0154" title="BarnesTRE , EdwardsJG . The side‐effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: BarnesTRE editor(s). Antipsychotic drugs and their side‐effects. London: Academic Press/Harcourt Brace &amp; Company, 1993. ">Barnes 1993</a>) and symptoms are often irreversible (<a href="./references#CD000459-bbs2-0157" title="BergenJA , EylandEA , CampbellJA . The course of tardive dyskinesia in patients on long‐term neuroleptics. British Journal of Psychiatry1989;154:523‐8. ">Bergen 1989</a>; <a href="./references#CD000459-bbs2-0183" title="FernandezHH , KruppB , FriedmanJH . The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14‐year follow‐up. Neurology2001;56:805‐7. ">Fernandez 2001</a>; <a href="./references#CD000459-bbs2-0188" title="GerlachJ , CaseyDE . Tardive dyskinesia. Acta Psychiatrica Scandinavica1988;77:369‐78. ">Gerlach 1988</a>; <a href="./references#CD000459-bbs2-0191" title="GlazerWM , MorgensternH , SchoolerN , BerkmanCS , MooreDC . Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. British Journal of Psychiatry1990;157:585‐92. ">Glazer 1990</a>). Additionally, TD is frequently associated with lower quality of life (<a href="./references#CD000459-bbs2-0151" title="Ascher‐SvanumH , ZhuB , FariesD , PengX , KinonBJ , TohenM . Tardive dyskinesia and the 3‐year course of schizophrenia: results from a large, prospective, naturalistic study. Journal of Clinical Psychiatry2008;69(10):1580‐8. ">Ascher‐Svanum 2008</a>) and a greater mortality rate (<a href="./references#CD000459-bbs2-0168" title="ChongSA , TayJA , SubramaniamM , PekE , MachinD . Mortality rates among patients with schizophrenia and tardive dyskinesia. Journal of Clinoca; Psychopharmacology2009;29:5‐8. ">Chong 2009</a>). Several antipsychotic medications have been produced in recent decades that claim to cause less or no TD (<a href="./references#CD000459-bbs2-0209" title="LiebermanJA , FleishhackerW . Introduction. British Journal of Psychiatry1996;168(Supplement 29):7‐8. ">Lieberman 1996</a>). These claims may or may not be true, and certainly evidence does suggest that thoughtful use of older generation drugs is not associated with more TD than newer treatments (<a href="./references#CD000459-bbs2-0170" title="ChouinardG , ChouinardVA . Atypical antipsychotics: CATIE study, drug‐induced movement disorder and resulting iatrogenic psychiatric‐like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics2008;77(2):69‐77. ">Chouinard 2008</a>). However, in a global context, it is likely that the less expensive and more familiar drugs ‐ such as chlorpromazine or haloperidol ‐ will continue to be the mainstay of treatment of people with schizophrenia (<a href="http://www.who.int/medicines/publications/essentialmedicines/Updated_sixteenth_adult_list_en.pdf" target="_blank">WHO Essential List 2010</a>). Use of drugs such as these is associated with emergence of TD and, therefore, this condition will remain a problem for years to come. </p> <p>Given the high incidence and prevalence of TD among people taking antipsychotic medication, the need for prevention or treatment is clear. Unfortunately, there has been sparse evidence to guide clinicians (<a href="./references#CD000459-bbs2-0219" title="NICE . Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178 (guidance.nice.org.uk/cg178)2014. ">NICE 2014</a>; <a href="./references#CD000459-bbs2-0236" title="TaylorD , PatonC , KapurS . The Maudsley Prescribing Guidelines (10th Edition). London: Informa Healthcare, 2009. ">Taylor 2009</a>). Although many treatments have been tested, no one intervention has been shown clearly to be effective. </p> <p>This review is one in a series of Cochrane Reviews (see <a href="#CD000459-tbl-0012">Table 1</a>) evaluating treatments for antipsychotic‐induced TD, and is an update of a Cochrane Review first published in 1998 (<a href="./references#CD000459-bbs2-0241" title="McGrathJJ , Soares‐WeiserKVS . Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000459] ">McGrath 1998</a>), and previously updated in 2000 (<a href="./references#CD000459-bbs2-0242" title="McGrathJ , SoaresK . Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000459.pub2] ">McGrath 2000</a>) and in 2006 (<a href="./references#CD000459-bbs2-0243" title="Soares‐WeiserK , RathboneJ . Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000459.pub2] ">Soares‐Weiser 2006</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000459-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000459-sec-0028"></div> <p>To determine whether a reduction or cessation of antipsychotic drugs is associated with a reduction in TD for people with schizophrenia (or other chronic mental illnesses) who have existing TD. Our secondary objective was to determine whether the use of specific antipsychotics for similar groups of people could be a treatment for already established TD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000459-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000459-sec-0029"></div> <section id="CD000459-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000459-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials. Had there been trials that were described as double‐blind, but that did not mention whether the study was randomised, we would have included them in a sensitivity analysis. If there had been no substantive difference within primary outcomes (see 'Types of outcome measures') when these studies were added, then we would have included them in the final analysis. If there had been a substantive difference, we would have used only clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi‐randomised studies, such as those allocating by using alternate days of the week. </p> </section> <section id="CD000459-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included people with schizophrenia or any other serious mental illness, diagnosed by any criteria, irrespective of gender, age, or nationality who required the use of antipsychotics for more than three months and who developed TD (diagnosed by any criteria) during antipsychotic treatment, and for whom the dose of antipsychotic medication had been stable for one month or more. We made a post hoc change to include studies that did not require antipsychotic medication to have been stable for one month prior to randomisation. We felt it important to include these studies as they provide additional important information. However, we planned to analyse these separately, so that they would not change existing outcome data. </p> </section> <section id="CD000459-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD000459-list-0001"> <li> <p>Reduction or cessation of the dose of antipsychotic drugs compared with the continuation of standard dose of the same compound. For the purposes of this review, we divided these trials into those that aimed to reduce the total dosage of antipsychotic medication, for example reduced‐dose and intermittent‐dosage schedule studies, and those that ceased antipsychotics (sometimes after variable periods of dose reduction). </p> </li> <li> <p>Specific antipsychotic drugs proposed to have TD‐lessening qualities compared with placebo or no intervention. We made a decision post hoc to broaden this criteria to also include antipsychotic versus antipsychotic and antipsychotic versus other drugs for the treatment of TD. </p> </li> </ol> </p> </section> <section id="CD000459-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>We have defined clinical efficacy as an improvement in the symptoms of TD of more than 50%, on any scale. We grouped outcomes into short term (less than six weeks), medium term (between six weeks and six months) and long term (more than six months). </p> <section id="CD000459-sec-0035"> <h5 class="title">Primary outcomes</h5> <section id="CD000459-sec-0036"> <h6 class="title">1. Tardive dyskinesia (TD) symptoms</h6> <p>No clinically important improvement in the symptoms of individuals, defined as more than 50% improvement on any TD scale ‐ any time period. </p> </section> <section id="CD000459-sec-0037"> <h6 class="title">2. Adverse effects</h6> <p>No clinically significant extrapyramidal adverse effects ‐ any time period.</p> </section> </section> <section id="CD000459-sec-0038"> <h5 class="title">Secondary outcomes</h5> <section id="CD000459-sec-0039"> <h6 class="title">1. Tardive dyskinesia (TD) symptoms</h6> <p>1.1 Any improvement in the symptoms of individuals on any TD scale, as opposed to no improvement<br/> 1.2 Deterioration in the symptoms of individuals, defined as any deleterious change on any TD scale<br/> 1.3 Average change in severity of TD during the trial period<br/> 1.4 Average difference in severity of TD at the end of the trial </p> </section> <section id="CD000459-sec-0040"> <h6 class="title">2. General mental state changes</h6> <p>2.1 The number of people per treatment group who were defined as relapsed (according to any definition)<br/> 2.2 Deterioration in general psychiatric symptoms (such as delusions and hallucinations) defined as any deleterious change on any scale<br/> 2.3 Average difference in severity of psychiatric symptoms at the end of the trial </p> </section> <section id="CD000459-sec-0041"> <h6 class="title">3. Acceptability of the treatment</h6> <p>3.1 Acceptability of the intervention to the participant group as measured by numbers of people leaving the study early (dropping out) during the trial. </p> </section> <section id="CD000459-sec-0042"> <h6 class="title">4. Adverse effects</h6> <p>4.1 The number of people per treatment group who had any adverse effect (other than deterioration of symptoms of TD or relapse).<br/> 4.2 Use of any antiparkinsonism drugs<br/> 4.3 Average score/change in extrapyramidal adverse effects<br/> 4.4 Acute dystonia </p> </section> <section id="CD000459-sec-0043"> <h6 class="title">5. Other adverse effects, general and specific</h6> </section> <section id="CD000459-sec-0044"> <h6 class="title">6. Hospital and service utilisation outcomes</h6> <p>6.1 Hospital admission<br/> 6.2 Average change in days in hospital<br/> 6.3 Improvement in hospital status (for example: change from formal to informal admission status, use of seclusion, level of observation) </p> </section> <section id="CD000459-sec-0045"> <h6 class="title">7. Economic outcomes</h6> <p>7.1 Average change in total cost of medical and mental health care<br/> 7.2 Total indirect and direct costs </p> </section> <section id="CD000459-sec-0046"> <h6 class="title">8. Social confidence, social inclusion, social networks, or personalised quality‐of‐life measures </h6> <p>8.1. No significant change in social confidence, social inclusion, social networks, or personalised quality‐of‐life measures<br/> 8.2 Average score/change in social confidence, social inclusion, social networks, or personalised quality‐of‐life measures </p> </section> <section id="CD000459-sec-0047"> <h6 class="title">9. Behaviour</h6> <p>9.1 Clinically significant agitation<br/> 9.2 Use of adjunctive medication for sedation<br/> 9.3 Aggression to self or others </p> </section> <section id="CD000459-sec-0048"> <h6 class="title">10. Cognitive state</h6> <p>10.1 No clinically important change<br/> 10.2 No change, general and specific </p> <p>In <a href="#CD000459-sec-0151">Effects of interventions</a> we reported on all TD symptom outcomes grouped together and all adverse effects outomes grouped together, whether or not they were primary or secondary, and we indicated primary outcomes with a '*'. </p> </section> <section id="CD000459-sec-0049"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD000459-bbs2-0225" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>) and used <a href="http://methods.cochrane.org/gradeing/gradepro-gdt" target="_blank">GRADEpro</a> to export data from this review to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from the included studies in the comparison, the magnitude of effects of interventions examined, and the sum of available data on all outcomes rated as important to patient care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table: </p> <p><b>1. Tardive dyskinesia</b><br/> 1.1 Improved to a clinically important extent<br/> 1.2 Deteriorated </p> <p><b>2. Mental state</b> </p> <p><b>3. Adverse effect</b><br/> 3.1 Any adverse event<br/> 3.2 Adverse effects: no clinically significant extrapyramidal adverse effects </p> <p><b>4. Acceptability of treatment</b><br/> 4.1 Leaving the study early </p> <p><b>5. Social confidence, social inclusion, social networks, or personalised quality of‐life‐measures</b><br/> 5.1 No significant change in social confidence, social inclusion, social networks, or personalised quality‐of‐life measures for either recipients of care or caregivers </p> <p>We used this summary to guide our conclusions.</p> <p>Personalised quality‐of‐life is an outcome designated important to patients. We wished to add perspectives from people’s personal experience with TD to the research agenda. We planned a consultation with service users, where the previously published version of a review in the Cochrane TD series (<a href="./references#CD000459-bbs2-0233" title="Soares‐WeiserK , MaayanN , McGrathJ . Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2] ">Soares‐Weiser 2011</a>; <a href="#CD000459-tbl-0012">Table 1</a>) and a lay overview of that review gave the foundation for the discussions. The session was planned to provide time to reflect on current research on TD and to consider gaps in knowledge. The report is published in the Health Technology Assessment (HTA) report for the UK National Institute of Health Research (<a href="./references#CD000459-bbs2-0159" title="BergmanH , WalkerDM , NikolakopoulouA , Soares‐WeiserK , AdamsCE . Systematic review of interventions for treating or preventing antipsychotic‐induced tardive dyskinesia. Health Technol Assess2017 Aug;21(43):1‐218. ">Bergman 2017</a>). We have added one figure showing one service user's expression of frustration concerning this neglected area of research (<a href="#CD000459-fig-0001">Figure 1</a>). Informed by the results of the consultation, for this review, we have included outcomes of the consultation in the 'Summary of findings' tables. </p> <div class="figure" id="CD000459-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Message from one of the participants of the public and patient involvement consultation of service user perspectives on tardive dyskinesia research" data-id="CD000459-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Message from one of the participants of the public and patient involvement consultation of service user perspectives on tardive dyskinesia research </p> </div> </div> </div> </section> </section> </section> </section> <section id="CD000459-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000459-sec-0051"> <h4 class="title">Electronic searches</h4> <p>The 2017 review update was carried out in parallel with updating eight other Cochrane TD Reviews and the search covered all nine reviews; see <a href="#CD000459-tbl-0012">Table 1</a> for details. </p> <section id="CD000459-sec-0052"> <h5 class="title">1. Cochrane Schizophrenia Group’s Study‐Based Register of Trials</h5> <p>On July 16, 2015 and April 26, 2017, the Information Specialist searched the register using the following string: </p> <p>*Tardive Dyskinesia* in Healthcare Condition Field of Study</p> <p>In a study‐based register, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics (<a href="./references#CD000459-bbs2-0227" title="ShokranehF , AdamsCE . Study‐based registers of randomized controlled trials: starting a systematic review with data extraction or meta‐analysis. BioImpacts2017;InPress:InPress. ">Shokraneh 2017</a>). </p> <p>This register is compiled by systematic searches of major resources (AMED, BIOSIS, CINAHL, ClinicalTrials.Gov, Embase, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly updates, ProQuest Dissertations and Theses A&amp;I and its quarterly update, Chinese databases (CBM, CNKI, and Wanfang) and their annual updates, hand‐searches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group’s Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> <p>For previous searches, please see <a href="./appendices#CD000459-sec-0246">Appendix 1</a>. </p> </section> </section> <section id="CD000459-sec-0053"> <h4 class="title">Searching other resources</h4> <section id="CD000459-sec-0054"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all identified studies for further relevant studies.</p> </section> <section id="CD000459-sec-0055"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study for information regarding unpublished trials. </p> </section> </section> </section> <section id="CD000459-sec-0056"> <h3 class="title" id="CD000459-sec-0056">Data collection and analysis</h3> <section id="CD000459-sec-0057"> <h4 class="title">Selection of studies</h4> <p>For the 2017 update, reviewers RA and AG (see <a href="#CD000459-sec-0243">Acknowledgements</a>) inspected all abstracts of studies identified as above and identified potentially relevant reports. We resolved disagreement by discussion, or where there was still doubt, we acquired the full article for further inspection. We acquired the full articles of relevant reports/abstracts meeting initial criteria for reassessment and carefully inspected for a final decision on inclusion (see <a href="#CD000459-sec-0030">Criteria for considering studies for this review</a>). RA and AG were not blinded to the names of the authors, institutions or journal of publication. Where difficulties or disputes arose, we asked review author HB for help and where it was impossible to decide or if adequate information was not available to make a decision, we added these studies to those awaiting assessment and contacted the authors of the papers for clarification. </p> </section> <section id="CD000459-sec-0058"> <h4 class="title">Data extraction and management</h4> <section id="CD000459-sec-0059"> <h5 class="title">1. Extraction</h5> <p>For the 2017 update, reviewers RA and HB independently extracted data from all included studies. Again, we discussed any disagreement and documented decisions. We extracted data presented only in graphs and figures whenever possible, but we included data only if two review authors independently had the same result. We attempted to contact study authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. If studies were multi‐centre, where possible, we extracted data relevant to each component centre separately. </p> </section> <section id="CD000459-sec-0060"> <h5 class="title">2. Management</h5> <section id="CD000459-sec-0061"> <h6 class="title">2.1 Forms</h6> <p>For the 2017 update we extracted data online in <a href="./references#CD000459-bbs2-0173" title="Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation. ">Covidence</a>. Extracted data are available <a href="https://www.researchgate.net/publication/308698005_Appendix_Traceable_Extracted_Data_from_Included_Studies_of_Tardive_Dyskinesia_Reviews?channel=doi%26linkId=57ebe1c508ae92a5dbd051c1%26showFulltext=true" target="_blank">here</a> with a link to the original source PDF for each item. </p> </section> <section id="CD000459-sec-0062"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> <br/> a) the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD000459-bbs2-0213" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b) the measuring instrument had not been written or modified by one of the trialists for that particular trial.<br/> <br/> Ideally the measuring instrument should either have been (a) a self‐report or (b) completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly, and we noted in <a href="#CD000459-sec-0103">Description of studies</a> if this was the case or not. </p> </section> <section id="CD000459-sec-0063"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult‐to‐measure conditions such as schizophrenia. We decided to primarily use endpoint data, and only to use change data if the former were not available. We combined endpoint and change data in the analysis as we preferred to use mean differences (MD) rather than standardised mean differences throughout (<a href="./references#CD000459-bbs2-0198" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> </section> <section id="CD000459-sec-0064"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to relevant data before inclusion. </p> <p>Please note, we entered data from studies of at least 200 participants in the analysis because skewed data pose less of a problem in large studies. We also entered all relevant change data, as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. </p> <p>For endpoint data from studies with fewer than 200 participants:</p> <p>(a) for scales starting from the ﬁnite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation. If this value was lower than 1, it strongly suggested a skew and we excluded these data. If this ratio was higher than one but below 2, there was suggestion of skew. We entered these data and tested whether their inclusion or exclusion changed the results substantially. Finally, if the ratio was larger than 2 we included these data, because skew was less likely (<a href="./references#CD000459-bbs2-0148" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="./references#CD000459-bbs2-0198" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> <p>(b) for scales starting from a positive value (such as the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD000459-bbs2-0204" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and 'S min' is the minimum score. </p> </section> <section id="CD000459-sec-0065"> <h6 class="title">2.5 Common measure</h6> <p>Where relevant, to facilitate comparison between trials, we converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week, or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD000459-sec-0066"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we converted continuous outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD000459-bbs2-0220" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the PANSS (<a href="./references#CD000459-bbs2-0204" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this can be considered as a clinically significant response (<a href="./references#CD000459-bbs2-0206" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005a</a>; <a href="./references#CD000459-bbs2-0207" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the study authors. </p> </section> <section id="CD000459-sec-0067"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for reduction or cessation of antipsychotic. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'not un‐improved') we presented data where the left of the line indicated an unfavourable outcome and noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD000459-sec-0068"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>RA (see <a href="#CD000459-sec-0243">Acknowledgements</a>) and HB independently assessed risk of bias within the included studies by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to assess trial quality (<a href="./references#CD000459-bbs2-0199" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting. </p> <p>If the raters disagreed, we made the final rating by consensus, with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. If non‐concurrence occurred, we reported this. </p> <p>We noted the level of risk of bias in the text of the review and in <a href="#CD000459-fig-0002">Figure 2</a>; <a href="#CD000459-fig-0003">Figure 3</a> and 'Summary of findings' tables. </p> <div class="figure" id="CD000459-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD000459-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD000459-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000459-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> </section> <section id="CD000459-sec-0069"> <h4 class="title">Measures of treatment effect</h4> <section id="CD000459-sec-0070"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD000459-bbs2-0162" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios, as odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD000459-bbs2-0174" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). </p> </section> <section id="CD000459-sec-0071"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD000459-sec-0072"> <h4 class="title">Unit of analysis issues</h4> <section id="CD000459-sec-0073"> <h5 class="title">1. Cluster‐randomised trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, study authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD000459-bbs2-0176" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, confidence intervals unduly narrow, and statistical significance overestimated. This causes type I errors (<a href="./references#CD000459-bbs2-0161" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD000459-bbs2-0192" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>If any of the included trials had randomised participants by clusters, and where clustering was not accounted for in primary studies, we would have presented such data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra‐class correlation coefficients for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD000459-bbs2-0192" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). Where clustering had been incorporated into the analysis of primary studies, we presented these data as if from a non‐cluster‐randomised study, but adjusted for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra‐class correlation coefficient (ICC) (design effect=1+(m‐1)*ICC) (<a href="./references#CD000459-bbs2-0177" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported we would assume it was 0.1 (<a href="./references#CD000459-bbs2-0237" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies were appropriately analysed, taking into account intra‐class correlation coefficients and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique. </p> </section> <section id="CD000459-sec-0074"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. The carry‐over effect occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a washout phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD000459-bbs2-0180" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtonHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross‐over studies. </p> </section> <section id="CD000459-sec-0075"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary we simply added and combined within the two‐by‐two table. If data were continuous we combined data following the formula in section 7.7.3.8  (Combining groups) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000459-bbs2-0198" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>)<i>.</i> We did not use data where the additional treatment arms were not relevant. </p> </section> </section> <section id="CD000459-sec-0076"> <h4 class="title">Dealing with missing data</h4> <section id="CD000459-sec-0077"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD000459-bbs2-0240" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We decided that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' tables by down‐rating quality. We also downgraded quality within the 'Summary of findings' tables should loss be 25% to 50% in total. </p> </section> <section id="CD000459-sec-0078"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50%, and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat (ITT) analysis). We assumed that all those leaving the study early had seen no improvement in TD symptoms. We undertook a sensitivity analysis, testing how prone the primary outcomes were to change by comparing data only from people who had completed the study to that point to the ITT analysis using the above assumptions. </p> </section> <section id="CD000459-sec-0079"> <h5 class="title">3. Continuous</h5> <section id="CD000459-sec-0080"> <h6 class="title">3.1 Attrition</h6> <p>We reported and used data where attrition for a continuous outcome was between 0% and 50%, and data only from people who had completed the study to that point were reported. </p> </section> <section id="CD000459-sec-0081"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations were not reported, we first tried to obtain the missing values from the study authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error and confidence intervals available for group means, and either P value or 't' value available for differences in mean, we calculated them according to the rules described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD000459-bbs2-0200" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). When only the standard error (SE) is reported, standard deviations (SDs) are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD000459-bbs2-0198" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>; <a href="./references#CD000459-bbs2-0200" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>) present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, ranges, or other statistics. If these formulae did not apply, we calculated the SDs according to a validated imputation method which was based on the SDs of the other included studies (<a href="./references#CD000459-bbs2-0185" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD000459-sec-0082"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who left the trials early or were lost to follow‐up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recently, methods such as multiple imputation or mixed effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem to be somewhat better than LOCF (<a href="./references#CD000459-bbs2-0205" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore did not exclude studies based on the statistical approach used. However, we preferred to use the more sophisticated approaches (e.g. MMRM or multiple‐imputation) and only presented completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item "incomplete outcome data" of the risk of bias tool. </p> </section> </section> </section> <section id="CD000459-sec-0083"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD000459-sec-0084"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations that we had not predicted would arise and discussed in the text if they arose. </p> </section> <section id="CD000459-sec-0085"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods that we had not predicted would arise and discussed in the text if they arose. </p> </section> <section id="CD000459-sec-0086"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD000459-sec-0087"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD000459-sec-0088"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> statistic method alongside the Chi<sup>2</sup> P value. The I<sup>2</sup> statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD000459-bbs2-0195" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> statistic depends on (a) magnitude and direction of effects and (b) strength of evidence for heterogeneity (e.g. P value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup> statistic). An I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic can be interpreted as evidence of substantial levels of heterogeneity (section 9.5.2 <i>Cochrane Handbook for Systematic Reviews of Interventions</i><a href="./references#CD000459-bbs2-0175" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We explored and discussed in the text potential reasons for substantial levels of heterogeneity (see <a href="#CD000459-sec-0091">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD000459-sec-0089"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD000459-bbs2-0178" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000459-bbs2-0197" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were ten or fewer studies, or where all studies were of similar sizes. In future versions of this review, if funnel plots are possible, we will seek statistical advice in their interpretation. </p> </section> <section id="CD000459-sec-0090"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model. It puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the fixed‐effect model for all analyses. </p> </section> <section id="CD000459-sec-0091"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD000459-sec-0092"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD000459-sec-0093"> <h6 class="title">1.1 Primary outcomes</h6> <p>We anticipated one subgroup analysis to test the hypothesis that the use of antipsychotic reduction, cessation or specific antipsychotics is most effective for those with early‐onset TD (less than five years). We hoped to present data for this subgroup for the primary outcomes. </p> </section> <section id="CD000459-sec-0094"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We proposed to undertake this review and provide an overview of the effects of antipsychotic reduction/cessation or specific antipsychotics for people with TD in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage, and with similar problems. </p> </section> </section> <section id="CD000459-sec-0095"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>We reported that inconsistency was high. First, we investigated whether data were entered correctly. Second, if data were correct, we visually inspected the graph and successively removed studies outside of the company of the rest to see if homogeneity was restored. For this review we decided that, should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present the data. If not, we did not pool such data and discussed issues. We know of no supporting research for this 10% cut‐off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>When unanticipated clinical or methodological heterogeneity were obvious, we simply discussed. We did not undertake sensitivity analyses relating to these. </p> </section> </section> <section id="CD000459-sec-0096"> <h4 class="title">Sensitivity analysis</h4> <section id="CD000459-sec-0097"> <h5 class="title">1. Implication of randomisation</h5> <p>If trials were described in some way as to imply randomisation we undertook a sensitivity analysis for the primary outcomes. We included these studies in the analyses, and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, we used relevant data from these studies. </p> </section> <section id="CD000459-sec-0098"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where we had to make assumptions regarding people lost to follow‐up (see <a href="#CD000459-sec-0076">Dealing with missing data</a>) we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption. </p> <p>Where we had to make assumptions regarding missing SD data (see <a href="#CD000459-sec-0076">Dealing with missing data</a>), we compared the findings on primary outcomes when we used our assumption compared with completer data only. We undertook a sensitivity analysis, testing how prone results were to change when completer data only were compared with the imputed data using the above assumption. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption. </p> </section> <section id="CD000459-sec-0099"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that we judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available) allocation concealment, blinding, and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, we included data from these trials in the analysis </p> </section> <section id="CD000459-sec-0100"> <h5 class="title">4. Imputed values</h5> <p>Had cluster‐randomised trials been included, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect. </p> <p>If we found substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately </p> </section> <section id="CD000459-sec-0101"> <h5 class="title">5. Fixed‐effect and random‐effects models</h5> <p>We synthesised data using a fixed‐effect model; however, we also synthesised data for the primary outcome using a random‐effects model to evaluate whether this altered the significance of the results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000459-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000459-sec-0102"></div> <section id="CD000459-sec-0103"> <h3 class="title">Description of studies</h3> <p>Please see <a href="./references#CD000459-sec-0274" title="">Characteristics of included studies</a>, <a href="./references#CD000459-sec-0275" title="">Characteristics of excluded studies</a> and <a href="./references#CD000459-sec-0276" title="">Characteristics of ongoing studies</a>. </p> <section id="CD000459-sec-0104"> <h4 class="title">Results of the search</h4> <p>The 2015 and 2017 searches for the 2017 review update also covered updates for the other eight Cochrane Reviews in the TD series, see <a href="#CD000459-tbl-0012">Table 1</a>. </p> <p>The 2015 search retrieved 704 references for 344 studies, see <a href="#CD000459-fig-0004">Figure 4</a> for study flow diagram (<a href="./references#CD000459-bbs2-0217" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. PLoS Medicine 6;7:e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>). We also screened all references of the previously published review, 99 of which were not covered in the updated search. We identified 18 new potentially relevant studies for this review for which we conducted full‐text screenings. Five of these studies are newly included in this review (<a href="./references#CD000459-bbs2-0002" title="BaiYM . Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S473. ">Bai 2005</a>; <a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>; <a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>; <a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>). A study previously awaiting classification was included as several more publications were identified in the new search (<a href="./references#CD000459-bbs2-0001" title="BaiYM , LinCC , YuSC . Risperidone for severe tardive dyskinesia: one year follow up study. International Journal of Neuropsychopharmacology2002;5:S165. BaiYM , YuSC , ChenJY , LinCY , ChouP , LinCC . Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. International Clinical Psychopharmacology2005;20(2):79‐85. BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64:1342‐8. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. ">Bai 2003</a>). Two studies were previously excluded because there was no placebo group, but as head‐to‐head comparisons of antipsychotic drugs for the treatment of TD has been added to the inclusion criteria in this review, these studies were subsequently included (<a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>; <a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a>). We also added 13 new excluded studies, and three studies previously awaiting classification were also excluded (<a href="./references#CD000459-bbs2-0020" title="BarnesT . A prospective study of tardive dyskinesia in the elderly; single‐blind comparison of amisulpride and risperidone. National Research Register2002. [N0195113456] ">Barnes 2002</a>; <a href="./references#CD000459-bbs2-0030" title="CaiN . A controlled study on the treatment of tardive dyskinesia using 1‐stepholidine. Chinese Journal of Neurology and Psychiatry1988;21(5):281‐3. ">Cai 1988</a>; <a href="./references#CD000459-bbs2-0145" title="ZengZX , LiZC , YuXW , ZhangYD , CaoZC . A double‐blind trial of flunarizine therapy for tardive dyskinesia. Chinese Journal of Pharmaco Epidemiology1994;3(4):183‐4. ">Zeng 1994</a>). </p> <div class="figure" id="CD000459-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Study flow diagram for 2015 and 2017 searches for this review" data-id="CD000459-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for 2015 and 2017 searches for this review</p> </div> </div> </div> <p>The 2017 search found 8 records (5 studies). Editorial base of Cochrane Schizophrenia screened these records and no new studies were relevant to this review. They could be relevant to the other reviews in this series of TD reviews (see <a href="#CD000459-tbl-0012">Table 1</a>), and have been put into awaiting assessment of the Miscellaneous treatments review <a href="./references#CD000459-bbs2-0243" title="Soares‐WeiserK , RathboneJ . Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000459.pub2] ">Soares‐Weiser 2006</a> and the benzodiazepines review <a href="./references#CD000459-bbs2-0160" title="BhoopathiPS , Soares‐WeiserK . Benzodiazepines for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD000205.pub2] ">Bhoopathi 2006</a>. </p> <p>Thirteen studies are now included in this review (<a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a>; <a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>; <a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000459-bbs2-0008" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3(5‐6):315‐20. [MEDLINE: 91129137; PMID 1980827] GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46(8):4‐7. [MEDLINE: 91129137; PMID 1980827] ">Glazer 1990a</a>; <a href="./references#CD000459-bbs2-0002" title="BaiYM . Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S473. ">Bai 2005</a>; <a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>; <a href="./references#CD000459-bbs2-0007" title="EmsleyR , TurnerHJ , SchronenJ , BothaK , SmitR , OosthuizenPP . A single‐blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry2004;65(5):696‐701. [MEDLINE: 15163258] EmsleyRA , TurnerJ , SchronenJ , BothaK , SmitR , OosthuizenPP . Quetiapine: greater improvements in tardive dyskinesia versus haloperidol. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, USA. 2004. [APA Conference Abstracts NR574] ">Emsley 2004</a>; <a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>; <a href="./references#CD000459-bbs2-0001" title="BaiYM , LinCC , YuSC . Risperidone for severe tardive dyskinesia: one year follow up study. International Journal of Neuropsychopharmacology2002;5:S165. BaiYM , YuSC , ChenJY , LinCY , ChouP , LinCC . Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. International Clinical Psychopharmacology2005;20(2):79‐85. BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64:1342‐8. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. ">Bai 2003</a>; <a href="./references#CD000459-bbs2-0010" title="KazamatsuriH , ChienC , ColeJO . Treatment of tardive dyskinesia. II. Short‐term efficacy of dopamine‐blocking agents haloperidol and thiopropazate. Archives of General Psychiatry1972;27(1):100‐3. ">Kazamatsuri 1972</a>; <a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>). </p> </section> <section id="CD000459-sec-0105"> <h4 class="title">Included studies</h4> <p>Overall the review now includes 13 studies with 711 participants published between 1972 and 2011. </p> <section id="CD000459-sec-0106"> <h5 class="title">1. Methods</h5> <p>Most studies stated that they were randomised and double‐blind. Two studies reported being only single‐blind (<a href="./references#CD000459-bbs2-0002" title="BaiYM . Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S473. ">Bai 2005</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>). For further details please see sections below on allocation and blinding. </p> </section> <section id="CD000459-sec-0107"> <h5 class="title">2. Design</h5> <p>All included studies presented a parallel longitudinal design. One of the 13 studies used a cross‐over design with two periods (<a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>). We had considered this as likely when embarking on the review and have used only the data from before the first cross‐over for the reasons outlined above (<a href="#CD000459-sec-0072">Unit of analysis issues</a>). </p> </section> <section id="CD000459-sec-0108"> <h5 class="title">3. Duration</h5> <p>We included three short‐term studies reporting data at two to four weeks (<a href="./references#CD000459-bbs2-0008" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3(5‐6):315‐20. [MEDLINE: 91129137; PMID 1980827] GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46(8):4‐7. [MEDLINE: 91129137; PMID 1980827] ">Glazer 1990a</a>; <a href="./references#CD000459-bbs2-0010" title="KazamatsuriH , ChienC , ColeJO . Treatment of tardive dyskinesia. II. Short‐term efficacy of dopamine‐blocking agents haloperidol and thiopropazate. Archives of General Psychiatry1972;27(1):100‐3. ">Kazamatsuri 1972</a>; <a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>). Five studies reported data at medium‐term, 8 to 24 weeks (<a href="./references#CD000459-bbs2-0001" title="BaiYM , LinCC , YuSC . Risperidone for severe tardive dyskinesia: one year follow up study. International Journal of Neuropsychopharmacology2002;5:S165. BaiYM , YuSC , ChenJY , LinCY , ChouP , LinCC . Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. International Clinical Psychopharmacology2005;20(2):79‐85. BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64:1342‐8. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. ">Bai 2003</a>; <a href="./references#CD000459-bbs2-0002" title="BaiYM . Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S473. ">Bai 2005</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>; <a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>; <a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>), and there were five long‐term studies reporting data at 44 weeks to 18 months (<a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>; <a href="./references#CD000459-bbs2-0007" title="EmsleyR , TurnerHJ , SchronenJ , BothaK , SmitR , OosthuizenPP . A single‐blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry2004;65(5):696‐701. [MEDLINE: 15163258] EmsleyRA , TurnerJ , SchronenJ , BothaK , SmitR , OosthuizenPP . Quetiapine: greater improvements in tardive dyskinesia versus haloperidol. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, USA. 2004. [APA Conference Abstracts NR574] ">Emsley 2004</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>; <a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a>). </p> </section> <section id="CD000459-sec-0109"> <h5 class="title">4. Participants</h5> <p>Participants, now totaling 711 people, were mostly men with aged 50 to 60 years with diagnoses of various chronic psychiatric disorders, but mainly schizophrenia. All had antipsychotic‐induced TD diagnosed using Schooler and Kane’s research diagnostic criteria, except <a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>, which did not report any criteria for the diagnosis of TD. The number of participants ranged from 8 to 200 (median 32). </p> </section> <section id="CD000459-sec-0110"> <h5 class="title">5. Setting</h5> <p>Most trials were conducted in hospital. The studies themselves were from around the world, with six conducted in the USA (<a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0008" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3(5‐6):315‐20. [MEDLINE: 91129137; PMID 1980827] GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46(8):4‐7. [MEDLINE: 91129137; PMID 1980827] ">Glazer 1990a</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>; <a href="./references#CD000459-bbs2-0010" title="KazamatsuriH , ChienC , ColeJO . Treatment of tardive dyskinesia. II. Short‐term efficacy of dopamine‐blocking agents haloperidol and thiopropazate. Archives of General Psychiatry1972;27(1):100‐3. ">Kazamatsuri 1972</a>; <a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a>), three in Taiwan (<a href="./references#CD000459-bbs2-0001" title="BaiYM , LinCC , YuSC . Risperidone for severe tardive dyskinesia: one year follow up study. International Journal of Neuropsychopharmacology2002;5:S165. BaiYM , YuSC , ChenJY , LinCY , ChouP , LinCC . Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. International Clinical Psychopharmacology2005;20(2):79‐85. BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64:1342‐8. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. ">Bai 2003</a>; <a href="./references#CD000459-bbs2-0002" title="BaiYM . Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S473. ">Bai 2005</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>), and one each in South Africa (<a href="./references#CD000459-bbs2-0007" title="EmsleyR , TurnerHJ , SchronenJ , BothaK , SmitR , OosthuizenPP . A single‐blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry2004;65(5):696‐701. [MEDLINE: 15163258] EmsleyRA , TurnerJ , SchronenJ , BothaK , SmitR , OosthuizenPP . Quetiapine: greater improvements in tardive dyskinesia versus haloperidol. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, USA. 2004. [APA Conference Abstracts NR574] ">Emsley 2004</a>), Canada (<a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>), Denmark/Finland (<a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>), and the UK (<a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>). </p> </section> <section id="CD000459-sec-0111"> <h5 class="title">6. Interventions</h5> <section id="CD000459-sec-0112"> <h6 class="title">6.1 Antipsychotic reduction</h6> <section id="CD000459-sec-0113"> <p><b>6.1.1 cis(z)‐flupenthixol decanoate</b></p> <p><a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a> used a reduction of 50% of the standard dose of cis(z)‐flupenthixol decanoate. </p> </section> <section id="CD000459-sec-0114"> <p><b>6.1.2 Fluphenazine decanoate</b></p> <p><a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a> compared a low dose of fluphenazine decanoate (1.25 mg to 5 mg for two weeks) to the standard dose (12.5 mg to 50 mg for two weeks). </p> </section> </section> <section id="CD000459-sec-0115"> <h6 class="title">6.2 Specific antipsychotics</h6> <section id="CD000459-sec-0116"> <p><b>6.2.1 Clozapine</b></p> <p><a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a> used clozapine in a mean (± SD) dose of 293.8 mg ± 171.9 mg a day for 12 months. </p> </section> <section id="CD000459-sec-0117"> <p><b>6.2.2 Risperidone</b></p> <p>Four studies used risperidone in a dose ranging from 1.5 mg a day to 16 mg a day (<a href="./references#CD000459-bbs2-0001" title="BaiYM , LinCC , YuSC . Risperidone for severe tardive dyskinesia: one year follow up study. International Journal of Neuropsychopharmacology2002;5:S165. BaiYM , YuSC , ChenJY , LinCY , ChouP , LinCC . Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. International Clinical Psychopharmacology2005;20(2):79‐85. BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64:1342‐8. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. ">Bai 2003</a>; <a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>; <a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>). </p> </section> <section id="CD000459-sec-0118"> <p><b>6.2.3 Olanzapine</b></p> <p>Three studies used olanzapine in a dose ranging from 7.5 mg a day to 12.6 mg a day (<a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>), <a href="./references#CD000459-bbs2-0002" title="BaiYM . Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S473. ">Bai 2005</a> did not report the dose. </p> </section> <section id="CD000459-sec-0119"> <p><b>6.2.4 Amisulpride</b></p> <p><a href="./references#CD000459-bbs2-0002" title="BaiYM . Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S473. ">Bai 2005</a> used amisulpride but did not report the dose. </p> </section> <section id="CD000459-sec-0120"> <p><b>6.2.5 Quetiapine</b></p> <p>Two studies used quetiapine in a dose ranging from 100 mg a day to 400 mg a day (<a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0007" title="EmsleyR , TurnerHJ , SchronenJ , BothaK , SmitR , OosthuizenPP . A single‐blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry2004;65(5):696‐701. [MEDLINE: 15163258] EmsleyRA , TurnerJ , SchronenJ , BothaK , SmitR , OosthuizenPP . Quetiapine: greater improvements in tardive dyskinesia versus haloperidol. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, USA. 2004. [APA Conference Abstracts NR574] ">Emsley 2004</a>). </p> </section> <section id="CD000459-sec-0121"> <p><b>6.2.6 Ziprasidone</b></p> <p><a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a> used ziprasidone in a flexible dose of 40 mg. </p> </section> <section id="CD000459-sec-0122"> <p><b>6.2.7 Haloperidol</b></p> <p>Seven studies used haloperidol in doses ranging from 2 mg a day to 34 mg a day (<a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>; <a href="./references#CD000459-bbs2-0007" title="EmsleyR , TurnerHJ , SchronenJ , BothaK , SmitR , OosthuizenPP . A single‐blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry2004;65(5):696‐701. [MEDLINE: 15163258] EmsleyRA , TurnerJ , SchronenJ , BothaK , SmitR , OosthuizenPP . Quetiapine: greater improvements in tardive dyskinesia versus haloperidol. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, USA. 2004. [APA Conference Abstracts NR574] ">Emsley 2004</a>; <a href="./references#CD000459-bbs2-0008" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3(5‐6):315‐20. [MEDLINE: 91129137; PMID 1980827] GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46(8):4‐7. [MEDLINE: 91129137; PMID 1980827] ">Glazer 1990a</a>; <a href="./references#CD000459-bbs2-0010" title="KazamatsuriH , ChienC , ColeJO . Treatment of tardive dyskinesia. II. Short‐term efficacy of dopamine‐blocking agents haloperidol and thiopropazate. Archives of General Psychiatry1972;27(1):100‐3. ">Kazamatsuri 1972</a>; <a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>; <a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a>). </p> </section> <section id="CD000459-sec-0123"> <p><b>6.2.8 Molindone</b></p> <p><a href="./references#CD000459-bbs2-0008" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3(5‐6):315‐20. [MEDLINE: 91129137; PMID 1980827] GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46(8):4‐7. [MEDLINE: 91129137; PMID 1980827] ">Glazer 1990a</a> used molindone in a dose from 75 mg to 145 mg. </p> </section> <section id="CD000459-sec-0124"> <p><b>6.2.9 Thiopropazate</b></p> <p><a href="./references#CD000459-bbs2-0010" title="KazamatsuriH , ChienC , ColeJO . Treatment of tardive dyskinesia. II. Short‐term efficacy of dopamine‐blocking agents haloperidol and thiopropazate. Archives of General Psychiatry1972;27(1):100‐3. ">Kazamatsuri 1972</a> used thiopropazate in a dose of 10 mg a day to 80 mg a day. </p> </section> <section id="CD000459-sec-0125"> <p><b>6.2.10 Zuclopenthixol</b></p> <p><a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a> used zuclopenthixol in a dose from 16.5 mg a day to 26.6 mg a day. </p> </section> </section> <section id="CD000459-sec-0126"> <h6 class="title">6.3 Other drugs</h6> <section id="CD000459-sec-0127"> <p><b>6.3.1 Tetrabenazine</b></p> <p><a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a> used tetrabenazine in a dose of 50 mg twice a day. </p> </section> </section> </section> <section id="CD000459-sec-0128"> <h5 class="title">7. Outcomes</h5> <section id="CD000459-sec-0129"> <h6 class="title">7.1 General</h6> <p>The included studies presented outcomes in graphs, inexact P values of differences, or a statement of significant or non‐significant difference. This made it impossible to acquire raw data for synthesis. We were unable to extract some continuous outcomes due to missing number of participants or missing means, standard deviations, or standard errors. All included studies used the LOCF strategy for the ITT analysis of dichotomous data. </p> </section> <section id="CD000459-sec-0130"> <h6 class="title">7.2 Scales used to measure the TD symptoms</h6> <p>We have shown details of the scales that provided usable data below. We have provided reasons for exclusions of data under 'Outcomes' in the <a href="./references#CD000459-sec-0274" title="">Characteristics of included studies</a> tables. </p> <section id="CD000459-sec-0131"> <p><b>7.2.1 Abnormal Involuntary Movement Scale (AIMS)</b></p> <p>The AIMS (<a href="./references#CD000459-bbs2-0193" title="GuyW , BonatoRR . Manual for the ECDEU Assessment Battery. National Institute of Mental Health. In: Guy W, Bonato RR, editor(s). Washington DC: NIMH, 1970. ">Guy 1970</a>) is a 12‐item scale consisting of a standardised examination followed by questions rating orofacial, extremity, and trunk movements, as well as three global measurements. Each of these 10 items can be scored from 0 (none) to 4 (severe). Two additional items assess dental status. The AIMS ranges from 0 to 40, with higher scores indicating greater severity. </p> </section> <section id="CD000459-sec-0132"> <p><b>7.2.2 Extrapyramidal symptom rating scale (ESRS)</b></p> <p>The ESRS was developed to assess four types of drug‐induced movement disorders (DIMD): parkinsonism, akathisia, dystonia, and TD (<a href="./references#CD000459-bbs2-0169" title="ChouinardG , MargoleseHC . Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Research2005;76(2‐3):247‐65. ">Chouinard 2005</a>). The score for TD, ranging from 0 to 42, is based on the sum of all seven items in the TD objective examination. </p> </section> <section id="CD000459-sec-0133"> <p><b>7.2.3 St. Hans Rating Scale for extrapyramidal syndromes (SHRS)</b></p> <p>The SHRS is a multidimensional rating scale for the evaluation of antipsychotic‐induced hyperkinesia, parkinsonism, akathisia, and dystonia (<a href="./references#CD000459-bbs2-0189" title="GerlachJ , KorsgaardS , ClemmesenP , LauersenAML , MagelundG , NoringU , et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatrica Scandinavica1993;87(4):244‐52. ">Gerlach 1993</a>). Each item is rated from 0 (not present) to 6 (present to an extreme degree). This gives a total score from 0 to 48 for hyperkinesia and parkinsonism. </p> </section> </section> <section id="CD000459-sec-0134"> <h6 class="title">7.3 Scales used to measure adverse events related to antipsychotic medication</h6> <section id="CD000459-sec-0135"> <p><b>7.3.1 Simpson‐Angus Scale (SAS)</b></p> <p>The SAS (<a href="./references#CD000459-bbs2-0228" title="SimpsonGM , AngusJWS . A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica1970;212:11‐19. ">Simpson 1970</a>) is a 10‐item scale, with a scoring system of 0 to 4 for each item, that measures drug‐induced parkinsonism, a short‐term drug‐induced movement disorder. A low score indicates low levels of parkinsonism. </p> </section> <section id="CD000459-sec-0136"> <p><b>7.3.2 Barnes Akathisia Scale (BAS)</b></p> <p>The BAS (<a href="./references#CD000459-bbs2-0153" title="BarnesTR , CharingC . Westminster Medical School HHES. A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. ">Barnes 1989</a>) is a 12‐item scale consisting of a standardised examination followed by questions rating orofacial, extremity, and trunk movements, as well as three global measurements. Each of these 10 items can be scored from 0 (none) to 4 (severe). Two additional items assess dental status. The BAS ranges from 0 to 40, with higher scores indicating greater severity. </p> </section> <section id="CD000459-sec-0137"> <p><b>7.3.3 UKU‐Side Effect Rating Scale</b></p> <p>The UKU was developed to provide a comprehensive side effect rating scale with well‐defined and operationalised items to assess the side effects of psychopharmacological medications (<a href="./references#CD000459-bbs2-0210" title="LingjærdeO , AhlforsUG , BechP , DenckerSJ , ElgenK . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients. Acta Psychiatrica Scandinavica1987;76:Suppl. 334. ">Lingjaerde 1987</a>). The scoring sheet includes 48 items with higher scores indicating more side effects. </p> </section> </section> <section id="CD000459-sec-0138"> <h6 class="title">7.4 Scales used to measure mental state and behaviour</h6> <section id="CD000459-sec-0139"> <p><b>7.4.1 Brief Psychiatric Rating Scale (BPRS)</b></p> <p>The BPRS is an 18‐item scale measuring positive symptoms, general psychopathology and affective symptoms (<a href="./references#CD000459-bbs2-0220" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>). The original scale has 16 items, although a revised 18‐item scale is commonly used. Total scores can range from 0 to 126. Each item is rated on a seven‐point scale, with high scores indicating more severe symptoms. </p> </section> <section id="CD000459-sec-0140"> <p><b>7.4.2 Positive and Negative Syndrome Scale (PANSS)</b></p> <p>The PANSS is a medical scale used for measuring symptom severity of people with schizophrenia (<a href="./references#CD000459-bbs2-0204" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>). The individual is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. </p> </section> <section id="CD000459-sec-0141"> <p><b>7.4.3 Clinical Global Impression</b></p> <p>The CGI is a three‐item scale commonly used in studies on schizophrenia to enable clinicians to quantify severity of illness and overall clinical improvement (<a href="./references#CD000459-bbs2-0194" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. Revised Edition. Washington, DC: Department of Health, Education and Welfare, 1976. ">Guy 1976</a>). The items are: severity of illness, global improvement, and efficacy index. A seven‐point scoring system is usually employed with low scores indicating decreased severity or greater recovery, or both. </p> </section> </section> </section> </section> <section id="CD000459-sec-0142"> <h4 class="title">Excluded studies</h4> <p>There are 133 excluded studies (163 references); the majority (n = 74) were excluded because they were not randomised. Thirty‐nine studies included participants with schizophrenia or other mental disorders who did not have TD. One study did not provide separate data from the included minority with TD; we contacted study authors who confirmed that these data were not available. Five studies investigated interventions that were not relevant for this review. Seven studies were cross‐over studies that did not provide data from the phase before crossing over to the next treatment. We contacted authors for three of these studies: author of <a href="./references#CD000459-bbs2-0091" title="LalS , EttigiP . Comparison of thiopropazate and trifluoperazine on oral dyskinesia ‐ a double blind study. Current Therapeutic Research, Clinical and Experimental1974;16(9):990‐7. ">Lal 1974</a> confirmed that no separate data were available, and we received no reply from authors of <a href="./references#CD000459-bbs2-0095" title="LiebermanJ , PollackS , LesserM , KaneJ . Pharmacologic characterization of tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(4):254‐60. ">Lieberman 1988</a> or <a href="./references#CD000459-bbs2-0104" title="GerlachJ . Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale1988;XIV:227‐32. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology1986;90(4):423‐9. PovlsenUJ , NoringU , MeidahlB , KorsgaardS , WaehrensJ , GerlachJ . [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger1987;149(25):1682‐5. ">NDSG 1986</a>, which were also excluded as they were published over 20 years ago and we assumed it very unlikely to receive a reply with data so many years later. We did not find up‐to‐date contact details for authors of four of the cross‐over studies (<a href="./references#CD000459-bbs2-0021" title="BatemanDN , DuttaDK , McClellandHA , RawlinsMD . The effect of metoclopramide and haloperidol on tardive dyskinesia. British Journal of Pharmacology1979;66(3):475‐6. ">Bateman 1979</a>; <a href="./references#CD000459-bbs2-0055" title="DelwaidePJ , DesseillesM . Controlled therapeutic study of spontaneous bucco‐linguo‐facial dyskinesias [Etude therapeutique controlee des dyskinesies bucco‐linguo‐faciales spontanees]. Semaine des Hopitaux1979;55(35‐6):1585‐9. [MEDLINE: 97392141; PMID 9248874] ">Delwaide 1979</a>; <a href="./references#CD000459-bbs2-0121" title="SchwartzM , MoguillanskyL , LanyiG , SharfB . Sulpiride in tardive dyskinesia. Journal of Neurology, Neurosurgery &amp; Psychiatry1990;53(9):800‐2. ">Schwartz 1990</a>; <a href="./references#CD000459-bbs2-0124" title="SingerK , ChengMN . Thiopropazate hydrochloride (Dartalan) in persistent dyskinesia with phenothiazine therapy. 5th World Congress of Psychiatry; 1971 Nov 28 ‐ Dec 4; Ciudad de Mexico, Mexico. 1971:528. [MEDLINE: 79081577; PMID 215095] SingerK , ChengMN . Thiopropazate hydrochloride in persistent dyskinesia. British Medical Journal1971;4:22‐5. ">Singer 1971</a>), and decided to also exclude these as they were published 25 to 45 years ago and we assumed it very unlikely to receive a reply so many years later. Seven studies did not provide any usable data. Authors of five of these studies (<a href="./references#CD000459-bbs2-0074" title="HerzMI , GlazerWM , MostertMA , SheardMA , SzymanskiHV , HafezH , et al. Intermittent versus maintenance medication in schizophrenia: two‐year results. Archives of General Psychiatiry1991;48:333‐9. ">Herz 1991</a>; <a href="./references#CD000459-bbs2-0083" title="JohnsonDA , LudlowJM , StreetK , TaylorRD . Double‐blind comparison of half‐dose and standard‐dose flupenthixol decanoate in the maintenance treatment of stabilised out‐patients with schizophrenia. British Journal of Psychiatry1987;151:634‐8. ">Johnson 1987</a>; <a href="./references#CD000459-bbs2-0114" title="QuinnN , MarsdenCD . A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. Journal of Neurology Neurosurgery and Psychiatry1984;47(8):844‐7. QuinnN , Marsden , CD . Double blind trial of Dogmatil in Huntington chorea and tardive dyskinesia [Essai en double insu du Dogmatil dans la choree de Huntington et la dyskinesie tardive]. Semaine des Hopitaux1985;61(19):1376‐80. ">Quinn 1984</a>; <a href="./references#CD000459-bbs2-0131" title="SpohnHE , CoyneL , SprayJ . The effect of neuroleptics and tardive dyskinesia on smooth‐pursuit eye movement in chronic schizophrenia. Archives of General Psychiatry1988;45:833‐40. ">Spohn 1988</a>; <a href="./references#CD000459-bbs2-0132" title="SpohnHE , CoyneL . The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics. Special Issue: tardive dyskinesia and cognitive dysfunction. Brain and Cognition1993;23(1):28‐39. ">Spohn 1993</a>) confirmed that no further data were available. Authors of one of these studies did not reply (<a href="./references#CD000459-bbs2-0017" title="AndiaI , ZumarragaM , ZabaloMJ , BulbenaA , DavilaR . Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia. Biological Psychiatry1998;43:20‐3. ">Andia 1998</a>) and we could not find up‐to‐date contact details for authors of a final study (<a href="./references#CD000459-bbs2-0024" title="BorisonRL , ShahC , WhiteTH , DiamondBI . Atypical and typical neuroleptics and tardive dyskinesia. Psychopharmacology Bulletin1987;23(1):218‐20. ">Borison 1987</a>). We excluded these two studies as they were published 15 to 25 years ago and we assumed it very unlikely to receive a reply with data so many years later. </p> <section id="CD000459-sec-0143"> <h5 class="title">Studies awaiting classification</h5> <p>There are currently no studies awaiting assessment for inclusion in this review.</p> </section> <section id="CD000459-sec-0144"> <h5 class="title">Ongoing studies</h5> <p>There is one ongoing study (<a href="./references#CD000459-bbs2-0146" title="N0546099389 . A six month, rater blind comparison of quetiapine and risperidone in the treatment of tardive dyskinesia in patients with schizophrenia. National Research Register (first received 16 July 2015). [N0546099389] ">N0546099389</a>), which compares quetiapine and risperidone. This study was excluded in the previous review, but we have decided to move it to the ongoing studies section. It is a record from a trial registry, and at the time of preparing this update we were unable to locate author contact details or any more information about the study. </p> </section> </section> </section> <section id="CD000459-sec-0145"> <h3 class="title">Risk of bias in included studies</h3> <p>Please refer to <a href="#CD000459-fig-0002">Figure 2</a> and <a href="#CD000459-fig-0003">Figure 3</a> for graphical overviews of the risk of bias in the included studies. </p> <section id="CD000459-sec-0146"> <h4 class="title">Allocation</h4> <p>While all 13 included studies stated that they randomised participants, we considered only three studies to be at low risk of selection bias. Two of these studies explicitly described how they generated the randomisation sequence (<a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>), whereas one described block randomisation with stratification, and we assumed low risk of bias (<a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>). None of the studies described how they concealed allocation and we rated all of them at unclear risk of selection bias. </p> </section> <section id="CD000459-sec-0147"> <h4 class="title">Blinding</h4> <p>Eight studies stated that they were conducted on a double‐blind basis, but none tested the blindness of raters, clinicians and trial participants. Only four studies (<a href="./references#CD000459-bbs2-0001" title="BaiYM , LinCC , YuSC . Risperidone for severe tardive dyskinesia: one year follow up study. International Journal of Neuropsychopharmacology2002;5:S165. BaiYM , YuSC , ChenJY , LinCY , ChouP , LinCC . Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. International Clinical Psychopharmacology2005;20(2):79‐85. BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64:1342‐8. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. ">Bai 2003</a>; <a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>; <a href="./references#CD000459-bbs2-0008" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3(5‐6):315‐20. [MEDLINE: 91129137; PMID 1980827] GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46(8):4‐7. [MEDLINE: 91129137; PMID 1980827] ">Glazer 1990a</a>) explicitly described how they blinded participants and personnel, and we rated them at low risk of performance bias. Five studies did not mention blinding of participants or personnel, or that the study was double‐blind (<a href="./references#CD000459-bbs2-0002" title="BaiYM . Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S473. ">Bai 2005</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>; <a href="./references#CD000459-bbs2-0007" title="EmsleyR , TurnerHJ , SchronenJ , BothaK , SmitR , OosthuizenPP . A single‐blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry2004;65(5):696‐701. [MEDLINE: 15163258] EmsleyRA , TurnerJ , SchronenJ , BothaK , SmitR , OosthuizenPP . Quetiapine: greater improvements in tardive dyskinesia versus haloperidol. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, USA. 2004. [APA Conference Abstracts NR574] ">Emsley 2004</a>; <a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>); these studies were at high risk of performance bias. The remaining four studies were at unclear risk of performance bias; they stated that the study was double‐blind but did not describe further details of blinding. </p> <p>Six studies had blinded raters and were at low risk of detection bias (<a href="./references#CD000459-bbs2-0001" title="BaiYM , LinCC , YuSC . Risperidone for severe tardive dyskinesia: one year follow up study. International Journal of Neuropsychopharmacology2002;5:S165. BaiYM , YuSC , ChenJY , LinCY , ChouP , LinCC . Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. International Clinical Psychopharmacology2005;20(2):79‐85. BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64:1342‐8. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. ">Bai 2003</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>; <a href="./references#CD000459-bbs2-0010" title="KazamatsuriH , ChienC , ColeJO . Treatment of tardive dyskinesia. II. Short‐term efficacy of dopamine‐blocking agents haloperidol and thiopropazate. Archives of General Psychiatry1972;27(1):100‐3. ">Kazamatsuri 1972</a>; <a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>; <a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a>). The remaining seven studies were at unclear risk of detection bias. </p> </section> <section id="CD000459-sec-0148"> <h4 class="title">Incomplete outcome data</h4> <p>Eight studies were at low risk of attrition bias; they either had no dropouts (<a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>) or low dropout rate and reported on dropouts adequately (<a href="./references#CD000459-bbs2-0001" title="BaiYM , LinCC , YuSC . Risperidone for severe tardive dyskinesia: one year follow up study. International Journal of Neuropsychopharmacology2002;5:S165. BaiYM , YuSC , ChenJY , LinCY , ChouP , LinCC . Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. International Clinical Psychopharmacology2005;20(2):79‐85. BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64:1342‐8. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. ">Bai 2003</a>; <a href="./references#CD000459-bbs2-0002" title="BaiYM . Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S473. ">Bai 2005</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>; <a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>; <a href="./references#CD000459-bbs2-0008" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3(5‐6):315‐20. [MEDLINE: 91129137; PMID 1980827] GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46(8):4‐7. [MEDLINE: 91129137; PMID 1980827] ">Glazer 1990a</a>; <a href="./references#CD000459-bbs2-0010" title="KazamatsuriH , ChienC , ColeJO . Treatment of tardive dyskinesia. II. Short‐term efficacy of dopamine‐blocking agents haloperidol and thiopropazate. Archives of General Psychiatry1972;27(1):100‐3. ">Kazamatsuri 1972</a>; <a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>). Five studies had a greater than 30% loss to follow‐up (<a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0007" title="EmsleyR , TurnerHJ , SchronenJ , BothaK , SmitR , OosthuizenPP . A single‐blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry2004;65(5):696‐701. [MEDLINE: 15163258] EmsleyRA , TurnerJ , SchronenJ , BothaK , SmitR , OosthuizenPP . Quetiapine: greater improvements in tardive dyskinesia versus haloperidol. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, USA. 2004. [APA Conference Abstracts NR574] ">Emsley 2004</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>; <a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a>), or unbalanced loss to follow‐up between groups (<a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>), and did not report outcomes for participants lost to follow‐up. These studies were rated at high risk of attrition bias. In all cases, however, we tried to ensure that every person randomised was analysed. </p> </section> <section id="CD000459-sec-0149"> <h4 class="title">Selective reporting</h4> <p>The majority of data in this review originates from published reports. Most of the included studies reported expected outcomes (impact on TD symptoms). Only two trials fully reported outcomes outlined in protocols and were at low risk of reporting bias (<a href="./references#CD000459-bbs2-0002" title="BaiYM . Tardive dyskinesia and cognitive function. clinicaltrials.gov/ct2/show/record/NCT00926965 accessed on 20 June 2016. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. 8th World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BaiYM , PingLY , LinCC , WangYC , LiouYJ , WuBJ , et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24‐week randomized, single‐blind, controlled study. European Neuropsychopharmacology2005;15(Suppl 3):S473. ">Bai 2005</a>; <a href="./references#CD000459-bbs2-0004" title="ChanHY , ChiangSC , ChangCJ , GauSS , ChenJJ , ChenCH , et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. Journal of Clinical Psychiatry2010;71(9):1226‐33. NCT00621998 . Risperidone and olanzapine for the schizophrenic patients with neuroleptic‐induced tardive dyskinesia. www.clinicaltrials.gov2008. ">Chan 2010</a>). Four trials were at unclear risk of bias, as we have had no opportunity to see protocols of these trials to compare the outcomes reported in the full publications with what was measured during the conduct of the trial (<a href="./references#CD000459-bbs2-0001" title="BaiYM , LinCC , YuSC . Risperidone for severe tardive dyskinesia: one year follow up study. International Journal of Neuropsychopharmacology2002;5:S165. BaiYM , YuSC , ChenJY , LinCY , ChouP , LinCC . Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. International Clinical Psychopharmacology2005;20(2):79‐85. BaiYM , YuSC , LinCC . Risperidone for severe tardive dyskinesia: a 12‐week randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64:1342‐8. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. PaiYM , YuSC , LinCC . Risperidone in reducing tardive dyskinesia: a double‐blind, placebo‐controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001. ">Bai 2003</a>; <a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>; <a href="./references#CD000459-bbs2-0008" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3(5‐6):315‐20. [MEDLINE: 91129137; PMID 1980827] GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46(8):4‐7. [MEDLINE: 91129137; PMID 1980827] ">Glazer 1990a</a>; <a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a>). Seven studies did not report results of all outcomes listed in the methods section fully (<a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>; <a href="./references#CD000459-bbs2-0007" title="EmsleyR , TurnerHJ , SchronenJ , BothaK , SmitR , OosthuizenPP . A single‐blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry2004;65(5):696‐701. [MEDLINE: 15163258] EmsleyRA , TurnerJ , SchronenJ , BothaK , SmitR , OosthuizenPP . Quetiapine: greater improvements in tardive dyskinesia versus haloperidol. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, USA. 2004. [APA Conference Abstracts NR574] ">Emsley 2004</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>; <a href="./references#CD000459-bbs2-0010" title="KazamatsuriH , ChienC , ColeJO . Treatment of tardive dyskinesia. II. Short‐term efficacy of dopamine‐blocking agents haloperidol and thiopropazate. Archives of General Psychiatry1972;27(1):100‐3. ">Kazamatsuri 1972</a>; <a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>) and were at high risk of reporting bias. Attempts to contact authors of trials for additional data were mostly unsuccessful, but we did receive some additional data from four of the trialists (<a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>; <a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>). </p> </section> <section id="CD000459-sec-0150"> <h4 class="title">Other potential sources of bias</h4> <p>Four studies reported details such as baseline characteristics with sufficient detail to rate them at low risk of other bias. Four studies were at unclear risk of other bias, three (<a href="./references#CD000459-bbs2-0011" title="KazamatsuriH , ChienCP , ColeJO . Long‐term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry1973;130(4):479‐83. ">Kazamatsuri 1973</a>; <a href="./references#CD000459-bbs2-0010" title="KazamatsuriH , ChienC , ColeJO . Treatment of tardive dyskinesia. II. Short‐term efficacy of dopamine‐blocking agents haloperidol and thiopropazate. Archives of General Psychiatry1972;27(1):100‐3. ">Kazamatsuri 1972</a>; <a href="./references#CD000459-bbs2-0012" title="LublinH , GerlachJ , HagertU , MeidahlB , MolbjergC , PedersenV , et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology1991;1(4):541‐8. ">Lublin 1991</a>) because of insufficiently detailed reporting to rule out any other bias, and one (<a href="./references#CD000459-bbs2-0013" title="TammingaCA , ThakerGK , MoranM , KakigiT , GaoXM . Clozapine in tardive dyskinsia: observations from human and animal model studies. Journal of Clinical Psychiatry1994;55(9, Suppl B):102‐6. ">Tamminga 1994</a>) because the report was on a preliminary analysis with four of 49 subjects not yet having completed the study. Despite randomisation, two studies reported having unequal groups at baseline on important prognostic factors, and thus were at high risk of other bias (<a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>; <a href="./references#CD000459-bbs2-0008" title="GlazerWM , HafezH . A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research1990;3(5‐6):315‐20. [MEDLINE: 91129137; PMID 1980827] GlazerWM , HafezHM , BenarrocheCL . Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry1985;46(8):4‐7. [MEDLINE: 91129137; PMID 1980827] ">Glazer 1990a</a>). Three studies randomised participants with schizophrenia, and this review included secondary reports of post hoc analyses of participants with TD. These studies were therefore at high risk of other bias (<a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a>; <a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>). </p> </section> </section> <section id="CD000459-sec-0151"> <h3 class="title" id="CD000459-sec-0151">Effects of interventions</h3> <p>See: <a href="./full#CD000459-tbl-0001"><b>Summary of findings for the main comparison</b> Reduced dose of antipsychotics compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</a>; <a href="./full#CD000459-tbl-0002"><b>Summary of findings 2</b> Antipsychotic cessation compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</a>; <a href="./full#CD000459-tbl-0003"><b>Summary of findings 3</b> Switch to another antipsychotic compared with antipsychotic cessation for antipsychotic‐induced tardive dyskinesia</a>; <a href="./full#CD000459-tbl-0004"><b>Summary of findings 4</b> Switch to a specific antipsychotic compared with switch to a different specific antipsychotic for antipsychotic‐induced tardive dyskinesia</a>; <a href="./full#CD000459-tbl-0005"><b>Summary of findings 5</b> Specific antipsychotic compared with other drugs for antipsychotic‐induced tardive dyskinesia</a> </p> <p>* indicates primary outcomes.</p> <section id="CD000459-sec-0152"> <h4 class="title">Comparison 1. Reduced overall dose of antipsychotic versus antipsychotic maintenance</h4> <section id="CD000459-sec-0153"> <h5 class="title">1.1 TD symptoms</h5> <p>We had chosen 'No clinically important improvement in TD symptoms' for any time period as a primary outcome, with clinically important improvement defined as more than 50% improvement on any TD scale. Although the data we found in trials did not fit this exactly we feel that the outcome 'not improved to a clinically important extent' fits best with what we had hoped to find. </p> <p>The authors of two RCTs of antipsychotic reduction provided additional data (<a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>). </p> <section id="CD000459-sec-0154"> <h6 class="title">1.1.1 No clinically important improvement*</h6> <p>No clinically important improvement in TD severity was associated with antipsychotic reduction compared with antipsychotic maintenance at 44 to 48 weeks (very low‐quality evidence, 2 RCTs, 17 people, RR 0.42 95% CI 0.17 to 1.04, <a href="./references#CD000459-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD000459-sec-0155"> <h6 class="title">1.1.2 Not any improvement</h6> <p>When the outcome criterion was broadened from clinically significant improvement to improvement of any degree in TD severity, the result persisted at 44 to 48 weeks (very low‐quality evidence, 2 RCTs, 17 people, RR 0.42 95% CI 0.17 to 1.04, <a href="./references#CD000459-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD000459-sec-0156"> <h6 class="title">1.1.3 Deterioration of symptoms</h6> <p>Antipsychotic reduction was not associated with deterioration of TD symptoms compared with continued dose at 44 to 48 weeks (very low‐quality evidence, 2 RCTs, 17 people, RR 0.61 95% CI 0.11 to 3.31, <a href="./references#CD000459-fig-0007" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD000459-sec-0157"> <h5 class="title">1.2 General mental state</h5> <section id="CD000459-sec-0158"> <h6 class="title">1.2.1 Relapse</h6> <p>The number of those relapsing was equivocal over the long term (1 RCT, 8 people, RR 3.00 95% CI 0.16 to 57.36, <a href="./references#CD000459-fig-0008" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD000459-sec-0159"> <h5 class="title">1.3 Acceptability of the treatment: leaving the study early</h5> <p>The number of people leaving the study early was not statistically different for either the antipsychotic reduction group (1/4) or the antipsychotic maintained group (3/4) at 44 to 48 weeks (very low‐quality evidence, 1 RCT, 8 people, RR 0.33 95% CI 0.06 to 1.99, <a href="./references#CD000459-fig-0009" title="">Analysis 1.5</a>). </p> <p>We did not identify any studies that reported on adverse events, hospital and service utilisation outcomes, economic outcomes, social confidence, social inclusion, social networks, personalised quality of life, behaviour, or cognitive state. </p> </section> <section id="CD000459-sec-0160"> <h5 class="title">1.4 Subgroup analysis</h5> <section id="CD000459-sec-0161"> <h6 class="title">1.4.1 Clinical stage: recent‐onset TD</h6> <p>It was not possible to evaluate whether those with recent‐onset TD responded differently to those with more established problems, since neither trial reported data for groups with different durations of TD that could be extracted for separate analyses. </p> </section> <section id="CD000459-sec-0162"> <h6 class="title">1.4.2 Duration of follow‐up</h6> <p>We were unable to investigate any effects that a reduced dose of antipsychotics may have had in relation to duration of follow‐up because both studies had very similar length: 44 and 48 weeks. </p> </section> </section> <section id="CD000459-sec-0163"> <h5 class="title">1.5 Heterogeneity</h5> <p>Data were homogeneous. We did not detect clinical, methodological or statistical heterogeneity as described in <a href="#CD000459-sec-0083">Assessment of heterogeneity</a>. </p> </section> <section id="CD000459-sec-0164"> <h5 class="title">1.6 Sensitivity analyses</h5> <section id="CD000459-sec-0165"> <h6 class="title">1.6.1 Implication of randomisation</h6> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. As both studies stated that they randomised participants, we have not undertaken this sensitivity analysis. </p> </section> <section id="CD000459-sec-0166"> <h6 class="title">1.6.2 Assumptions for lost binary data</h6> <p>At the time of updating this review, we were unable to compare the findings with completer data only, as the previous review authors held data received from study authors. </p> </section> <section id="CD000459-sec-0167"> <h6 class="title">1.6.3 Risk of bias</h6> <p>We judged both studies in this comparison to be at high risk of bias across one or more domains. Therefore, we were unable to perform a sensitivity analysis in this instance. </p> </section> <section id="CD000459-sec-0168"> <h6 class="title">1.6.4 Imputed values</h6> <p>We would have undertaken a sensitivity analysis to assess the effects of including data from cluster‐randomised trials where we used imputed values for ICC in calculating the design effect, however, no cluster‐randomised trials were included in this comparison. </p> </section> <section id="CD000459-sec-0169"> <h6 class="title">1.6.5 Fixed‐effect and random‐effects models</h6> <p>We also synthesised data for the primary outcome using a random‐effects model. This did not alter the significance of the results (2 RCTs, 17 people, RR 0.43, 95% CI 0.17 to 1.08). </p> </section> </section> </section> <section id="CD000459-sec-0170"> <h4 class="title">Comparison 2. Switch to a specific antipsychotic versus placebo (cessation of antipsychotic)</h4> <section id="CD000459-sec-0171"> <h5 class="title">2.1 TD symptoms</h5> <section id="CD000459-sec-0172"> <h6 class="title">2.1.1 No clinically important improvement*</h6> <p>One study found a benefit in favour of antipsychotics against placebo for clinically important improvement in TD symptoms at 12 weeks (low‐quality evidence, 1 RCT, 42 people, RR 0.45 95% CI 0.23 to 0.89, <a href="./references#CD000459-fig-0010" title="">Analysis 2.1</a>). </p> </section> <section id="CD000459-sec-0173"> <h6 class="title">2.1.2 Average difference in severity of TD at the end of the trial</h6> <p>TD symptoms were also measured using the continuous AIMS scale (see <a href="#CD000459-sec-0103">Description of studies</a>, Outcomes). One study found a beneficial effect of antipsychotics when comparing average endpoint scores of the AIMS to placebo at 12 weeks (very low‐quality evidence, 1 RCT, 42 people, MD ‐5.50 95% CI ‐8.60 to ‐2.40, <a href="./references#CD000459-fig-0011" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD000459-sec-0174"> <h5 class="title">2.2 General mental state</h5> <section id="CD000459-sec-0175"> <h6 class="title">2.2.1 Average difference in severity of psychiatric symptoms at the end of the trial</h6> <p>General mental state was measured using the continuous BPRS scale (see <a href="#CD000459-sec-0103">Description of studies</a>, Outcomes). One study found no difference between antipsychotics and placebo on average endpoint score of the BPRS at 12 weeks (1 RCT, 42 people, MD ‐4.30 95% CI ‐10.48 to 1.88, <a href="./references#CD000459-fig-0012" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD000459-sec-0176"> <h5 class="title">2.3 Acceptability of the treatment: leaving the study early</h5> <p>Using antipsychotics did not significantly increase the chances of a person leaving the study early at 12 weeks (very low‐quality evidence, 1 RCT, 50 people, RR 0.60 95% CI 0.16 to 2.25, <a href="./references#CD000459-fig-0013" title="">Analysis 2.4</a>). </p> </section> <section id="CD000459-sec-0177"> <h5 class="title">2.4 Adverse effects</h5> <section id="CD000459-sec-0178"> <h6 class="title">2.4.1 Extrapyramidal symptoms*: need of antiparkinsonism drugs</h6> <p>We found no difference in the use of antiparkinsonism drugs between antipsychotic and placebo at 12 weeks (1 RCT, 48 people, RR 2.08 95% CI 0.74 to 5.86, <a href="./references#CD000459-fig-0014" title="">Analysis 2.5</a>). </p> </section> <section id="CD000459-sec-0179"> <h6 class="title">2.4.2 Average change in extrapyramidal adverse effects: Parkinsonism</h6> <p>One study measured parkinsonism on the continuous ESRS scale (see above). No difference was found between antipsychotics and placebo at 12 weeks (1 RCT, 42 people, MD ‐0.40 95% CI ‐1.25 to 0.45, <a href="./references#CD000459-fig-0015" title="">Analysis 2.6</a>). </p> </section> <section id="CD000459-sec-0180"> <h6 class="title">2.4.3 Average change in extrapyramidal adverse effects: Dystonia</h6> <p>One study measured dystonia using the continuous ESRS scale. No difference was found between those allocated to antipsychotics or placebo at 12 weeks (1 RCT, 42 people, MD ‐0.70 95% CI ‐1.76 to 0.36, <a href="./references#CD000459-fig-0016" title="">Analysis 2.7</a>). </p> <p>We did not identify any studies that reported on hospital and service utilisation outcomes, economic outcomes, social confidence, social inclusion, social networks, personalised quality of life, behaviour, or cognitive state. </p> <p>We also did not identify any studies that investigated the effect on TD of antipsychotic cessation compared with antipsychotic maintenance. </p> </section> </section> <section id="CD000459-sec-0181"> <h5 class="title">2.5 Subgroup and sensitivity analyses</h5> <p>There was only one included study in this comparison, and this study did not report on subgroups. Consequently, subgroup and sensitivity analyses were not carried out. </p> </section> </section> <section id="CD000459-sec-0182"> <h4 class="title">Comparison 3. Switch to a specific antipsychotic versus switch to another specific antipsychotic </h4> <section id="CD000459-sec-0183"> <h5 class="title">3.1 TD symptoms</h5> <section id="CD000459-sec-0184"> <h6 class="title">3.1.1 No clinically important improvement*</h6> <p>None of the four studies that reported on this outcome found a clinically important difference on improvement in TD symptoms between two specific antipsychotics (<a href="./references#CD000459-fig-0017" title="">Analysis 3.1</a>): short‐term: thiopropazate versus haloperidol (low‐quality evidence, 1 RCT, 20 people, RR 1.53, 95% CI 0.58 to 4.05), zuclopenthixol versus haloperidol (low‐quality evidence, 1 RCT, 15 people, RR 1.00, 95% CI 0.79 to 1.27); medium‐term: olanzapine versus risperidone (low‐quality evidence, 1 RCT, 60 people, RR 1.25, 95% CI 0.82 to 1.90), quetiapine versus haloperidol (low‐quality evidence, 1 RCT, 45 people, RR 0.80, 95% CI 0.52 to 1.22); long‐term: quetiapine versus haloperidol (low‐quality evidence, 1 RCT, 45 people, RR 0.88, 95% CI 0.64 to 1.21). </p> </section> <section id="CD000459-sec-0185"> <h6 class="title">3.1.2 Not any improvement</h6> <p>Neither of the two studies that reported on any improvement of TD symptoms found a difference between two specific antipsychotics (<a href="./references#CD000459-fig-0018" title="">Analysis 3.2</a>): short‐term: thiopropazate versus haloperidol (low‐quality evidence, 1 RCT, 20 people, RR 0.41, 95% CI 0.05 to 3.28), zuclopenthixol versus haloperidol (low‐quality evidence, 1 RCT, 15 people, RR 0.88, 95% CI 0.16 to 4.68). </p> </section> <section id="CD000459-sec-0186"> <h6 class="title">3.1.3 Deterioration of symptoms</h6> <p>Neither of the two studies that reported on deterioration of TD symptoms found a difference between two specific antipsychotics (<a href="./references#CD000459-fig-0019" title="">Analysis 3.3</a>): short‐term: thiopropazate versus haloperidol (low‐quality evidence, 1 RCT, 20 people, RR 1.22, 95% CI 0.09 to 16.92), zuclopenthixol versus haloperidol (low‐quality evidence, 1 RCT, 15 people, RR 0.88, 95% CI 0.16 to 4.68). </p> </section> <section id="CD000459-sec-0187"> <h6 class="title">3.1.2 Average difference in severity of TD at the end of the trial</h6> <p>A short‐term (two weeks) study of people with established withdrawal‐exacerbated TD found no difference on endpoint AIMS scores after the first week (1 RCT, 18 people, MD 1.87, 95% CI ‐0.20 to 3.94) for the groups receiving molindone or haloperidol at the standard dosage range. Results for the second week, using higher 'masking' dosages, significantly favoured the haloperidol group (1 RCT, 18 people, MD 3.44, 95% CI 1.12 to 5.76). Another short‐term study comparing zuclopenthixol and haloperidol found no difference between groups on endpoint SHRS scores (1 RCT, 15 people, MD ‐4.81, 95% CI ‐12.15 to 2.53). Finally, a medium‐term study found no difference between olanzapine and risperidone on endpoint AIMS scores (1 RCT, 60 people, MD 2.20, 95% CI ‐0.53 to 4.93). See <a href="./references#CD000459-fig-0020" title="">Analysis 3.4</a>. </p> </section> <section id="CD000459-sec-0188"> <h6 class="title">3.1.4 Average change in severity of TD during the trial period</h6> <p>One study found amisulpride favourable to olanzapine in reducing TD symptoms measured by AIMS change from baseline scores at medium term (1 RCT, 54 people, MD 2.48, 95% CI 0.44 to 4.52). Three other comparisons found no difference between specific antipsychotics at medium term: olanzapine versus unspecified FGAs (1 RCT, 53 people, MD 1.66, 95% CI ‐0.45 to 3.77), amisulpride vs unspecified FGAs (1 RCT, 53 people, MD ‐0.82, 95% CI ‐2.85 to 1.21), and olanzapine vs risperidone (1 RCT, 60 people, MD 1.20, 95% CI ‐2.58 to 4.98, <a href="./references#CD000459-fig-0021" title="">Analysis 3.5</a>). </p> </section> </section> <section id="CD000459-sec-0189"> <h5 class="title">3.2 General mental state</h5> <section id="CD000459-sec-0190"> <h6 class="title">3.2.1 Deterioration of mental state</h6> <p>No difference was found in the proportion with deterioration of mental state between specific antipsychotics: zuclopenthixol versus haloperidol at short term (1 RCT, 15 people, RR 0.30, 95% CI 0.01 to 6.29), olanzapine versus risperidone at medium term (1 RCT, 60 people, RR 1.00, 95% CI 0.15 to 6.64), quetiapine versus haloperidol at long term (1 RCT, 45 people, RR 1.83, 95% CI 0.62 to 5.39, <a href="./references#CD000459-fig-0022" title="">Analysis 3.6</a>). </p> </section> <section id="CD000459-sec-0191"> <h6 class="title">3.2.2 Average difference in severity of psychiatric symptoms at the end of the trial</h6> <p>No difference was found in average endpoint scores of the PANSS between quetiapine and haloperidol at long term (1 RCT, 45 people, MD ‐2.20, 95% CI ‐6.02 to 1.62, <a href="./references#CD000459-fig-0023" title="">Analysis 3.7</a>). </p> </section> <section id="CD000459-sec-0192"> <h6 class="title">3.2.3 Average change in severity of psychiatric symptoms during the trial period</h6> <p>There was also no difference on the average endpoint scores on the BPRS between specific antipsychotics at medium term: olanzapine versus unspecified FGAs (1 RCT, 53 people, MD ‐1.14, 95% CI ‐4.79 to 2.51), amisulpride versus unspecified FGAs (1 RCT, 53 people, MD ‐2.46, 95% CI ‐6.27 to 1.35), olanzapine versus risperidone (1 RCT, 60 people, MD ‐1.70, 95% CI ‐8.37 to 4.97), and olanzapine versus amisulpride (1 RCT, 54 people, MD 1.32, 95% CI ‐1.94 to 4.58, <a href="./references#CD000459-fig-0024" title="">Analysis 3.8</a>). </p> </section> </section> <section id="CD000459-sec-0193"> <h5 class="title">3.3 Acceptability of the treatment: leaving the study early</h5> <p>In the short term, a specific antipsychotic did not significantly increase the chances of a person leaving the study early compared with another specific antipsychotic: molindone versus haloperidol (1 RCT, 18 people, MD not estimable, there were no events), thiopropazate versus haloperidol (1 RCT, 20 people, MD 0.24, 95% CI 0.01 to 4.44, <a href="./references#CD000459-fig-0025" title="">Analysis 3.9</a>). In the medium term, switching to olanzapine significantly reduced the chances of a person leaving the study early compared with switching to risperidone (2 RCTs, 170 people, RR 0.73 95% CI 0.57 to 0.95, I<sup>2</sup> = 0, <a href="./references#CD000459-fig-0026" title="">Analysis 3.10</a>) or compared with switching to quetiapine (1 RCT, 116 people, RR 0.70 95% CI 0.54 to 0.90). For all other comparisons between specific antipsychotics at medium term, there was no difference in the chances of a person leaving the study early: olanzapine versus unspecified FGAs (1 RCT, 56 people, RR 1.86, 95% CI 0.18 to 19.38), amisulpride versus unspecified FGAs (1 RCT, 55 people, RR 0.96, 95% CI 0.06 to 14.65), olanzapine versus amisulpride (1 RCT, 57 people, RR 1.93, 95% CI 0.19 to 20.12), olanzapine versus ziprasidone (1 RCT, 82 people, RR 0.77, 95% CI 0.56 to 1.05), quetiapine versus risperidone (1 RCT, 118 people, RR 1.05, 95% CI 0.88 to 1.25), quetiapine versus ziprasidone (1 RCT, 90 people, RR 1.10, 95% CI 0.86 to 1.40), ziprasidone versus risperidone (1 RCT, 84 people, RR 0.95, 95% CI 0.74 to 1.23). Finally, in the long term, there was no difference between clozapine and haloperidol (1 RCT, 39 people, RR 3.36, 95% CI 0.45 to 25.16), or between quetiapine and haloperidol on the number leaving the study early (1 RCT, 45 people, RR 1.31, 95% CI 0.63 to 2.69, see <a href="./references#CD000459-fig-0027" title="">Analysis 3.11</a>). </p> </section> <section id="CD000459-sec-0194"> <h5 class="title">3.4 Adverse events</h5> <section id="CD000459-sec-0195"> <h6 class="title">3.4.1 Extrapyramidal symptoms*: need of antiparkinsonism drugs</h6> <p>A study comparing risperidone and haloperidol found no difference between groups at medium term (1 RCT, 37 people, RR 0.68, 95% CI 0.34 to 1.35, <a href="./references#CD000459-fig-0028" title="">Analysis 3.12</a>). Another study found that participants allocated to haloperidol were more likely to need antiparkinsonism drugs than those allocated to quetiapine in the long term (1 RCT, 45 people, RR 0.45, 95% CI 0.21 to 2.96, <a href="./references#CD000459-fig-0028" title="">Analysis 3.12</a>). </p> </section> <section id="CD000459-sec-0196"> <h6 class="title">3.4.2 Average change in extrapyramidal adverse effects: Parkinsonism</h6> <p>Symptoms of parkinsonism were measured using the continuous SAS, SHRS, and ESRS scales (see <a href="#CD000459-sec-0103">Description of studies</a>, Outcomes). At short term, one study found no difference in parkinsonism symptoms measured by SHRS endpoint scores between zuclopenthixol and haloperidol (1 RCT, 15 people, MD ‐4.81, 95% CI ‐12.15 to 2.53, <a href="./references#CD000459-fig-0029" title="">Analysis 3.13</a>). One study found those allocated to olanzapine were less likely to develop symptoms of parkinsonism than those allocated to risperidone measured by ESRS change scores at medium term (1 RCT, 60 people, MD ‐0.70, 95% CI ‐1.33 to ‐0.07). For all other comparisons between specific antipsychotics at medium term, there was no difference in symptoms of parkinsonism as measured by average change scores: olanzapine versus unspecified FGAs (1 RCT, 53 people, MD ‐0.85, 95% CI ‐2.55 to 0.85), amisulpride versus unspecified FGAs (1 RCT, 53 people, MD ‐0.50, 95% CI ‐2.45 to 1.45), and olanzapine versus amisulpride (1 RCT, 54 people, MD ‐0.35, 95% CI ‐2.44 to 1.74, <a href="./references#CD000459-fig-0030" title="">Analysis 3.14</a>). </p> </section> <section id="CD000459-sec-0197"> <h6 class="title">3.4.3 Average change in extrapyramidal adverse effects: Dyskinesia</h6> <p>Symptoms of dyskinesia were measured using the continuous ESRS scale. There was no difference in symptoms of dyskinesia between those switching to olanzapine and those switching to risperidone (1 RCT, 60 people, MD 0.30, 95% CI ‐0.91 to 1.51, <a href="./references#CD000459-fig-0031" title="">Analysis 3.15</a>). </p> </section> <section id="CD000459-sec-0198"> <h6 class="title">3.4.4 Average change in extrapyramidal adverse effects: Akathisia</h6> <p>Symptoms of akathisia were measured using the continuous BAS and ESRS scales (see <a href="#CD000459-sec-0103">Description of studies</a>, Outcomes, <a href="./references#CD000459-fig-0032" title="">Analysis 3.16</a>). There was no difference in symptoms of akathisia for those switching to olanzapine (1 RCT, 53 people, MD 0.08 95% CI ‐0.30 to 0.46) or amisulpride (1 RCT, 53 people, MD ‐0.11 95% CI ‐0.42 to 0.20) compared with those remaining on unspecified FGAs. There was also no difference for those switching to olanzapine compared with those switching to risperidone (1 RCT, 60 people, MD ‐0.80 95% CI ‐1.76 to 0.16) or amisulpride (1 RCT, 54 people, MD 0.19 95% CI ‐0.12 to 0.50). </p> </section> <section id="CD000459-sec-0199"> <h6 class="title">3.4.5 Average change in extrapyramidal adverse effects: Dystonia</h6> <p>Symptoms of dystonia were measured using the continuous ESRS scale. There was no difference in symptoms of dystonia in those switching to olanzapine compared with those switching to risperidone (1 RCT, 60 people, MD ‐0.70 95% CI ‐1.41 to 0.01, <a href="./references#CD000459-fig-0033" title="">Analysis 3.17</a>). </p> </section> <section id="CD000459-sec-0200"> <h6 class="title">3.4.6 Average change in general adverse events</h6> <p>General adverse events were measured using the continuous UKU scale (see <a href="#CD000459-sec-0103">Description of studies</a>, Outcomes, <a href="./references#CD000459-fig-0034" title="">Analysis 3.18</a>). There was no difference in general adverse events for those switching to olanzapine (1 RCT, 53 people, MD 0.08 95% CI ‐1.85 to 2.01) or amisulpride (1 RCT, 53 people, MD ‐0.55 95% CI ‐2.33 to 1.23) compared with those remaining on unspecified FGAs. There was also no difference for those switching to olanzapine compared with those switching to amisulpride (1 RCT, 54 people, MD 0.63 95% CI ‐0.93 to 2.19). </p> </section> </section> <section id="CD000459-sec-0201"> <h5 class="title">3.5 Global state</h5> <section id="CD000459-sec-0202"> <h6 class="title">3.5.1 Average change in global state</h6> <p>Global state was measured using the continuous CGI scale (see <a href="#CD000459-sec-0103">Description of studies</a>, Outcomes, <a href="./references#CD000459-fig-0035" title="">Analysis 3.19</a>). There was no difference in change scores of global state in those switching to olanzapine (1 RCT, 53 people, MD ‐0.07 95% CI ‐0.41 to 0.27) or amisulpride (1 RCT, 53 people, MD ‐0.19 95% CI ‐0.47 to 0.09) compared with those remaining on FGA. There was also no difference in those switching to olanzapine compared with those switching to risperidone (1 RCT, 60 people, MD 0.10 95% CI ‐0.61 to 0.81) or amisulpride (1 RCT, 54 people, MD 0.12 95% CI ‐0.19 to 0.43). </p> <p>We did not identify any studies that reported on hospital and service utilisation outcomes, economic outcomes, social confidence, social inclusion, social networks, personalised quality of life, behaviour, or cognitive state. </p> </section> </section> <section id="CD000459-sec-0203"> <h5 class="title">3.6 Subgroup and sensitivity analyses</h5> <p>There were no meta‐analyses for the primary outcomes of this comparison because studies were stratified by antipsychotic medication. Consequently, we did not carry out subgroup and sensitivity analyses. </p> </section> </section> <section id="CD000459-sec-0204"> <h4 class="title">Comparison 4. Specific antipsychotic versus other drug</h4> <section id="CD000459-sec-0205"> <h5 class="title">4.1 TD symptoms</h5> <section id="CD000459-sec-0206"> <h6 class="title">4.1.1 No clinically important improvement*</h6> <p>One study found no difference between haloperidol and tetrabenazine for clinically important improvement in TD symptoms at 24 weeks (very low‐quality evidence, 1 RCT, 13 people, RR 1.07 95% CI 0.51 to 2.23, <a href="./references#CD000459-fig-0036" title="">Analysis 4.1</a>). </p> </section> <section id="CD000459-sec-0207"> <h6 class="title">4.1.2 Not any improvement</h6> <p>One study found no difference between haloperidol and tetrabenazine for the outcome 'no improvement in TD symptoms' at 24 weeks (1 RCT, 13 people, RR 2.57 95% CI 0.35 to 18.68, <a href="./references#CD000459-fig-0037" title="">Analysis 4.2</a>). </p> </section> <section id="CD000459-sec-0208"> <h6 class="title">4.1.3 Deterioration of symptoms</h6> <p>One study found no difference on deterioration of TD symptoms between haloperidol and tetrabenazine at 24 weeks (very low‐quality evidence, 1 RCT, 13 people, RR 0.86 95% CI 0.07 to 10.96, <a href="./references#CD000459-fig-0038" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD000459-sec-0209"> <h5 class="title">4.2 Acceptability of the treatment: leaving the study early</h5> <p>One study found no difference in the proportion of people leaving the study early between haloperidol and tetrabenazine at 24 weeks (very low quality‐evidence, 1 RCT, 13 people, RR 4.38 95% CI 0.25 to 76.54, <a href="./references#CD000459-fig-0039" title="">Analysis 4.4</a>). </p> <p>We did not identify any studies that reported on mental state, adverse events, hospital and service utilisation outcomes, economic outcomes, social confidence, social inclusion, social networks, personalised quality of life, behaviour, or cognitive state. </p> </section> <section id="CD000459-sec-0210"> <h5 class="title">4.3 Subgroup and sensitivity analyses</h5> <p>There was only one included study in this comparison, and this study did not report on subgroups. Consequently, we did not carry out subgroup and sensitivity analyses. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000459-sec-0211" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000459-sec-0211"></div> <section id="CD000459-sec-0212"> <h3 class="title" id="CD000459-sec-0212">Summary of main results</h3> <section id="CD000459-sec-0213"> <h4 class="title">1. The search</h4> <p>This area of research does not seem to be active. We have identified additional data, but most trials predate the year 2000; only three were carried out after, published in 2004 to 2011. This could be due to a decreased concern with TD, or less emergence of the problem in research‐active communities because of more thoughtful use of antipsychotic drugs or loss of faith in potential treatments. </p> </section> <section id="CD000459-sec-0214"> <h4 class="title">2. Few data</h4> <p>Only a little over 700 people were included in this review. It is possible that real and important effects have not been highlighted because of the necessarily wide CIs of the findings. Many outcomes were not measured at all by the included studies (see <a href="#CD000459-sec-0221">Overall completeness and applicability of evidence</a>), including one of our outcome measures that was selected as important. We may have been overambitious in hoping for some of these outcomes in TD trials, but simple reporting of social impact and quality of life is of particular interest to patients and carers. Finally, we did not identify any RCTs of participants with TD that compared antipsychotic cessation with antipsychotic maintenance. </p> </section> <section id="CD000459-sec-0215"> <h4 class="title">3. Outcomes</h4> <section id="CD000459-sec-0216"> <h5 class="title">3.1 Tardive dyskinesia symptoms</h5> <p>We found low‐quality evidence of clinically important improvement in TD symptoms for switching antipsychotic to risperidone compared with antipsychotic cessation (with placebo) after 12 weeks (RR 0.45, 95% CI 0.23 to 0.89, 1 study, 42 participants). Because the quality of the evidence is low, we have limited confidence in the effect estimates and CIs; the true effects may be substantially different. </p> <p>For the remaining comparisons: antipsychotic reduction versus maintenance, switch to a new antipsychotic versus switch to a different new antipsychotic, and specific antipsychotic versus other drug, we found low to very low‐quality evidence of little or no difference between groups for no clinically important improvement in TD symptoms and deterioration of TD symptoms, but again, our confidence in these results is limited due to the poor‐quality evidence, not least because there were few participants (13 to 60 participants per comparison). </p> </section> <section id="CD000459-sec-0217"> <h5 class="title">3.2 Adverse effects</h5> <p>There was low‐quality evidence of fewer people that needed antiparkinsonism medication due to extrapyramidal side effects after switching to quetiapine compared with haloperidol after one year (RR 0.45, 95% CI 0.21 to 0.96, 1 study, 45 participants). Due to the low quality of this evidence, our confidence in these results is limited. For the other comparisons, switch to haloperidol or risperidone versus antipsychotic cessation, and risperidone versus haloperidol, we found very low‐quality evidence of little or no difference between groups. Therefore, we are very uncertain about these results, not least because there were few participants (37 and 48 participants per comparison). </p> </section> <section id="CD000459-sec-0218"> <h5 class="title">3.3 Mental state</h5> <p>We found low‐ to very low‐quality evidence of little or no difference in mental state: relapse, deterioration of mental state, or average endpoint scores on scales measuring mental state, between groups of the following comparisons: antipsychotic reduction versus maintenance, switch to risperidone versus antipsychotic cessation, switch to zuclopenthixol versus haloperidol, switch to olanzapine versus risperidone, and switch to quetiapine versus haloperidol. Again, our confidence in these results is limited due to the poor quality of evidence, not least because there were few participants (8 to 60 participants per comparison). </p> </section> <section id="CD000459-sec-0219"> <h5 class="title">3.4 Acceptability of treatment: leaving the study early</h5> <p>It is always unclear what leaving a study early means. It could be related to the participant not accepting treatment for a series of reasons, or to participants finding the trial intolerable. It also could be a function of a trial design in which willing participants are still asked to leave because of some degree of protocol violation. </p> <p>There was very low‐quality evidence for most of the comparisons that the number of participants leaving the study early was no different in either group. The small number of people randomised in these comparisons (8 to 170 participants) made the likelihood of an unequivocal outcome unlikely. However, we found very low‐quality evidence that fewer participants allocated to olanzapine left the study early compared with risperidone and compared with quetiapine. Since evidence was of very low quality for both comparisons, we have very little confidence in the effect estimates and CIs; the true effects are likely to be substantially different. </p> </section> <section id="CD000459-sec-0220"> <h5 class="title">3.5 Social confidence, social inclusion, social networks, or personalised quality of life </h5> <p>We selected this group of outcomes for the 2017 review update following a service‐user consultation, as being of importance to patients. We did not identify any studies that reported on any of these outcomes. </p> </section> </section> </section> <section id="CD000459-sec-0221"> <h3 class="title" id="CD000459-sec-0221">Overall completeness and applicability of evidence</h3> <section id="CD000459-sec-0222"> <h4 class="title">1. Completeness</h4> <p>No outcomes in this review involved large numbers of people. There is a large literature of trials assessing the impact of antipsychotic reduction or cessation, or both, on outcomes such as symptoms and relapse. Much of the initial impetus for these trials was derived from concerns about antipsychotic‐induced TD. It was disappointing to note that many of these trials did not systematically assess TD, and thus were not suitable for inclusion in this review. While many trials of antipsychotic reduction and/or cessation assess TD, the baseline and endpoint means are rarely presented for those with TD at baseline. Two authors (<a href="./references#CD000459-bbs2-0006" title="CooksonIB . The effects of a 50% reduction of cis(z)‐flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology1987;2:141‐9. ">Cookson 1987</a>; <a href="./references#CD000459-bbs2-0009" title="KaneJM , RifkinA , WoernerM , ReardonG , SarantokosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Archives of General Psychiatry1983;40(8):893‐6. ">Kane 1983</a>) kindly provided raw data from which we could extract the impact of antipsychotic reduction on those with TD at baseline. The very small sample size limits the confidence that one can place on the equivocal results. </p> <p>Post hoc analyses of the main efficacy and safety analyses for the newer atypicals have also been undertaken (for example, <a href="./references#CD000459-bbs2-0003" title="CaroffSN , DavisVG , MillerDD , DavisSM , RosenheckRA , McEvoyJP , et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry2011;72(3):295‐303. [DOI: 10.4088/JCP.09m05793yel] MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry2008; Vol. 193, issue 4:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005; Vol. 80, issue 1:33‐43. ">Caroff 2011</a> and <a href="./references#CD000459-bbs2-0005" title="ChouinardG , ArnottW . An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry. 1993; Vol. Jun 6‐12:22. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian multicenter placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(1):25‐40. Chouinard , G . Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology1995;15(Suppl 1):S36‐S44. Chouinard , G. ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology1992;15 (Suppl 1 Pt B):266. Chouinard , G. ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry1992;31:158. ">Chouinard 1995</a>). The analyses of results from these trials need to be interpreted with caution for several reasons: (a) suboptimal design for the assessment of treatment of TD (for example, pre‐entry washout or gradual conversion to study drug); (b) the analyses were post hoc; and (c) differences in results between different arms in the studies may reflect antipsychotic suppression due to differing dosing strategies. </p> <p>There were no data on the patient‐designated important outcomes social confidence, social inclusion, social networks, or personalised quality of life, nor were there data on hospital and service utilisation outcomes, economic outcomes, behaviour or cognitive response. </p> </section> <section id="CD000459-sec-0223"> <h4 class="title">2. Applicability</h4> <p>Trial participants were mostly men in their 50s with schizophrenia in hospital, but were nevertheless people who would be recognisable in everyday care. </p> <p>Reducing or stopping antipsychotic medication may not be clinically prudent in some situations. The current lack of evidence showing any improvement in TD with such strategies means that clinicians may be less inclined to use them in mentally stable patients. On the other hand, high‐quality evidence in this area would be very useful and applicable in everyday clinical practice to aid in the decision making around the risk and benefits of reducing or stopping antipsychotic medication following the emergence of TD. </p> </section> </section> <section id="CD000459-sec-0224"> <h3 class="title" id="CD000459-sec-0224">Quality of the evidence</h3> <p>Overall, the quality of the evidence is low to very low. This means that we have limited to very little confidence in the effect estimates, and the true effect may be, or is likely to be, substantially different from the estimate of the effect. The main reasons for our low confidence in the evidence were: </p> <p> <ol id="CD000459-list-0002"> <li> <p>poor study methodology and reporting of methods resulting in downgrading evidence for risk of bias; </p> </li> <li> <p>very small sample sizes resulting in downgrading evidence for imprecision;</p> </li> <li> <p>wide CIs (often due to low event rates) that included appreciable benefit or harm for the intervention as well as no effect, resulting in downgrading evidence for imprecision. </p> </li> </ol> </p> <p>Please see <a href="./full#CD000459-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD000459-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD000459-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD000459-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD000459-tbl-0005">summary of findings Table 5</a> for full details. </p> </section> <section id="CD000459-sec-0225"> <h3 class="title" id="CD000459-sec-0225">Potential biases in the review process</h3> <section id="CD000459-sec-0226"> <h4 class="title">1. Missing studies</h4> <p>Every effort was made to identify relevant trials. However, these studies were all small and it is likely that we have failed to identify other studies of limited power. We do not, however, think it likely that we have failed to identify large relevant studies. </p> </section> <section id="CD000459-sec-0227"> <h4 class="title">2. Missing data</h4> <p>We excluded 14 studies published between 1971 and 1998 that did not provide any usable data, see <a href="#CD000459-sec-0142">Excluded studies</a>. We contacted study authors and six replied to confirm no usable data were available. Authors of three studies did not reply, and we could not find up‐to‐date contact details for authors of five studies (all over 25 years old). We find it very unlikely that we would receive a reply from study authors regarding research conducted so many years ago; therefore, we also excluded these studies. </p> </section> <section id="CD000459-sec-0228"> <h4 class="title">3. Introducing bias</h4> <p>We have tried to be balanced in our appraisal of the evidence but could have inadvertently introduced bias. We welcome comments or criticisms. New methods and innovations now make it possible to report data where, in the past, we could not report data at all or had to report data in a different way. We believe the 'Summary of findings' tables are a valuable innovation – but problematic to those not ‘blind’ to the outcome data. It is possible to ‘cherry pick’ significant findings for presentation in this table. We have tried to decrease the chance of doing this by asking a new reviewer (HB) to select outcomes relevant for this table before becoming familiar with the data. </p> </section> </section> <section id="CD000459-sec-0229"> <h3 class="title" id="CD000459-sec-0229">Agreements and disagreements with other studies or reviews</h3> <p>While the reduction or cessation, or both, of antipsychotics appears a rational first line of treatment for TD, the evidence from systematic reviews such as <a href="./references#CD000459-bbs2-0190" title="GilbertPL , HarrisJ , McAdamLA , JesteDV . Neuroleptic withdrawal in schizophrenic patients ‐ a review of the literature. Archives of General Psychiatry1995;52:173‐88. ">Gilbert 1995</a> highlights the very high risk of relapse associated with both antipsychotic cessation and antipsychotic reduction. In addition, there is evidence from the literature that intermittent therapy may be associated with more unfavourable TD outcomes (higher scores, fewer eventual remissions etc.) (<a href="./references#CD000459-bbs2-0158" title="BerginJ , KitchinR , BerryG . Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biological Psychiatry1992;32:580‐94. ">Bergin 1992</a>; <a href="./references#CD000459-bbs2-0081" title="JesteDV , PotkinSG , SinhaS , FederS , WyattRJ . Tardive dyskinesia ‐ reversible and persistent. Archives of General Psychiatry1979;36(May):585‐90. ">Jeste 1979</a>; <a href="./references#CD000459-bbs2-0104" title="GerlachJ . Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale1988;XIV:227‐32. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology1986;90(4):423‐9. PovlsenUJ , NoringU , MeidahlB , KorsgaardS , WaehrensJ , GerlachJ . [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger1987;149(25):1682‐5. ">NDSG 1986</a>). </p> <p>It is of interest to note that naturalistic studies suggest that TD fluctuates over time, and often improves in spite of continuing antipsychotic exposure (<a href="./references#CD000459-bbs2-0164" title="CaseyD , GerlachJ . Tardive dyskinesia: what is the long‐term outcome?. In: CaseyD , GardosG editor(s). Tardive dyskinesia and neuroleptics: from dogma to reason. Washington DC: American Psychiatric Press, 1986. ">Casey 1986</a>). <a href="./references#CD000459-bbs2-0203" title="KaneJM , WoernerM , SatantakosS , KinonB , LiebermanJ . Do low‐dose neuroleptics prevent or ameliorate tardive dyskinesia?. In: CaseyD , GardosG editor(s). Tardive Dyskinesia and Neuroleptics: From Dogma to Reason. Washington DC: American Psychiatric Press, 1986. ">Kane 1986</a> analysed data on 98 people followed up for at least seven years and reported that those on lower doses of antipsychotics were more likely to have an improvement in their TD. <a href="./references#CD000459-bbs2-0186" title="GardosG , ColeJO , HaskellD , MarbyD , Schniebolk PaineS , MooreP . The natural history of tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8:31S‐7S. ">Gardos 1988</a> reported that improvement in TD was associated with lower antipsychotic doses after TD onset. Using a sophisticated epidemiological approach, <a href="./references#CD000459-bbs2-0218" title="MorgensternH , GlazerWM . Identifying risk factors for tardive dyskinesia among long‐term outpatients maintained with neuroleptic medication. Results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry1993;50:723‐33. ">Morgenstern 1993</a> looked at risk factors for new cases of TD. Higher average antipsychotic medication was associated with an increased risk of developing persistent TD. However, <a href="./references#CD000459-bbs2-0167" title="CavallaroR , RegazzettiMG , MundoE , BrancatoV , SmeraldiE . Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence. Neuropsychopharmacology1993;8(3):233‐9. ">Cavallaro 1993</a> assessed TD prognosis (persistent, remitting etc) with respect to antipsychotic dose change (decreased, increased, unchanged) in 125 inpatients followed up for three years. They found no significant association between antipsychotic reduction and improved TD outcome. As with all uncontrolled studies, these data need to be interpreted cautiously, because those who have less responsive psychoses may require higher doses and have higher rates of TD regardless of treatment. </p> <p>Also of note, in more recent years commentators are more likely to concede that no change in antipsychotic medications may be required for those with TD (<a href="./references#CD000459-bbs2-0187" title="GardosG , CaseyDE , ColeJO , PerenyiA , KocsisE , AratoM , et al. Ten‐year outcome of tardive dyskinesia. American Journal of Psychiatry1994;151:836‐41. ">Gardos 1994</a>). <a href="./references#CD000459-bbs2-0164" title="CaseyD , GerlachJ . Tardive dyskinesia: what is the long‐term outcome?. In: CaseyD , GardosG editor(s). Tardive dyskinesia and neuroleptics: from dogma to reason. Washington DC: American Psychiatric Press, 1986. ">Casey 1986</a> suggested, "therefore, antipsychotics in low to moderate doses are not contra‐indicated in patients with psychosis and will not inevitably aggravate TD" (p. 89). There is some evidence to suggest that younger people (under 60 years) who develop TD are three times more likely to recover when compared with those who develop TD after that age (<a href="./references#CD000459-bbs2-0229" title="SmithJM , BalessariniRJ . Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry1980;37:1368‐73. ">Smith 1980</a>). One interpretation of the data would suggest that, for younger people who develop TD that is not associated with significant impairment, no change to treatment is required other than regular monitoring and reassurance. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000459-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Message from one of the participants of the public and patient involvement consultation of service user perspectives on tardive dyskinesia research" data-id="CD000459-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Message from one of the participants of the public and patient involvement consultation of service user perspectives on tardive dyskinesia research </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD000459-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000459-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for 2015 and 2017 searches for this review" data-id="CD000459-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Study flow diagram for 2015 and 2017 searches for this review</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Reduced overall dose of antipsychotic vs antipsychotic maintenance, Outcome 1 Tardive dyskinesia: no clinically important improvement (long term)." data-id="CD000459-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Reduced overall dose of antipsychotic vs antipsychotic maintenance, Outcome 1 Tardive dyskinesia: no clinically important improvement (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Reduced overall dose of antipsychotic vs antipsychotic maintenance, Outcome 2 Tardive dyskinesia: no improvement (long term)." data-id="CD000459-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Reduced overall dose of antipsychotic vs antipsychotic maintenance, Outcome 2 Tardive dyskinesia: no improvement (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Reduced overall dose of antipsychotic vs antipsychotic maintenance, Outcome 3 Tardive dyskinesia: deterioration (long term)." data-id="CD000459-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Reduced overall dose of antipsychotic vs antipsychotic maintenance, Outcome 3 Tardive dyskinesia: deterioration (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Reduced overall dose of antipsychotic vs antipsychotic maintenance, Outcome 4 General mental state: relapse (long term)." data-id="CD000459-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Reduced overall dose of antipsychotic vs antipsychotic maintenance, Outcome 4 General mental state: relapse (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Reduced overall dose of antipsychotic vs antipsychotic maintenance, Outcome 5 Acceptability of the treatment: leaving the study early (long term)." data-id="CD000459-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Reduced overall dose of antipsychotic vs antipsychotic maintenance, Outcome 5 Acceptability of the treatment: leaving the study early (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 1 Tardive dyskinesia: no clinically important improvement (medium term)." data-id="CD000459-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 1 Tardive dyskinesia: no clinically important improvement (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 2 Tardive dyskinesia: average endpoint score (AIMS, high = poor) (medium term)." data-id="CD000459-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 2 Tardive dyskinesia: average endpoint score (AIMS, high = poor) (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 3 General mental state: average endpoint score (BPRS, high = poor) (medium term)." data-id="CD000459-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 3 General mental state: average endpoint score (BPRS, high = poor) (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 4 Acceptability of the treatment: leaving the study early (medium term)." data-id="CD000459-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 4 Acceptability of the treatment: leaving the study early (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 5 Adverse effects: use of antiparkinsonism drugs (medium term)." data-id="CD000459-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 5 Adverse effects: use of antiparkinsonism drugs (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 6 Adverse effects: parkinsonism ‐ average endpoint score (ESRS) (medium term)." data-id="CD000459-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 6 Adverse effects: parkinsonism ‐ average endpoint score (ESRS) (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 7 Adverse effects: dystonia ‐ average endpoint score (ESRS) (medium term)." data-id="CD000459-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Switch to specific antipsychotic vs antipsychotic cessation, Outcome 7 Adverse effects: dystonia ‐ average endpoint score (ESRS) (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 1 Tardive dyskinesia: no clinically important improvement." data-id="CD000459-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 1 Tardive dyskinesia: no clinically important improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 2 Tardive dyskinesia: not any improvement (short term)." data-id="CD000459-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 2 Tardive dyskinesia: not any improvement (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 3 Tardive dyskinesia: deterioration (short term)." data-id="CD000459-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 3 Tardive dyskinesia: deterioration (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 4 Tardive dyskinesia: average endpoint score (various scales)." data-id="CD000459-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 4 Tardive dyskinesia: average endpoint score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 5 Tardive dyskinesia: average change score (AIMS, low = better) (medium term)." data-id="CD000459-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 5 Tardive dyskinesia: average change score (AIMS, low = better) (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 6 General mental state: deterioration." data-id="CD000459-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 6 General mental state: deterioration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 7 General mental state: average endpoint score (PANSS‐general psychopathology, low = better) (long term)." data-id="CD000459-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 7 General mental state: average endpoint score (PANSS‐general psychopathology, low = better) (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 8 General mental state: average change score (BPRS, low = better) (medium term)." data-id="CD000459-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 8 General mental state: average change score (BPRS, low = better) (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 9 Acceptability of the treatment: leaving the study early (short term)." data-id="CD000459-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 9 Acceptability of the treatment: leaving the study early (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 10 Acceptability of the treatment: leaving the study early (medium term)." data-id="CD000459-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 10 Acceptability of the treatment: leaving the study early (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 11 Acceptability of the treatment: leaving the study early (long term)." data-id="CD000459-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 11 Acceptability of the treatment: leaving the study early (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 12 Adverse events: extrapyramidal symptoms (need of antiparkinsonism drugs)." data-id="CD000459-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 12 Adverse events: extrapyramidal symptoms (need of antiparkinsonism drugs). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 13 Adverse effects: parkinsonism (SHRS) ‐ average endpoint scores (short term)." data-id="CD000459-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 13 Adverse effects: parkinsonism (SHRS) ‐ average endpoint scores (short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 14 Adverse effects: parkinsonism (SAS, ESRS, low = better) ‐ average change score (medium term)." data-id="CD000459-fig-0030" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 14 Adverse effects: parkinsonism (SAS, ESRS, low = better) ‐ average change score (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 15 Adverse effects: dyskinesia (ESRS, low = better) ‐ average change score (medium term)." data-id="CD000459-fig-0031" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 15 Adverse effects: dyskinesia (ESRS, low = better) ‐ average change score (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 16 Adverse effects: akathisia (BAS, ESRS, low = better) ‐ average change scores (medium term)." data-id="CD000459-fig-0032" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 16 Adverse effects: akathisia (BAS, ESRS, low = better) ‐ average change scores (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 17 Adverse effects: dystonia (ESRS, low = better) ‐ average change score (medium term)." data-id="CD000459-fig-0033" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 17 Adverse effects: dystonia (ESRS, low = better) ‐ average change score (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 18 Adverse effects: general adverse events (UKU, low = better) ‐ average change score (medium term)." data-id="CD000459-fig-0034" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 18 Adverse effects: general adverse events (UKU, low = better) ‐ average change score (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 19 General global state: average change score (CGI) (medium term)." data-id="CD000459-fig-0035" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 Switch to a specific antipsychotic vs switch to a different antipsychotic, Outcome 19 General global state: average change score (CGI) (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Specific antipsychotic vs other drugs, Outcome 1 Tardive dyskinesias: no clinically important improvement (medium term)." data-id="CD000459-fig-0036" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Specific antipsychotic vs other drugs, Outcome 1 Tardive dyskinesias: no clinically important improvement (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Specific antipsychotic vs other drugs, Outcome 2 Tardive dyskinesia: no improvement (medium term)." data-id="CD000459-fig-0037" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Specific antipsychotic vs other drugs, Outcome 2 Tardive dyskinesia: no improvement (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Specific antipsychotic vs other drugs, Outcome 3 Tardive dyskinesia: deterioration (medium term)." data-id="CD000459-fig-0038" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Specific antipsychotic vs other drugs, Outcome 3 Tardive dyskinesia: deterioration (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000459-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/urn:x-wiley:14651858:media:CD000459:CD000459-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_t/tCD000459-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Specific antipsychotic vs other drugs, Outcome 4 Acceptability of the treatment: leaving the study early (medium term)." data-id="CD000459-fig-0039" src="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Specific antipsychotic vs other drugs, Outcome 4 Acceptability of the treatment: leaving the study early (medium term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/media/CDSR/CD000459/image_n/nCD000459-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD000459-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies relevant to schizophrenia: comparisons for existing or potential reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants – people with:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison for review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cochrane Review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0030" title="CaiN . A controlled study on the treatment of tardive dyskinesia using 1‐stepholidine. Chinese Journal of Neurology and Psychiatry1988;21(5):281‐3. ">Cai 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐stepholidine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐stepholidine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0129" title="BarnesTRE , SpellerJC , CursonDA , PantelisC , AlbertsJL . A one‐year dose reduction study in chronic schizophrenic inpatients: amisulpride vs haloperidol. Schizophrenia Research1992;6(2):107. [EMBASE 1997383387] SpellerJC , BarnesTRE , CursonDA , PantelisC , AlbertsJL . One‐year, low‐dose neuroleptic study of in‐patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. British Journal of Psychiatry1997;171(December):564‐8. [EMBASE 1997383387] ">Speller 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amisulpride vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amisulpride versus haloperidol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0063" title="GerlachJ , SimmelsgaardH . Tardive dyskinesia during and following treatment with haloperidol, haloperidol and biperiden, thioridazine and clozapine. Psychopharmacology1978;59:105‐12. ">Gerlach 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biperiden vs no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Anticholinergic drugs for tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0104" title="GerlachJ . Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale1988;XIV:227‐32. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology1986;90(4):423‐9. PovlsenUJ , NoringU , MeidahlB , KorsgaardS , WaehrensJ , GerlachJ . [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger1987;149(25):1682‐5. ">NDSG 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorprothixene versus haloperidol vs perphenazine vs haloperidol + biperiden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0070" title="GreilW , HaagH , RossnaglG , RutherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. [MEDLINE: 85001048; PMID 6148119] ">Greil 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biperiden vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0041" title="ChouinardG , AnnableL , Ross‐ChouinardA , KropskyML . Ethopropazine and benztropine in neuroleptic‐induced parkinsonism. Journal of Clinical Psychiatry1979;40(3):147‐52. ">Chouinard 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethopropazine vs benztropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergics for parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0131" title="SpohnHE , CoyneL , SprayJ . The effect of neuroleptics and tardive dyskinesia on smooth‐pursuit eye movement in chronic schizophrenia. Archives of General Psychiatry1988;45:833‐40. ">Spohn 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abrupt neuroleptic cessation vs neuroleptic maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>Antipsychotic reduction or withdrawal for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0132" title="SpohnHE , CoyneL . The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics. Special Issue: tardive dyskinesia and cognitive dysfunction. Brain and Cognition1993;23(1):28‐39. ">Spohn 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abrupt neuroleptic cessation vs neuroleptic maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0140" title="WistedtB , WilesD , JorgensenA . A depot neuroleptic withdrawal study neurological effects. Psychopharmacology1983;80:101‐5. ">Wistedt 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine/flupenthixol decanoate continuation vs withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0069" title="GoldbergSC , ShenoyRS , SadlerA , HamerR , RossB . The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics. Psychopharmacology Bulletin1981;17(1):116‐7. [MEDLINE: 81200009; PMID 7232638] ShenoyRS , SadlerAG , GoldbergSC , HamerRM , RossB . Effects of a six‐week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology1981;1(3):141‐5. ">Goldberg 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal of fluphenazine decanoate vs continuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0073" title="HershonHI , KennedyPF , McGuireRJ . Persistence of extra‐pyramidal disorders and psychiatric relapse after withdrawal of long‐term phenothiazine therapy. British Journal of Psychiatry1972;120(554):41‐50. ">Hershon 1972</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trifluoperazine withdrawal vs trifluoperazine continuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0083" title="JohnsonDA , LudlowJM , StreetK , TaylorRD . Double‐blind comparison of half‐dose and standard‐dose flupenthixol decanoate in the maintenance treatment of stabilised out‐patients with schizophrenia. British Journal of Psychiatry1987;151:634‐8. ">Johnson 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose reduction vs maintenance (both arms used flupenthixol decanoate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0088" title="KinonB , StaufferVL , WangL , ThiKT , Kollack‐WalkerS . Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study. International Journal of Neuropsychopharmacology. Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum2002;5(Suppl 1):S165. KinonBJ , JesteDV , Kollack‐WalkerS , StaufferV , Liu‐SeifertH . Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Progress in neuro‐psychopharmacology &amp; biological psychiatry2004;28(6):985‐96. KinonBJ , StaufferVL , WangL , ThiK , NiewoehnerJ , Kollack‐WalkerS . Olanzapine improves dyskinesia in patients with schizophrenia. International Congress on Schizophrenia Research (ICSR) March 29‐April 2, 2003, Colorado Springs, Colorado. 2003. KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA, USA. 2002. KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophrenia Research2002;53(3 Suppl.1):191. [MEDLINE: 96173072; PMID 11580001] Kollack‐WalkerS , KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophrenia Research2003;60:359. [PsycINFO 2003‐06156‐011; PMID 12765745] ">Kinon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine with different timings of dose‐reduction periods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0094" title="LevineJ , SchoolerNR , SevereJ , EscobarJ , GelenbergA , MandelM , et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Advances in Biochemical Psychopharmacology1980;24:483‐93. ">Levine 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine withdrawal vs continuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0100" title="MarderSR , VanPuttenT , MintzJ , LebellM , McKenzieJ , MayPRA . Low‐ and conventional‐dose maintenance therapy with fluphenazine decanoate: two‐year outcome. Archives of General Psychiatry1987;44:518‐21. MarderSR , VanPuttenT , MintzJ , McKenzieJ , LebellM , FalticoG , et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry1984;41:1025‐9. ">Marder 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐ vs conventional‐dose maintenance therapy with fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0105" title="NewcomerJW , RineySJ , VinogradovS , CsernanskyJG . Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease. Psychopharmacology Bulletin1992;28(1):101‐7. ">Newcomer 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol dose reduction vs maintained dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0125" title="SinghH , HuntJI , VitielloB , SimpsonGM . Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Journal of Clinical Psychiatry1990;51:319‐21. ">Singh 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abrupt neuroleptic cessation vs neuroleptic maintenance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0145" title="ZengZX , LiZC , YuXW , ZhangYD , CaoZC . A double‐blind trial of flunarizine therapy for tardive dyskinesia. Chinese Journal of Pharmaco Epidemiology1994;3(4):183‐4. ">Zeng 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flunarizine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcium channel blockers for neuroleptic‐induced tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0080" title="JesteDV , OlgiatiSG , GhaliAY . Masking of tardive dyskinesia with four times‐a‐day administration of chlorpromazine. Diseases of the Nervous System1977;38(9):755‐8. ">Jeste 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorpromazine schedule A vs chlorpromazine schedule B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorpromazine timing of dose for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0104" title="GerlachJ . Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale1988;XIV:227‐32. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology1986;90(4):423‐9. PovlsenUJ , NoringU , MeidahlB , KorsgaardS , WaehrensJ , GerlachJ . [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger1987;149(25):1682‐5. ">NDSG 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorprothixene vs haloperidol vs perphenazine vs haloperidol + biperiden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorprothixene for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0017" title="AndiaI , ZumarragaM , ZabaloMJ , BulbenaA , DavilaR . Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia. Biological Psychiatry1998;43:20‐3. ">Andia 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clozapine versus haloperidol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0062" title="GerlachJ , ThorsenK , FogR . Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia1975;40(4):341‐50. ">Gerlach 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0022" title="BitterI , SlabberM , PretoriusJ , BartkoGY , DanicsZ , DossenbachM , et al. Olanzapine versus clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S141. ">Bitter 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clozapine versus olanzapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0079" title="Jean‐NoelB , WoodAJ , KieslerGM , BirkettM , TollefsonGD . Olanzapine vs. clozapine: an international double blind study in the treatment of resistant schizophrenia. 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999; Vol. 2:143. ">Jean‐Noel 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0031" title="CaineED , PolinskyRJ , KartzinelR , EbertMH . The trial use of clozapine for abnormal involuntary movement disorders. American Journal of Psychiatry1979;136:317‐20. ">Caine 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gilles de la Tourette's, Huntington's disease and drug‐induced atypical dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine versus placebo for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0043" title="ChouinardG , VainerJL , BelangerMC , TurnierL , BeaudryP , RoyJY , et al. Risperidone and clozapine in the treatment of drug‐resistant schizophrenia and neuroleptic‐induced supersensitivity psychosis. Progress in Neuro‐psychopharmacology &amp; Biological Psychiatry1994;18(7):1129‐41. ">Chouinard 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine versus risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clozapine versus risperidone for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0042" title="ChouinardG , AnnableL , CampbellW . A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of Clinical Psychopharmacology1989;9(4):247‐53. ">Chouinard 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol decanoate vs fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Depot fluphenazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0045" title="CooksonJC . Side effects during long‐term treatment with depot antipsychotic medication. Clinical Neuropharmacology1991;14(Suppl 2):S24‐32. ">Cookson 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs haloperidol decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0052" title="CursonDA , BarnesTR , BamberRW , PlattSD , HirschSR , DuffyJC . Long term depot maintenance of chronic schizophrenic out patients: the seven year follow up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side effects, neurotic symptoms and depression. British Journal of Psychiatry1985;146:469‐74. ">Curson 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0101" title="McCreadieRG , DingwallJM , WilesDH , HeykantsJJ . Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1980;137(6):510‐7. ">McCreadie 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs intermittent pimozide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0107" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry1982;43:195‐6. ">Odejide 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs vitamin B complex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0040" title="ChouinardG , AnnableL , KropskyM . A double‐blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Pharmacology1978;18(2‐3):148‐54. ">Chouinard 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine ethanoate vs pipothiazine palmitate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0042" title="ChouinardG , AnnableL , CampbellW . A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of Clinical Psychopharmacology1989;9(4):247‐53. ">Chouinard 1989</a>, <a href="./references#CD000459-bbs2-0045" title="CooksonJC . Side effects during long‐term treatment with depot antipsychotic medication. Clinical Neuropharmacology1991;14(Suppl 2):S24‐32. ">Cookson 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol decanoate vs fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depot haloperidol decanoate for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0040" title="ChouinardG , AnnableL , KropskyM . A double‐blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Pharmacology1978;18(2‐3):148‐54. ">Chouinard 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine ethanoate vs pipothiazine palmitate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depot pipothiazine for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0028" title="BurnerM , GirouxC , L'HeritierC , GarreauM , MorselliPL . Preliminary observations on the therapeutic action of progabide in tardive dyskinesia. Brain Dysfunction1989;2(6):289‐96. [MEDLINE: 87273387; PMID 2886223] ">Burner 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Progabide vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GABA for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0021" title="BatemanDN , DuttaDK , McClellandHA , RawlinsMD . The effect of metoclopramide and haloperidol on tardive dyskinesia. British Journal of Pharmacology1979;66(3):475‐6. ">Bateman 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia and psychiatric history</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metoclopramide (10 mg, 20 mg or 40 mg) vs haloperidol (5 mg or 10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperdiol dose for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0136" title="TranPV , DellvaMA , TollefsonGD , BeasleyCMJr , PotvinJH , KieslerGM . Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of clinical psychiatry1997; Vol. 58, issue 5:205‐11. ">Tran 1997</a>, <a href="./references#CD000459-bbs2-0118" title="RosenheckR , PerlickD , BinghamS , Liu‐MaresW , CollinsJ , WarrenS , et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA2003;290(20):2693‐702. ">Rosenheck 2003</a>, <a href="./references#CD000459-bbs2-0135" title="BeasleyCM , DellvaMA , TamuraRN , MorgensternH , GlazerWM , FergusonK , et al. A randomised double‐blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long‐term treatment with olanzapine or haloperidol. British Journal of Psychiatry1999;174:23‐30. TamuraRN , TollefsonGD , DellvaMA , BeasleyCM , GlazerWM , MorgensternH . What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?. Schizophrenia Research1998;29:176. TollefsonGD , BeasleyCM , TamuraRN , TranPV , PotvinJH . Blind, controlled, long term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry1997;154:1248‐54. ">Tollefson 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs olanzapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0104" title="GerlachJ . Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale1988;XIV:227‐32. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology1986;90(4):423‐9. PovlsenUJ , NoringU , MeidahlB , KorsgaardS , WaehrensJ , GerlachJ . [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger1987;149(25):1682‐5. ">NDSG 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorprothixene vs haloperidol vs perphenazine vs haloperidol + biperiden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs perphenazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0090" title="KopalaL , RabinowitzJ , EmsleyR , McGorryP . Extra‐pyramidal signs and symptoms (EPS) in recent onset schizophrenia: a comparison of risperidone and haloperidol. Schizophrenia Research2004;67(1):187. ">Kopala 2004</a>, <a href="./references#CD000459-bbs2-0139" title="WirshingDA , MarshallBDJr , GreenMF , MintzJ , MarderSR , WirshingWC . Risperidone in treatment‐refractory schizophrenia. American Journal of Psychiatry1999;156(9):1374‐9. ">Wirshing 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="21" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs risperidone for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0084" title="JolleyAG , HirschSR , McRinkA , ManchandaR . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ1989;298(6679):985‐90. JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301(6756):837‐42. ">Jolley 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brief intermittent antipsychotic treatment vs fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Intermittent antipsychotic treatment for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0101" title="McCreadieRG , DingwallJM , WilesDH , HeykantsJJ . Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1980;137(6):510‐7. ">McCreadie 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs intermittent pimozide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0106" title="NewtonJE , CannonDJ , CouchL , FodyEP , McMillanDE , MetzerWS , et al. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. Journal of Clinical Psychiatry1989;50:132‐5. ">Newton 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol with 'drug holiday' vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0069" title="GoldbergSC , ShenoyRS , SadlerA , HamerR , RossB . The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics. Psychopharmacology Bulletin1981;17(1):116‐7. [MEDLINE: 81200009; PMID 7232638] ShenoyRS , SadlerAG , GoldbergSC , HamerRM , RossB . Effects of a six‐week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology1981;1(3):141‐5. ">Goldberg 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal of fluphenazine decanoate vs continuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0099" title="MacKayAV , SheppardGP , SahaBK , MotleyB , JohnsonA , MarsdenCD . Failure of lithium treatment in established tardive dyskinesia. Psychological Medicine1980;10(3):583‐7. ">MacKay 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithium vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithium for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0024" title="BorisonRL , ShahC , WhiteTH , DiamondBI . Atypical and typical neuroleptics and tardive dyskinesia. Psychopharmacology Bulletin1987;23(1):218‐20. ">Borison 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Molidone vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Molidone vs haloperidol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0138" title="WilliamsonDJ , TranPV , BeasleyCM , TollefsonGD , SangerT , SatterleeWG . Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Journal of Psychopharmacology1995;9:A47. ">Williamson 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine 1 mg vs olanzapine 10 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine dose for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0054" title="deJesus MariJ , LimaMS , CostaAN , AlexandrinoN , Rodrigues‐FilhoS , deOliveiraIR , et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. European Archives of Psychiatry and Clinical Neuroscience2004;254(6):356‐61. [DOI: 10.1007/s00406‐004‐0514‐1] ">de Jesus Mari 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine vs "conventional antipsychotic drugs"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Olanzapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0111" title="PelusoMJ , LewisSW , BarnesTRE , JonesPB . Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. British Journal of Psychiatry2012;200(5):387‐92. ">Peluso 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First‐generation antipsychotic vs second‐generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0088" title="KinonB , StaufferVL , WangL , ThiKT , Kollack‐WalkerS . Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study. International Journal of Neuropsychopharmacology. Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum2002;5(Suppl 1):S165. KinonBJ , JesteDV , Kollack‐WalkerS , StaufferV , Liu‐SeifertH . Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Progress in neuro‐psychopharmacology &amp; biological psychiatry2004;28(6):985‐96. KinonBJ , StaufferVL , WangL , ThiK , NiewoehnerJ , Kollack‐WalkerS . Olanzapine improves dyskinesia in patients with schizophrenia. International Congress on Schizophrenia Research (ICSR) March 29‐April 2, 2003, Colorado Springs, Colorado. 2003. KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA, USA. 2002. KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophrenia Research2002;53(3 Suppl.1):191. [MEDLINE: 96173072; PMID 11580001] Kollack‐WalkerS , KinonBJ , StaufferVL , WangL , ThiKT . Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophrenia Research2003;60:359. [PsycINFO 2003‐06156‐011; PMID 12765745] ">Kinon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine with different timings of dose reduction periods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine reduction for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0111" title="PelusoMJ , LewisSW , BarnesTRE , JonesPB . Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. British Journal of Psychiatry2012;200(5):387‐92. ">Peluso 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First‐generation antipsychotic versus second‐generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine vs other atypical antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0138" title="WilliamsonDJ , TranPV , BeasleyCM , TollefsonGD , SangerT , SatterleeWG . Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Journal of Psychopharmacology1995;9:A47. ">Williamson 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine 1 mg vs olanzapine 10 mg vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine vs placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0111" title="PelusoMJ , LewisSW , BarnesTRE , JonesPB . Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. British Journal of Psychiatry2012;200(5):387‐92. ">Peluso 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First‐generation antipsychotic vs second‐generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perphenazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0101" title="McCreadieRG , DingwallJM , WilesDH , HeykantsJJ . Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1980;137(6):510‐7. ">McCreadie 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs intermittent pimozide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pimozide for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0046" title="CorteseL , CaligiuriMP , WilliamsR , SchieldropP , ManchandaR , MallaA , et al. Reduction in neuroleptic‐induced movement disorders after a switch to quetiapine in patients with schizophrenia. Journal of Clinical Psychopharmacology2008;28(1):69‐73. ">Cortese 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quetiapine vs continuation of usual antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quetiapine vs continuation of usual antipsychotic for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD000459-bbs2-0111" title="PelusoMJ , LewisSW , BarnesTRE , JonesPB . Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. British Journal of Psychiatry2012;200(5):387‐92. ">Peluso 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>First generation antipsychotic vs second‐generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quetiapine vs other atypical antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quetiapine vs typical antipsychotic medications for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone vs olanzapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone vs other atypical antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0046" title="CorteseL , CaligiuriMP , WilliamsR , SchieldropP , ManchandaR , MallaA , et al. Reduction in neuroleptic‐induced movement disorders after a switch to quetiapine in patients with schizophrenia. Journal of Clinical Psychopharmacology2008;28(1):69‐73. ">Cortese 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quetiapine vs continuation of usual antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switching antipsychotic for schizophrenia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0124" title="SingerK , ChengMN . Thiopropazate hydrochloride (Dartalan) in persistent dyskinesia with phenothiazine therapy. 5th World Congress of Psychiatry; 1971 Nov 28 ‐ Dec 4; Ciudad de Mexico, Mexico. 1971:528. [MEDLINE: 79081577; PMID 215095] SingerK , ChengMN . Thiopropazate hydrochloride in persistent dyskinesia. British Medical Journal1971;4:22‐5. ">Singer 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiopropazate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiopropazate for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD000459-bbs2-0091" title="LalS , EttigiP . Comparison of thiopropazate and trifluoperazine on oral dyskinesia ‐ a double blind study. Current Therapeutic Research, Clinical and Experimental1974;16(9):990‐7. ">Lal 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thiopropazine vs trifluoperazine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiopropazine vs placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiopropazine vs trifluoperazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD000459-bbs2-0055" title="DelwaidePJ , DesseillesM . Controlled therapeutic study of spontaneous bucco‐linguo‐facial dyskinesias [Etude therapeutique controlee des dyskinesies bucco‐linguo‐faciales spontanees]. Semaine des Hopitaux1979;55(35‐6):1585‐9. [MEDLINE: 97392141; PMID 9248874] ">Delwaide 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thioproperazine and tiapride vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thioproperazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tiapride for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0029" title="BurumaOJ , RoosRA , BruynGW , KempB , Van derVeldeEA . Tiapride in the treatment of tardive dyskinesia. Acta Neurologica Scandinavica1982;65(1):38‐44. [MEDLINE: 82155989; PMID 6121443] ">Buruma 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiapride vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD000459-bbs2-0050" title="CraneGH . High doses of trifluperazine and tardive dyskinesia. Archives of Neurology1970;22(2):176‐80. ">Crane 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trifluoperazine high‐dose vs trifluoperazine low‐dose vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trifluoperazine dose for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trifluoperazine vs placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0091" title="LalS , EttigiP . Comparison of thiopropazate and trifluoperazine on oral dyskinesia ‐ a double blind study. Current Therapeutic Research, Clinical and Experimental1974;16(9):990‐7. ">Lal 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thiopropazine vs trifluoperazine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0107" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry1982;43:195‐6. ">Odejide 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluphenazine decanoate vs vitamin B complex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamins for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000459-bbs2-0111" title="PelusoMJ , LewisSW , BarnesTRE , JonesPB . Extrapyramidal motor side‐effects of first‐ and second‐generation antipsychotic drugs. British Journal of Psychiatry2012;200(5):387‐92. ">Peluso 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>First‐generation antipsychotic vs second‐generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ziprasidone vs other atypical antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies relevant to schizophrenia: comparisons for existing or potential reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000459-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggestions for design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, with sequence generation and concealment of allocation clearly described<br/> Blindness: double, tested<br/> Duration: 12 months beyond end of intervention at least<br/> Raters: independent </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with antipsychotic‐induced tardive dyskinesia<sup>a</sup><br/> Age: any<br/> Sex: both<br/> History: any<br/> N = 300<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Antipsychotic reduction/cessation (N = 150) vs antipsychotic maintenance (N = 150)</p> <p>OR</p> <p>2. Specific antipsychotic (N = 150) vs other specific antipsychotic (N = 150)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tardive dyskinesia: any clinically important improvement in tardive dyskinesia, any improvement, deterioration<sup>c</sup><br/> Adverse effects: no clinically significant extrapyramidal adverse effects ‐ any time period<sup>c</sup>, use of any antiparkinsonism drugs, other important adverse events<br/> Leaving the study early<br/> Service outcomes: admitted, number of admissions, length of hospitalisation, contacts with psychiatric services<br/> Compliance with drugs<br/> Economic evaluations: cost‐effectiveness, cost‐benefit<br/> General state: relapse, frequency and intensity of minor and major exacerbations<br/> Social confidence, social inclusion, social networks, or personalised quality of life: binary measure<br/> Distress among relatives: binary measure<br/> Burden on family: binary measure </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>a</sup>This could be diagnosed by clinical decision. If funds were permitting all participants could be screened using operational criteria, otherwise a random sample should suffice. </p> <p><sup>b</sup>Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.<br/> <sup>c</sup>Primary outcome. The same applies to the measure of primary outcome as for diagnosis. Not everyone may need to have operational criteria applied if clinical impression is proved to be accurate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggestions for design of future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000459-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Reduced dose of antipsychotics compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Reduced dose of antipsychotic compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychiatric patients (schizophrenia or schizoaffective disorder) with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients and outpatients in the UK (1 study) and the USA (1 study)<br/> <b>Intervention</b> : Reduced dose of antipsychotic<br/> <b>Comparison:</b> Antipsychotic maintenance </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antipsychotic maintenance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with reduced dose of antipsychotic</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: no clinically important improvement<br/> Follow‐up: 44‐48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.42<br/> (0.17 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>875 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1000<br/> (149 to 910) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: deterioration of symptoms<br/> Follow‐up: 44‐48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.61<br/> (0.11 to 3.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000<br/> (28 to 828) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>General mental state: relapse<br/> Follow‐up: 44‐48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.00<br/> (0.16 to 57.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effect: any ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effect: extrapyramidal symptoms ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acceptability of the treatment: leaving the study early<br/> Follow‐up: 44‐48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.06 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000<br/> (45 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for risk of bias: none of the studies adequately described allocation concealment, one study was a subsample from one site of an RCT, and one study's baseline characteristics were not balanced between study groups.<br/> <sup>2</sup>Downgraded two levels for imprecision: 95% CI includes both no effect and appreciable benefit for antipsychotic reduced dose; very small sample size.<br/> <sup>3</sup>Downgraded one level for risk of bias: allocation concealment was not adequately described, only a subsample from one site of an RCT qualified for inclusion.<br/> <sup>4</sup>Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Reduced dose of antipsychotics compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000459-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antipsychotic cessation compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antipsychotic cessation compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> psychiatric patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients and outpatients in any country<br/> <b>Intervention:</b> Antipsychotic cessation<br/> <b>Comparison:</b> Antipsychotic maintenance </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antipsychotic maintenance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antipsychotic cessation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>There is no evidence about the effects of withdrawal of antipsychotics compared with continuation of antipsychotics; none of the included studies evaluated this comparison. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antipsychotic cessation compared with antipsychotic maintenance for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000459-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Switch to another antipsychotic compared with antipsychotic cessation for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Switch to another antipsychotic compared with antipsychotic cessation for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients in Canada (1 study) and Taiwan (1 study)<br/> <b>Intervention:</b> Switch to another antipsychotic (risperidone, haloperidol)<br/> <b>Comparison:</b> Antipsychotic cessation (with placebo; from FGAs) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with antipsychotic cessation (placebo)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with switch to another antipsychotic</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: no clinically important improvement<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.45<br/> (0.23 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>315 per 1000<br/> (161 to 623) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tardive dyskinesia: deterioration of symptoms ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General mental state: average endpoint score (BPRS, high = poor)<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general mental state average endpoint score (BPRS, high = poor) was 19</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.30 lower<br/> (10.48 lower to 1.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effect: any ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: use of antiparkinsonism drugs<br/> Follow‐up: 8‐12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.08<br/> (0.74 to 5.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>48<br/> (1 RCT) <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Another study reported ESRS scale data for parkinsonism and also found little or no difference between groups (MD ‐0.4 95% CI ‐1.25 to 0.45, 42 participants). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>567 per 1000<br/> (202 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acceptability of the treatment: leaving the study early<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/> (0.16 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000<br/> (32 to 450) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FGA:</b> first‐generation antipsychotic; <b>MD</b> : mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for risk of bias: generation of random sequence and allocation concealment not adequately described.<br/> <sup>2</sup> Downgraded one level for imprecision: very small sample size.<br/> <sup>3</sup> Downgraded two levels for imprecision: 95% CI includes appreciable benefit for both interventions as well as no effect; very small sample size.<br/> <sup>4</sup> Two comparisons from one study.<br/> <sup>5</sup> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Switch to another antipsychotic compared with antipsychotic cessation for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000459-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Switch to a specific antipsychotic compared with switch to a different specific antipsychotic for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Switch to specific antipsychotic compared with switch to a different specific antipsychotic for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychiatric patients (mainly schizophrenia) with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients and outpatients in Canada (1 study), Denmark and Finland (1 study), South Africa (1 study), Taiwan (2 studies) and the USA (5 studies)<br/> <b>Interventions:</b> switch to specific antipsychotic (amisulpride, clozapine, haloperidol, molindone, olanzapine, risperidone, thiopropazate, quetiapine, ziprasidone, zuclopenthixol) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with specific antipsychotic 1</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with specific antipsychotic 2</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: no clinically important improvement</p> <p>Follow‐up: 3‐50 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>140<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No meta‐analysis, studies stratified by antipsychotic. The following comparisons found no clinically important improvement: THI vs HAL, ZUC vs HAL, OLZ vs RIS, QUE vs HAL </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: deterioration</p> <p>Follow‐up: 3‐4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No meta‐analysis, studies stratified by antipsychotic. The following comparisons found no difference in deterioration: THI vs HAL, ZUC vs HAL </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>General mental state: deterioration</p> <p>Follow‐up: 3‐50 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>120<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No meta‐analysis, studies stratified by antipsychotic. The following comparisons found no difference in mental state deterioration: ZUC vs HAL, OLZ vs RIS, QUE vs HAL </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: extrapyramidal symptoms (need of antiparkinsonism drugs)</p> <p>Follow‐up: 8‐50 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>53<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No meta‐analysis, studies stratified by antipsychotic. HAL more likely to need antiparkinsonism drugs than QUE (1 RCT, 45 participants, RR 0.45, 95% CI 0.21 to 0.96). No difference: RIS vs HAL </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: general adverse events (UKU Average change score)</p> <p>Follow‐up: 24 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No meta‐analysis, 3‐arm study comparing OLZ, ASP and unspecified FGAs found no difference in general adverse events for all pairwise comparisons. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acceptability of the treatment: leaving the study early</p> <p>Follow‐up: 2 weeks ‐ 18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>466<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RIS more likely to leave study early than OLZ (2 RCTs, 130 participants, RR 0.73, 95% CI 0.57 to 0.95). Remaining studies no meta‐analysis, no difference (6 RCTs, 450 participants): MOL/THI/CLO/QUE vs HAL, OLZ/ASP vs unspecified FGAs, OLZ vs QUE/ZIP, QUE vs ZIP/RIS, ZIP vs RIS </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>ASP:</b> amisulpride; <b>CI:</b> confidence interval; <b>CLO:</b> clozapine; <b>FGA:</b> first‐generation anti‐psychotic; <b>HAL:</b> haloperidol; <b>MOL:</b> molindone; <b>OLZ:</b> olanzapine; <b>RCT:</b> randomised controlled trial; <b>RIS:</b> risperidone; <b>RR:</b> risk ratio; <b>THI:</b> thiopropazate; <b>QUE:</b> quetiapine; <b>ZIP:</b> ziprasidone; <b>ZUC:</b> zuclopenthixol </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one step for risk of bias: randomisation procedure, allocation concealment or blinding were not adequately described.<br/> <sup>2</sup>Downgraded two steps for imprecision: small sample size, and 95% CI includes appreciable benefit for both or one of the interventions as well as no effect.<br/> <sup>3</sup>Downgraded one step for imprecision: small sample size.<br/> <sup>4</sup>Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Switch to a specific antipsychotic compared with switch to a different specific antipsychotic for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000459-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Specific antipsychotic compared with other drugs for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Specific antipsychotic compared with other drugs for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychiatric patients (mainly schizophrenia) with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> inpatients in the USA (1 study)<br/> <b>Intervention</b> : specific antipsychotic (haloperidol)<br/> <b>Comparison</b>: other drugs (tetrabenazine) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tetrabenazine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with haloperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: not improved to a clinically important extent<br/> Follow‐up: 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.51 to 2.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>713 per 1000<br/> (340 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardive dyskinesia: deterioration of symptoms<br/> Follow‐up: 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.07 to 10.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000<br/> (12 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effect: any ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effect: extrapyramidal symptoms ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acceptability of the treatment: leaving the study early<br/> Follow‐up: 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.38<br/> (0.25 to 76.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one step for risk of bias: randomisation procedure, allocation concealment and blinding were not adequately described.<br/> <sup>2</sup>Downgraded two steps for imprecision: small sample size, and 95% CI includes appreciable benefit for both interventions.<br/> <sup>3</sup>Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Specific antipsychotic compared with other drugs for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/full#CD000459-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000459-tbl-0012"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other Cochrane Reviews in this series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Current reference (updates underway)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticholinergic medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000459-bbs2-0231" title="Soares‐WeiserK , MobsyC , HollidayE . Anticholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews1997, Issue 2. [DOI: 10.1002/14651858.CD000204] ">Soares‐Weiser 1997</a>; <a href="./references#CD000459-bbs2-0230" title="SoaresK , McGrathJ . Anticholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000204; MEDLINE: 20257419] ">Soares 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000459-bbs2-0160" title="BhoopathiPS , Soares‐WeiserK . Benzodiazepines for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD000205.pub2] ">Bhoopathi 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000459-bbs2-0181" title="EssaliA , DeirawanH , Soares‐WeiserK , AdamsCE . Calcium channel blockers for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD000206.pub3] ">Essali 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholinergic medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000459-bbs2-0234" title="TammenmaaI , McGrathJ , SailasE , Soares‐WeiserK . Cholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD000207; MEDLINE: 22133093] ">Tammenmaa 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gamma‐aminobutyric acid agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000459-bbs2-0147" title="AlabedS , LatifehY , MohammadHA , RifaiA . Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD000203.pub3] ">Alabed 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miscellaneous treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000459-bbs2-0232" title="Soares‐WeiserK , JoyC . Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000208] ">Soares‐Weiser 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroleptic reduction and/or cessation and neuroleptics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐neuroleptic catecholaminergic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000459-bbs2-0179" title="El‐SayehHG , Lyra da SilvaJP , RathboneJ , Soares‐WeiserK . Non‐neuroleptic catecholaminergic drugs for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000458.pub2] ">El‐Sayeh 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000459-bbs2-0233" title="Soares‐WeiserK , MaayanN , McGrathJ . Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2] ">Soares‐Weiser 2011</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other Cochrane Reviews in this series</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/information#CD000459-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000459-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Reduced overall dose of antipsychotic vs antipsychotic maintenance</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tardive dyskinesia: no clinically important improvement (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.17, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tardive dyskinesia: no improvement (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.17, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Tardive dyskinesia: deterioration (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.11, 3.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 General mental state: relapse (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.16, 57.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Acceptability of the treatment: leaving the study early (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.06, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Reduced overall dose of antipsychotic vs antipsychotic maintenance</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000459-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Switch to specific antipsychotic vs antipsychotic cessation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tardive dyskinesia: no clinically important improvement (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.23, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tardive dyskinesia: average endpoint score (AIMS, high = poor) (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.5 [‐8.60, ‐2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 General mental state: average endpoint score (BPRS, high = poor) (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.30 [‐10.48, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Acceptability of the treatment: leaving the study early (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.16, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: use of antiparkinsonism drugs (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.74, 5.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.56, 7.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.37, 13.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: parkinsonism ‐ average endpoint score (ESRS) (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.25, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: dystonia ‐ average endpoint score (ESRS) (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.76, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Switch to specific antipsychotic vs antipsychotic cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000459-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Switch to a specific antipsychotic vs switch to a different antipsychotic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tardive dyskinesia: no clinically important improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Thiopropazate vs haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.58, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Zuclopenthixol vs haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.79, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Olanzapine vs risperidone ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.82, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Quetiapine vs haloperidol ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.52, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Quetiapine vs haloperidol ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.64, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tardive dyskinesia: not any improvement (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Thiopropazate vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.05, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Zuclopenthixol vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.16, 4.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Tardive dyskinesia: deterioration (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Thiopropazate vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.09, 16.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Zuclopenthixol vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.16, 4.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Tardive dyskinesia: average endpoint score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Molindone vs haloperidol, 100% masking dose (AIMS, short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [‐0.20, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Molindone vs haloperidol, 200% masking dose (AIMS, short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.44 [1.12, 5.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Zuclopenthixol vs haloperidol (SHRS, short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.81 [‐12.15, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Olanzapine vs risperidone (AIMS, medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐0.53, 4.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Tardive dyskinesia: average change score (AIMS, low = better) (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Olanzapine vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [‐0.45, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Amisulpride vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐2.85, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Olanzapine vs amisulpride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [0.44, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Olanzapine vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐2.58, 4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 General mental state: deterioration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Zuclopenthixol vs haloperidol ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 6.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Olanzapine vs risperidone ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Quetiapine vs haloperidol ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.62, 5.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General mental state: average endpoint score (PANSS‐general psychopathology, low = better) (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐6.02, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Quetiapine vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐6.02, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 General mental state: average change score (BPRS, low = better) (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Olanzapine vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.14 [‐4.79, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Amisulpride vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.46 [‐6.27, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Olanzapine vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐8.37, 4.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Olanzapine vs amisulpride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [‐1.94, 4.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Acceptability of the treatment: leaving the study early (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Molindone vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Thiopropazate vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.01, 4.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Acceptability of the treatment: leaving the study early (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Olanzapine vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.18, 19.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Amisulpride vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 14.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Olanzapine vs amisulpride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.19, 20.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Olanzapine vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.57, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Olanzapine vs quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.54, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Olanzapine vs ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.56, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 Quetiapine vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.88, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8 Quetiapine vs ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.86, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.9 Ziprasidone vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.74, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Acceptability of the treatment: leaving the study early (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Clozapine vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [0.45, 25.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Quetiapine vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.63, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events: extrapyramidal symptoms (need of antiparkinsonism drugs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Risperidone vs haloperidol (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.34, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Quetiapine vs haloperidol (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.21, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: parkinsonism (SHRS) ‐ average endpoint scores (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.81 [‐12.15, 2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Zuclopenthixol vs haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.81 [‐12.15, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: parkinsonism (SAS, ESRS, low = better) ‐ average change score (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Olanzapine vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐2.55, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Amisulpride vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐2.45, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Olanzapine vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.7 [‐1.33, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Olanzapine vs amisulpride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐2.44, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: dyskinesia (ESRS, low = better) ‐ average change score (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Olanzapine vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.91, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: akathisia (BAS, ESRS, low = better) ‐ average change scores (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Olanzapine vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.30, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Amisulpride vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.42, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Olanzapine vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.8 [‐1.76, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Olanzapine vs amisulpride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.12, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: dystonia (ESRS, low = better) ‐ average change score (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Olanzapine vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.7 [‐1.41, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: general adverse events (UKU, low = better) ‐ average change score (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Olanzapine vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐1.85, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Amisulpride vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐2.33, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Olanzapine vs amisulpride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [‐0.93, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 General global state: average change score (CGI) (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Olanzapine vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.41, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Amisulpride vs FGA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.47, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Olanzapine vs risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.61, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 Olanzapine vs amisulpride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.19, 0.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Switch to a specific antipsychotic vs switch to a different antipsychotic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000459-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Specific antipsychotic vs other drugs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tardive dyskinesias: no clinically important improvement (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.51, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Haloperidol vs tetrabenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.51, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tardive dyskinesia: no improvement (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.35, 18.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Haloperidol vs tetrabenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.35, 18.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Tardive dyskinesia: deterioration (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.07, 10.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Haloperidol vs tetrabenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.07, 10.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Acceptability of the treatment: leaving the study early (medium term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.38 [0.25, 76.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Haloperidol vs tetrabenazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.38 [0.25, 76.54]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Specific antipsychotic vs other drugs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000459.pub3/references#CD000459-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000459.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000459-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000459-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD000459-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000459-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000459\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000459\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000459\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000459\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000459\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000459.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000459.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000459.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000459.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000459.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714309026"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000459.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714309030"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000459.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6b82989ff3cd',t:'MTc0MDcxNDMwOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 